High level recombinant antibody production in Chinese hamster ovary (CHO) cells and characterisation of the carcinoembryonic antigen (CEA) specific human full-size IgG1 H10 by Peuscher, Anne Verena
 High level recombinant antibody production in Chinese hamster 
ovary (CHO) cells and characterisation of the carcinoembryonic 
antigen (CEA) specific human full-size IgG1 H10 
 
 
 
Von der Fakultät für Mathematik, Informatik und Naturwissenschaften der 
RWTH Aachen University zur Erlangung des akademischen Grades einer 
Doktorin der Naturwissenschaften genehmigte Dissertation 
 
 
 
 
vorgelegt von 
 
Diplom Biologin 
Anne Verena Peuscher 
 
aus Freiburg im Breisgau 
 
 
 
 
Berichter:  Universitätsprofessor Dr. rer. nat. Rainer Fischer 
Universitätsprofessor Dr. rer. nat. Dr. rer. medic. Stefan Barth 
 
 
 
Tag der mündlichen Prüfung:  8.4.2011 
Diese Dissertation ist auf den Internetseiten der Hochschulbibliothek online verfügbar. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Für meine Familie  
Eidesstattliche Erklärung: 
 
Hiermit bestätige ich, die vorliegende Arbeit selbständig angefertigt zu haben und keine 
anderen Hilfsmittel und Quellen als die im Text erwähnten verwendet zu haben.  
 
 
Aachen, im April 2011                                                                       
         (Anne Peuscher) 
 
Table of contents   
I  Introduction .................................................................................................. 1 
I.1  Recombinant protein production in Chinese hamster ovary (CHO) cells ........ 1 
I.1.1  Chinese hamster ovary cells ............................................................................... 2 
I.1.2  MTX-mediated gene amplification .................................................................... 3 
I.1.3  Generation of a monoclonal production cell line ............................................... 4 
I.2  Biopharmaceutical monoclonal antibodies ....................................................... 5 
I.2.1  Glycostructure dependent effector function ....................................................... 5 
I.2.2  Glyco-modification of Fc linked oligosaccharides ............................................ 7 
I.2.3  The carcinoembryonic antigen (CEA) as a tumor marker ................................. 8 
I.2.4  Anti-CEA antibodies ........................................................................................ 10 
I.3  Aim of the PhD thesis ..................................................................................... 12 
II  Material and methods ................................................................................ 15 
II.1  Material ........................................................................................................... 15 
II.1.1  Chemicals and consumables ............................................................................. 15 
II.1.2  Enzymes and reaction kits ................................................................................ 15 
II.1.3  Antibodies, ligands and antigens ...................................................................... 16 
II.1.4  Substrates ......................................................................................................... 17 
II.1.5  Bacterial strain .................................................................................................. 17 
II.1.6  Mammalian cell lines ....................................................................................... 17 
II.1.7  Human tissue .................................................................................................... 18 
II.1.8  Plasmids ........................................................................................................... 18 
II.1.9  Oligonucleotides ............................................................................................... 19 
II.1.10  Solutions, media and buffers ............................................................................ 19 
II.1.11  Media and supplements for the cultivation and isolation of mammalian cells 19 
II.1.12  Matrices and membranes .................................................................................. 21 
II.1.13  Equipment ........................................................................................................ 21 
II.1.14  Software ........................................................................................................... 22 
II.2  Methods ........................................................................................................... 23 
II.2.1  Recombinant DNA technology ........................................................................ 23 
II.2.1.1  Cultivation of E. coli ............................................................................................... 23 
II.2.1.2  Generation of electrocompetent E. coli................................................................... 23 
II.2.1.3  Electrotransformation of E. coli .............................................................................. 23 
II.2.1.4  Generation of glycerol stocks for long-term storage of E. coli strains ................... 24 
II.2.1.5  Isolation of plasmid DNA from E. coli ................................................................... 24 
Table of contents   
II.2.1.6  Agarose gelelectrophoresis of DNA ....................................................................... 24 
II.2.1.7  Polymerase Chain Reaction (PCR) ......................................................................... 25 
II.2.1.8  Restriction enzyme digestion of DNA and cohesive end fill-in ............................. 26 
II.2.1.9  Dephosphorylation and ligation of restriction enzyme digested DNA ................... 26 
II.2.1.10  Dialysis of ligation samples for salt removal .......................................................... 27 
II.2.1.11  Sequencing of plasmid DNA .................................................................................. 27 
II.2.1.12  Phenol-chloroform-isoamyl alcohol (PCI) and ethanol precipitation ..................... 27 
II.2.2  Mammalian cell culture methods ..................................................................... 28 
II.2.2.1  Cultivation of mammalian cell cultures .................................................................. 28 
II.2.2.2  Cryopreservation and thawing of mammalian cells ................................................ 28 
II.2.2.3  Transfection and generation of stable transfected DG44 cells ................................ 28 
II.2.2.4  MTX-mediated gene amplification ......................................................................... 29 
II.2.2.5  Limiting dilution (LD) ............................................................................................ 29 
II.2.2.6  Flow cytometric analysis and sorting...................................................................... 30 
II.2.2.6.1  Flow cytometric analysis ................................................................................ 31 
II.2.2.6.2  Fluorescence activated cell sorting (FACS) ................................................... 32 
II.2.2.7  Procedure of whole cell extract preparation ........................................................... 32 
II.2.2.8  Nomenclature of H10 producing DG44 cells ......................................................... 33 
II.2.2.9  Separation of peripheral blood mononuclear cells (PBMC) from blood and       
                 isolation of natural killer (NK) cells ........................................................................ 33 
II.2.2.10  ADCC assay ............................................................................................................ 34 
II.2.3  H10 purification and labeling ........................................................................... 35 
II.2.3.1  Purification of H10 via Protein A affinity chromatography ................................... 35 
II.2.3.2  Buffer exchange of protein solutions ...................................................................... 35 
II.2.3.3  Conjugation of H10 with biotin or DyLight549 ..................................................... 36 
II.2.4  Proteinchemical and immunological methods ................................................. 36 
II.2.4.1  SDS-Polyacrylamide gelelectrophoresis (SDS-PAGE) and Coomassie staining ... 36 
II.2.4.2  Immunoblot analysis ............................................................................................... 38 
II.2.4.3  Enzyme linked immuno sorbent assay (ELISA) ..................................................... 38 
II.2.4.4  Surface plasmon resonance (SPR) based quantification and analysis .................... 39 
II.2.4.5  Immunofluorescence staining ................................................................................. 40 
II.2.4.5.1  Immunofluorescence staining of fixed cells ................................................... 40 
II.2.4.5.2  Immunofluorescence staining of tissue sections (immunohistochemistry) .... 41 
II.2.5  Matrix assisted laser desorption/ionisation (MALDI) glycopeptide analysis .. 42 
 
 
Table of contents   
III  Results .......................................................................................................... 43 
III.1  Establishment of a CHO platform for high level monoclonal antibody 
production ....................................................................................................... 43 
III.1.1  Establishment and comparison of two polycistronic vector systems ............... 43 
III.1.1.1  Vector design and cloning ...................................................................................... 44 
III.1.1.1.1  Tricistronic vector pAPI:H10 ......................................................................... 44 
III.1.1.1.2  Bicistronic tandem vector pAPT:H10 ............................................................ 47 
III.1.1.2  Comparison of the tricistronic and bicistronic-tandem vector system .................... 48 
III.1.1.2.1  Comparision of H10 expression levels in the presence of various MTX                           
                       levels…….…………………………………………………………………  48 
III.1.1.2.2  Growth and production characteristics ........................................................... 51 
III.1.1.2.3  HC:LC ratio determination ............................................................................. 54 
III.1.1.3  Functional comparison of H10 derived from tricistronic and bicistronic-tandem  
                 vector system ........................................................................................................... 59 
III.1.1.3.1  Small-scale H10 production, purification and quantification......................... 59 
III.1.1.3.2  Functional analysis ......................................................................................... 60 
III.1.2  Optimisation of production conditions ............................................................. 61 
III.1.2.1  Medium testing ....................................................................................................... 62 
III.1.2.2  Long-term cultivation in the presence and absence of MTX .................................. 63 
III.1.2.3  Cultivation vessel testing for large-scale protein production .................................. 65 
III.1.3  Establishment of an efficient gene amplification procedure ............................ 67 
III.1.3.1  Pool strategy ........................................................................................................... 67 
III.1.3.2  Individual clone strategy ......................................................................................... 68 
III.1.4  Summary of improvement steps ....................................................................... 72 
III.2  Production and analysis of two H10 glycoforms in CHO cells ...................... 77 
III.2.1  Production and purification of H10 bearing a complex or a bisected N-glycan 
structure ............................................................................................................ 77 
III.2.1.1  Cloning of pTRACER:GnTIII ................................................................................ 78 
III.2.1.2  Generation of glycoengineered monclonal DG44 cell lines producing H10 with a  
                 bisecting N-glycan structure .................................................................................... 79 
III.2.1.3  H10_CHO_WT and H10_CHO_GnTIII large-scale production and purification .. 82 
III.2.1.3.1  Production of H10_CHO_WT in square bottles ............................................ 82 
III.2.1.3.2  Production of H10_CHO_GnTIII in a two-compartment bioreactor ............. 83 
III.2.1.4  N-glycan analysis .................................................................................................... 85 
III.2.1.5  Stability of H10 at -20°C ........................................................................................ 86 
III.2.2  Characterisation of the H10 binding to CEA ................................................... 87 
Table of contents   
III.2.2.1  Functional binding of H10 to recombinant CEANA3 ............................................ 87 
III.2.2.2  Specific detection of CEA in human cell extract .................................................... 89 
III.2.2.3  Localisation of H10 binding on fixed cells ............................................................. 91 
III.2.2.4  Flow cytometric analysis of H10 ............................................................................ 92 
III.2.2.4.1  Generation of a monoclonal HEK293T-CEA cell line producing elevated                             
                      levels of CEANA3 ......................................................................................... 93 
III.2.2.4.2  Flow cytometric analysis of H10 glycovariants on HEK293T-CEA cells ..... 94 
III.2.2.5  Specific binding of H10 to CEA-positive tissue ..................................................... 96 
III.2.3  Characterisation of the ability of H10 to activate effector responses .............. 98 
III.2.3.1  ADCC ..................................................................................................................... 98 
III.2.3.2  Affinity of the two H10 glycovariants to FcγRIIIa ............................................... 100 
IV  Discussion .................................................................................................. 102 
IV.1  Establishment of a CHO platform for monoclonal antibody production ..... 102 
IV.1.1  Generation of two polycistronic vector systems for high-level antibody 
production ....................................................................................................... 103 
IV.1.1.1  Arrangement of expression cassettes .................................................................... 105 
IV.1.1.2  Comparison of the tricistronic and the bicistronic tandem vector system ............ 107 
IV.1.1.2.1  Different, optimal MTX concentration for both vector systems .................. 107 
IV.1.1.2.2  The influence of MTX on cell growth and the formation of resistant        
                      clones………………..……………………………………………………...110 
IV.1.1.2.3  The impact of HC:LC ratio on the IgG production level ............................. 111 
IV.1.1.3  Functional comparison of H10 derived from both vector system ......................... 114 
IV.1.2  Testing of different production conditions ..................................................... 115 
IV.1.2.1  Testing of serum-free CHO cultivation media ...................................................... 115 
IV.1.2.2  Long-term cultivation in the presence and absence of MTX ................................ 116 
IV.1.2.3  Testing of different cultivation vessels ................................................................. 119 
IV.1.3  Establishment of a high level IgG producing cell culture .............................. 120 
IV.2  Production and analysis of two H10 glycoforms in CHO cells .................... 123 
IV.2.1  Production and purification of H10 bearing a complex and a bisected  
N-glycan structure .......................................................................................... 124 
IV.2.1.1  Establishment of an H10_CHO_GnTIII producing cell line ................................ 124 
IV.2.1.2  Production and purification of H10_CHO_WT and H10_CHO_GnTIII ............. 125 
IV.2.2  H10 binding to CEA ....................................................................................... 126 
IV.2.2.1  Binding characteristic of H10 to recombinant CEANA3 and CEA-positive cells 126 
IV.2.2.2  Specific binding to CEA-positive tissue ............................................................... 128 
IV.2.3  H10 mediated induction of ADCC ................................................................. 130 
Table of contents   
V  Outlook ...................................................................................................... 133 
VI  Summary ................................................................................................... 137 
VII Attachment ................................................................................................ 139 
VII.1  Vector maps .................................................................................................. 139 
VII.2  List of oligonucleotides ................................................................................. 141 
VII.3  List of abbreviation ....................................................................................... 143 
VII.4  List of figures ................................................................................................ 145 
VII.5  List of tables .................................................................................................. 147 
VII.6  Literature ....................................................................................................... 148 
I Introduction  1 
I Introduction 
I.1 Recombinant protein production in Chinese hamster ovary (CHO) 
cells 
As reported in 2009, there are approximately 165 recombinant pharmaceuticals currently 
approved for human use. Furthermore, another 500 protein candidates are in preclinical and 
clinical development, whereas 70% of them are glycoproteins (Durocher and Butler 2009). At 
the present time, the production of complex glycoproteins, like monoclonal antibodies (mAb), 
takes place preferably in eucaryotic expression systems, because of their ability to carry out 
posttranslational modifications. These modifications are in particular important for the 
pharmacokinetic property of therapeutic proteins, as well as their solubility, stability against 
proteolysis, biological activity and residence time in humans (Jayapal et al. 2007). Important 
post-translational modifications are for example glycosylation, phosphorylation on tyrosine, 
serine and threonine residues or the addition of fatty acid chains (Geisse et al. 1996). Even 
though there is a wide range of different eukaryotic production hosts nowadays available, like 
plants (Bortesi et al. 2009), yeast (Stockmann et al. 2009) and insect cells (Hitchman et al. 
2010), mammalian production systems still remain the most widely spread host for 
pharmaceutical protein production. Commonly used, recombinant, mammalian production 
cell lines are for example human embryonic kidney 293 cells (HEK293), baby hamster kidney 
cells (BHK21) and mouse myeloma cells (NS0, SP2/0). Approximately 60-70% of 
recombinant glycoproteins, however, are currently produced with Chinese hamster ovary cells 
(CHO) (Wurm 2004, Cacciatore et al. 2010). Over time, this production host has been 
established as a standard in the biopharmaceutical industry for several reasons:  
First of all, this cell line poses a low risk for the transmission of the main 44 human 
viruses, including HIV, influenza, polio, herpes and measles (Wiebe 1989). This property 
combined with its ability to be cultivated in serum-free, chemically defined production media, 
makes CHO cells a quite safe organism for pharmaceutical proteins, with a low risk of 
humanpathogenic contamination (Jacobs and Callewaert 2009).  
Another aspect of biosafety is the ability of CHO cells to modify its protein products 
with glycosylation patterns similar to those found in humans. This property is in particular 
important, because a non-human glycosylation pattern on recombinant, therapeutic 
glycoproteins might induce immunogenicity and allergic reactions after administration in 
human (Bardor et al. 2003, Westphal et al. 2003). Compared to other expression systems, like 
insect cells, yeast and plants, CHO cells are more capable of producing proteins with 
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glycoforms that are both compatible and bioactive in humans (Jacobs and Callewaert 2009). 
However, there are still ongoing efforts in CHO cell glycoengineering, which seek to generate 
recombinant proteins with an even more human-like glycan structures and enhanced 
biopharmaceutical properties (Jefferis 2009b). 
Moreover, the CHO cell line exhibits an unstable genome, making it a suitable 
candidate for gene amplificaction and other genetic manipulations which enable further 
improvement of the target protein yield. In addition, its transfection procedure and the 
subsequent generation of cells with stably integrated expression vectors is a relatively easy 
and time saving process (Cacciatore et al. 2010). 
Another argument for choosing CHO cells as a production host is that they are quite 
adaptable to grow as single cell suspension, preferably in serum-free media, with a high 
proliferation rate, while being robust against the impacts of industrial handling, like pumping, 
pressure, pH, temperature, oxygen level variations, etc. (Wurm 2007). These features, as well 
as their ability of being cultivated in high cell densities of routinely more than 3*106 cells/ml, 
makes them attractive for recombinant protein production in large scale stirred-tank 
bioreactors of up to 20,000 L (Werner et al. 2007, Wurm 2004, Jayapal et al. 2007).  
Last but not least, CHO cells represent a well characterised production organism, 
whose cultivation as well as its production properties has been improved over years and 
production levels of 1-5 g/L recombinant proteins with specific productivities of 
20-90 pg/cell/day are currently realised in industrial processes (Wurm 2004, Lindgren et al. 
2009).  
I.1.1 Chinese hamster ovary cells 
Currently a variety of CHO cells are being used for recombinant protein production. The most 
popular ones, however, are CHO-S (Baumann et al. 2010), CHO-K1 (Du et al. 2010), CHO-
DUKX  (Carrick et al. 2008) and CHO-DG44 (Lee et al. 2010). In 1957 the initial CHO strain 
was established as an immortalised cell from a primary culture of ovarian cells from a 
Chinese hamster (Cricetulus griseus) (Puck et al. 1958). From this initial cell line, a glycine-
dependent strain (CHO-K1) was generated and subsequently mutagenised to the CHO variant 
CHO-DXB11 (also referred to as CHO-DUKX or CHO-DUK-XB11) (Urlaub and Chasin 
1980). This cell line exhibits a deletion of one dihydrofolate reductase (dhfr) allele and a 
missense mutation in the other. Three years later, the proline-dependent CHO-pro3-strain, 
another derivative of the original CHO cell line, was mutagenised to yield CHO-DG44, a cell 
line with deletion of both dhfr alleles (Urlaub et al. 1983).  
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DHFR catalyses the reduction of folic acid to tetrahydrofolate and is necessary for 
biosynthetic pathways that produce glycine, purines, and thymidylic acid. Therefore, DHFR-
deficient, auxotrophic cell lines, like CHO-DHB11 and CHO-DG44, require glycine as well 
as the purine precursors hypoxanthine and thymidine (HT) for growth. Due to this 
auxotrophic need, DHFR represents a suitable selection marker for recombinant protein 
expression. DHFR-deficient CHO cells, which had been transfected with a dhfr gene 
containing plasmid, are able to exhibit cell growth in HT-depleted cultivation medium as soon 
as the vector is stably integrated into their genome (Cacciatore et al. 2010). By the co-
transfection of the gene of interest (GOI) on the same vector, the surviving cell pool is 
capable of producing the target protein in parallel. Since the genomic integration of the 
plasmid is a random process in mammalian cells, each transfected cell exhibits different 
expression levels which are dependent on the surrounding sequence into which the vector and 
its GOI has been integrated.  
I.1.2 MTX-mediated gene amplification 
A frequently used method to increase product expression levels is the gene amplification of 
the GOI. The whole process of gene amplification not yet fully understood, but it is known 
that it is induced by chromosome breaks followed by chromosome duplication (Omasa 2002). 
There are several gene amplification strategies nowadays available. The most popular one in 
the pharmaceutical industry, however, remains the DHFR-system, which is induced by 
methotrexate (MTX) (Cacciatore et al. 2010). For this, a DHFR-deficient CHO cell line is 
required, whereas the DG44 variant mainly represents the cell line of choice (Wurm 2007). 
MTX is a folic acid antagonist that is actively transported into cells by a folate transporter. 
Inside the cell it is converted to a high molecular weight polyglutamate metabolite by 
folylpolyglutamate synthase, which binds to DHFR and inhibits its activity.  
If MTX is present in the medium, cells compensate its inhibitory effect by increasing 
the dhfr gene copy number in the genome which results in turn in elevated DHFR protein 
levels (Nunberg et al. 1978). As the average amplification unit is much larger (100 –
 3,000 kilobases (kb)) than the size of the dhfr gene, the GOI, located in the same expression 
vector as the dhfr gene or adjacent regions in the host chromosomal DNA, are co-amplified 
(Kaufman 1990). This amplification in turn leads to an increased production level of the target 
protein (Chusainow et al. 2009). However, the majority of cells, which have not undergone 
gene amplification, are unable to survive the inhitory action of MTX. By this, only high 
productive cell lines are generated whose production can even be more elevated via gradually 
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increasing selection pressure. The result is a heterogenous pool of cells with varying 
integration sites and increased gene copy numbers of the GOI and the dhfr gene (Chusainow 
et al. 2009). Kingston et al. 2002 described that empirically, the presence of 0.005 µM MTX 
requires approximately four times more DHFR protein to be synthesised in the cell compared 
to cells cultivated in HT-supplemented medium in the absence of MTX. The gene of interest 
can be further amplified by up to 2000 copies, whereas the copy number of the amplified gene 
is dependent on the strength of promoter activity, the characteristics of the gene, the selection 
conditions, the host cell line and other environmental factors (Omasa 2002). Furthermore, 
Jiang et al. 2006 stated that the MTX-mediated recombinant mAb overexpression results from 
both an increase in the gene copy number and more efficient transcription of each gene copy, 
which favors a highly transcriptional active integration locus for the GOI and its 5’-3’ 
flanking regolatory gene sequences.  
I.1.3 Generation of a monoclonal production cell line 
Polyclonal cell populations are quite instable regarding protein production levels because high 
producing clones, which often exhibit lower growth rates compared to low producers, are 
overgrown by low producing clones with increasing cultivation time (Imanaka and Aiba 
1981, Cacciatore et al. 2010). In order to maintain a relatively constant production level and 
in order to increase the product yield, it is useful to isolate high producing, monoclonal cell 
lines which are stable.  
There are two main strategies for the generation of gene amplified, high producing 
monoclonal cell lines. The first strategy (pool strategy) involves several rounds of gene 
amplification with the whole transfected pool of cells, followed by limiting dilution (LD). The 
resulting monoclonal cell lines are subsequently screened for increased production levels 
(Jiang et al. 2006). The second strategy (individual clone strategy) involves the performance 
of an early LD, two weeks after transfection. Subsequent screening leads to the identification 
of high producers followed by gene amplification of the GOI using via gradually increasing, 
MTX-mediated selection pressure. Finally, a second LD is performed to isolate high 
producers from the resulting, genomic amplified pool (Chusainow et al. 2009). Even though 
the 2nd strategy promises higher productivities of the monoclonal cell lines, the first strategy is 
more widely used, since it is more time saving compared to the 2nd strategy, which requires 
two rounds of LD (Jun et al. 2005). 
 
I Introduction  5 
I.2 Biopharmaceutical monoclonal antibodies  
More than 20 recombinant, monoclonal antibodies (rMAb) are currently licensed for the 
treatment of a variety of cancers and chronic diseases (Jefferis 2009b). Therapeutic antibodies 
exhibit a range of different pharmaceutical properties. They can be used to neutralise soluble 
molecules like cytokines in chronic disease, toxins in infections or virus particles. 
Furthermore, they can function as an agonist or antagonist of cellular activity or as an inducer 
of apoptosis. Moreover, their conjugation to a chemotherapeutic drug, a catalytic toxin, a 
radioisotope or an enzyme characterises them as immunofusions. Finally, recombinant mAbs 
can induce the specific killing of cells, like cancer cells or bacteria (Gerber et al. 2009, 
Cacciatore et al. 2010). 
In total, there are five classes of human antibodies defined (Immungloblin, Ig): IgM, 
IgG, IgA, IgD and IgE. Within IgG (IgG1, IgG2, IgG3, IgG4) and IgA (IgA1, IgA2) four and 
two subclasses are designated, respectively. Considering that IgG antibodies predominates 
quantitatively in blood and extra vasculare space and since they are relatively easy to purify 
from whole serum, they have been the subject of structural and functional studies over 
decades (Jefferis 2009b). This might be one reason why all currently licensed recombinant 
mAbs are of the IgG class, in particular of the IgG1 subclass. In oncology for example the 
IgG1 subclass has been the isotype of choice as it has maximal potential to eliminate targeted 
cancer cells by inducing antibody-dependent cellular cytotoxicity (ADCC) and/or 
complement-dependent cytotoxicity (CDC). Several therapeutic mAbs are capable of ADCC, 
such as anti-CD20 rituximab (Rituxan) and anti-Her2 trastuzumab (Herceptin) (Cartron et al. 
2002, Musolino et al. 2008). CDC is also considered a possible anti-tumor mechanism of 
rituximab and anti-CD52 alemtuzumab (Campath-1H) (Idusogie et al. 2000, Crowe et al. 
1992). 
I.2.1 Glycostructure dependent effector function  
The Fc region of IgG (IgG-Fc) is a homodimer comprising covalent inter-heavy chain (HC) 
disulfide bonded hinge regions and non-covalently paired constant domains three of the HC 
(CH3). The constant domain two of the HC (CH2), however, are not paired. Moreover, the 
exposed hydrophobic surface is overlayed by oligosaccharide moieties covalently attached at 
asparagine at amino acid position 297 (Asn297) (Jefferis 2007). The normal, polyclonal, 
human IgG-Fc exhibis an N-glycan structure of a core fucosylated complex biantennary type 
with heterogeneity due to additional sialylation and galactosylation. Moreover, there is a 
minor amount of nonfucosylated glycans with or without bisecting N-acetylglucosamine (Gn) 
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residue in human IgG. Furthermore, small amounts of high mannose (Man) and hybrid 
structures may also occur (Raju et al. 2000, Mizuochi et al. 1982, Hamako et al. 1993). This 
heterogeneity in terminal sugars creates a variety of more than 30 different human glycoforms 
(Natsume et al. 2009). Glycosylation is highly dependent on the production system. The 
glycosylation pattern of IgG-Fc produced in CHO and NS0 cells, which represent the current 
gold-standard for the production of therapeutic antibodies, exhibit a slightly different glycan 
pattern compared to those found in humans. The glycoforms of CHO produced IgGs for 
example lack the third Gn bisecting arm, which represent around 10% of human IgGs 
glycoforms. In addition, it exhibits very low amounts of <5% of terminal sialic acid compared 
to 10%  found in humans (Kobata 2000, Raju 2008). Murine NS0 cells produced IgGs show 
more differences. They contain small amounts of N-glycan structures with additional 
galactose and two different forms of sialic acids: N-glycolylneuraminic acid (NGNA) and 
Neuraminic acid (NANA). NGNA is the predominant sialic acid present in glycoproteins 
produced by mouse cells and only in traces when derived from CHO cells (Chenu et al. 
2003). NGNA is reported as immunogenic in human since this oligosaccharide can not be 
formed in humans (Ghaderi et al. 2010). The possible oligosaccharide structures of human, 
hamster (CHO) and murine (NS0) IgG-Fc are shown in Figure I-1. 
 
Figure I-1: Possible oligosaccharide structures attached to human, hamster (CHO) and murine (NS0) 
IgG-Fc at Asn297. Asn297 = asparagine at amino acid position 297; Xxx = any amino acid except prolin; 
Thr = threonine (modified from Beck et al. 2008). (Beck et al. 2008) 
 
Although accounting for only 2-3% of the antibody mass, glycosylation of the IgG-Fc is 
essential for the activation of effector functions. Interaction sites for the Fc-receptors FcγRI, 
Human 
-Asn297-Xxx-Thr-
CHO 
-Asn297-Xxx-Thr-
NS0
-Asn297-Xxx-Thr-
N-acetylglucosamine (Gn)
Fucose (Fuc)
Mannose (Man)
Galactose (Gal)
Sialic acid
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FcγRII, FcγRIII as well as C1q, a component of the complement system, have been mapped 
to the lower hinge region of the IgG-Fc domain and its binding requires a specific protein 
conformation which is mediated by IgG-Fc glycosylation (Jefferis 2007, Jefferis 2009a, 
Yamaguchi et al. 2006). The two major mechanisms induced by N-glycosylated IgG-Fc 
leading to death of the target cell, e.g. a cancer or bacterial cell, are CDC and ADCC. In 
general, the order of potency are IgG3≥IgG1>>IgG2=IgG4 for CDC and 
IgG1≥IgG3>>IgG4≥IgG2 for ADCC (Natsume et al. 2009). 
CDC is mediated by specific IgG binding to the target cell and the activation of the 
component system cascade which eventually leads to cell death (Wang and Weiner 2008, 
Jefferis 2009b). The main focus in this thesis, however, layed on antibody-mediated ADCC 
induction. Target cell opsonisation, mediated by specific surface antigen binding, induces the 
attachment of cytotoxic effector cells, like natural killer cells (NK) and macrophages, via their 
FcγRIIIa (CD16a). Consequently, the target cell is lysed by the release of cytotoxic granules, 
like granzymes and perforins, which eventually lead to cell death by triggering apoptosis. The 
level to which a cell is opsonised by the binding of antibody as well as the NK-cell-mediated 
killing is dependent, in part, on the affinity of the antibody and the number of antigens 
expressed on the target cell’s plasma membrane (Jefferis 2009b). 
I.2.2 Glyco-modification of Fc linked oligosaccharides  
Currently licensed therapeutic, recombinant mAbs are mainly produced in CHO, NS0 or 
Sp2/0, and therefore predominantly comprise core fucosylated N-glycan structures. These cell 
lines do not express the β1-4-N-acetylglucosaminyltransferase III (GnTIII) that adds a 
bisecting Gn sugar residue. Although these antibodies are functionally active, it has been 
shown that effector activities can be modulated by manipulation of antibody glycoform 
through protein and /or cell engineering (Umana et al. 1999b, Ferrara et al. 2006a). In 
general, it is known that terminal galactose (Gal), Gn, and Man residues affect C1q binding 
and in turn CDC activity. Furthermore, terminal sialic acid, Man, fucose (Fuc) and bisecting 
Gn affect FcγRIIIa binding and ADCC (Raju 2008) (Table I-1).  
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Table I-1: Effect of oligosaccharides on CDC and ADCC if its presence on IgG N-glycans is increased. 
Terminal oligosaccharides  CDC  ADCC Reference 
Galactose ↑ - (Hodoniczky et al. 2005) 
Mannose ↓ ↑ (Zhou et al. 2008) 
Fucose - ↓ (Shields et al. 2002, Natsume et al. 2009) 
Sialic acid n.k. ↓ (Scallon et al. 2007) 
N-acetylglucosamine - - (Hodoniczky et al. 2005) 
Bisecting  N-acetylglucosamine n.k. ↑ (Umana et al. 1999b) 
↑ = increase; ↓ = decrease; -  = no effect; n.k. = not known 
 
Some of the stated effects of terminal oligosaccharides in Table I-1 are controversial, because 
a reduction of one terminal oligosaccharide often comes along with another one (Shinkawa et 
al. 2003, Raju 2008). In general, however, the strongest ADCC in a comparison of different 
glycoforms is induced by IgG1 bearing the biantennary-complex type of Fc-linked 
oligosaccharides lacking core fucosylation (Kanda et al. 2007). In human, Fc-linked 
oligosaccharides bearing this glycan structure exist as portion of naturally occurring 
heterogeneities, and therefore there is little concern regarding its intrinsic immunogenicity 
(Mizuochi et al. 1982, Natsume et al. 2009). 
By cotransfection of IgG1 producing CHO cell lines with GnTIII, for example, it was 
demonstrated that besides the addition of bisecting Gn to the oligosaccharide, the addition of 
fucose was inhibited (Umana et al. 1999b, Davies et al. 2001, Schuster et al. 2005, Ferrara et 
al. 2006a). An alternative strategy was the knock out of the alpha-1-6 fucosyl transferase 
leading to afucosylated glycoforms (Mori et al. 2007, Shinkawa et al. 2003). The absence of 
core Fuc residues in the Fc glycans increases the ADCC activity of IgG as nonfucosylated 
antibodies are bound by the FcγRIIIa receptor with significantly increased affinity (Shields et 
al. 2002). A number of recombinant IgGs, containing no or significantly reduced core fucose, 
are currently in clinical trials for the development as human therapeutics (Satoh et al. 2006, 
Imai-Nishiya et al. 2007). 
I.2.3 The carcinoembryonic antigen (CEA) as a tumor marker 
The carcionoembryonic antigen (CEA) was discovered by Gold and Freedman in 1965 in 
adenocarcinomas of the human gastrointestinal tract and in the fetal digestive system (Gold 
and Freedman 1965a, Gold and Freedman 1965b). Currently it is known that CEA is also 
expressed in other tissues like lung, breast, ovary, pancreas and stomach (Hammarstrom 
1999). The highly glycosylated macromolecule with approximal 50% carbohydrate content 
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and a molecular weight of approximately 200 kDa is part of the CEA-related cell adhesion 
molecule (CEACAM) family and is also referred to as CEACAM5 or CD66a. It is attached to 
the cell membrane via a glycosyl phosphatidyl inositol (GPI) anchor and consists of three A, 
three B and one N domain with the domain formula N-A1-B1-A2-B2-A3-B3-GPI 
(Hammarstrom 1999, Kuespert et al. 2006) (Figure I-3). In the colon, CEA is exclusively 
produced by epithelial and goblet cells (Gold and Freedman 1965b, Hammarstrom 1999). 
There it is mainly found in the glycocalyx at the top of microvilli and is released from the cell 
via CEA-coated vesicules (Hammarstrom 1999). 
Like other members of the CEACAM family, CEA is involved in cell-cell recognition 
and modulates cellular processes like the shaping of tissue architecture (Kuespert et al. 2006). 
In particular the N-domain of CEA is involved in cell adhesion processes (Taheri et al. 2000). 
Additionally, CEA plays a role in the innate immunity. In colon, it has been shown that 
microorganisms are bound to CEA and are released from the body together with CEA and the 
goblet cells produced muscus through the digestive tract (Virji et al. 1996, Bos et al. 1997, 
Hammarstrom 1999). 
 The normal, polarised expression of CEA in the epithelial and goblet cell in 
coloncarcinoma tissue is changed (Figure I-2 A). The epithelial cells, facing ‘blind’ tumor 
gland lumens, however, still release CEA in a polarised manner, but neoplastic cells located 
deep inside tumor glands are unpolarised and express CEA on the whole cell surface. As a 
result, secreted CEA can access the blood- or lymphatic vessels through the intercellular 
space (Figure I-2 B) (Hammarstrom 1999). Therefore, elevated CEA levels are found in the 
sera of patients with colorectal, pancreatic, gastric, breast and lung cancer (Benchimol et al. 
1989, Seregni et al. 1992). In addition, the content of CEA in the normal mucosa from cancer 
patients is statistically higher than that found in healthy donors (Guadagni et al. 1997). The 
degree of CEA expression is related to the state of differentiation of the normal or cancerous 
cell, whereas highly differentiated cells expressing the highest levels (Hammarstrom 1999). 
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Figure I-2: CEA excretion in normal colon and colon cancer. In the normal colon mucosa, CEA is 
exclusively expressed in the apical surface of epithelial and goblet cells. Since its expression takes place only on 
the apical surface and since it is released into the colon lumen, it has no access to blood capillaries (A). In 
coloncarcinoma tissue, the epithelial cells are as well partly polarised and release CEA into the tumor gland 
lumens. Neoplastic cells located deep inside tumor glands are, in contast to this, unpolarised. They express CEA 
on the whole cell surface resulting in CEA which has access to blood-or lymphatic vessels through the 
intercellular space (B). (Modified from Kuroki et al. 2004) (Kuroki et al. 2004) 
 
CEA can be detected in almost all human coloncarcinomas, 50% of breast cancers as well as 
in other adenocarcinomas. This widely spread occurrence and up-regulation in carcinoma 
tissue as well as its elevated secretion into the blood and its non-polarised expression pattern, 
makes CEA a suitable tumor marker for cancer prevention, tumor detection and therapy 
(Hammarstrom 1999). Besides several approaches for the clinical development of a CEA-
based vaccine against CEA-positive tumors (Wang et al. 2008), there is already the murine, 
radioactively labled anti-CEA Fab-fragment Arcitumomab (CEA-Scan®, Immunomedics) on 
the market, which specifically localises and identifies cancerous lesions. For the targeted 
therapy of CEA-positive cancer mAbs represent a very promising tool to specifically detect 
neoplastic cells which are in turn destroyed by mechanisms like ADCC and CDC. Even 
though CEA is expressed in normal tissue, it is inaccessible to IgG antibodies, since it is 
localised on the luminal surface of the cell. In neoplastic cells, however, it is additionally 
expressed on the basal and lateral cell membrane and can be reached by therapeutic IgGs 
where they can take action (Hammarstrom 1999). 
I.2.4 Anti-CEA antibodies 
Currently there is no therapeutic anti-CEA antibody on the market. Though, there are several 
recombinant mAbs published which specifically target CEA. The most popular ones are 
T84.66, MN-14 and PR1A3, which are all CEA specific and do not cross react with other 
colon lumen
Blood 
capillaries Blood 
capillaries
tumor gland lumen
Normal colon mucosa Coloncarcinoma
Muscularis 
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A  B 
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members of the CEA family, in particular with the non-specific cross reacting antigen (NCA) 
(Esteban et al. 1993, Blumenthal et al. 2007, Ashraf et al. 2009). All three anti-CEA 
antibodies already went into clinical trials and are currently tested for their suitabililty as a 
potential therapeutic (Wong et al. 2006, Li et al. 2008, Liersch et al. 2005, Zbar et al. 2005). 
The chimeric mAb T84.66, which specifically binds an epitope on the A3 domain of CEA 
(Hefta et al. 1998) (Figure I-3) is radioactively labeled and specifically destroys CEA-positive 
tumor cells via local radiation of target cells (Wong et al. 2006, Li et al. 2008). Another anti-
CEA antibody represents the human mAb MN-14, also referred as hMN-14 or labetuzumab, 
which binds to the A3B3 domain of CEA (Figure I-3), and has the capacity to induce ADCC 
and CDC (Blumenthal et al. 2005b). Last but not least, there is the humanised mAb PR1A3, 
which is specific for the B3 domain of CEA (Figure I-3) and induces target cell killing via 
ADCC. Due to its membrane proximate epitope it is able to detect membrane bound CEA 
only and not to those forms secreted in the blood (Conaghan et al. 2008). Glycoengineering of 
this antibody by the addition of a bisecting Gn recently lead to a 10-fold increase in ADCC 
(Ashraf et al. 2009). 
In 2000 the anti-CEA single chain variable fragment (scFv) H10 was published. It had 
been generated via phage display using a human library and was initially produced in E. coli 
(Cloutier et al. 2000). Seven years later Hombach et al. 2007 showed that the scFvH10 
specifically binds an epitope of the CEA N-domain (Hombach et al. 2007) (Figure I-3). 
Finally, within the same year a completely human full-size IgG1 version of H10 was 
generated at the Fraunhofer IME (Thomas Rademacher, Holger Spiegel) by the assembly of 
synthetically produced human sequences.       
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Figure I-3: Schematic diagram showing the binding site of H10, T84.66, PR1A3 and MN-14 on CEA. H10 
recognises an epitope on the N-domain of CEA whereas T84.66, PR1A3 and MN-14 bind nearby the cell 
membrane to the A3, B3 and A3B3 domains, respectively (Hombach et al. 2007, Hefta et al. 1998, Conaghan et 
al. 2008, Ma et al. 2004, Blumenthal et al. 2005b). (Modified from Conaghan et al. 2008). 
 
Like other therapeutic proteins, antibodies can be immunogenic as a result of their murine 
background or their non-human glycan structure. Their administration into humans may result 
in an anti-antibody response and eventually in an anaphylactic shock. In addition, anti-
antibody response can influence their pharmacokinetics, or reduce the efficacy of the injected 
antibody through neutralisation (Ruuls et al. 2008). In contrast to the mAbs T84.66, PR1A3 
and MN-14, H10 is completely human and its expression in a mammalian expression system 
might, theoretically, even reduce its immunogenicity in humans due to the attachment of a 
human or human-similar N-glycan structure. 
I.3 Aim of the PhD thesis 
As mentioned before (I.1.1), CHO cells represent the currently most widely spread, 
recombinant production system for industrial glycoproteins, including therapeutic, 
recombinant mAbs (Cacciatore et al. 2010). With the intention to produce the human, full-
size IgG1 H10 (I.2.4) in this production host at maximum leels, a suitable CHO-based 
production system had to be established within this thesis. Furthermore, this anti-CEA 
antibody should be produced and characterised as well as a glycoengineered version, bearing 
a bisected N-glycan structure, which is more similar to those found in humans and supposed 
to exhibit the potential of a more efficient ADCC mediated target cell killing (Ashraf et al. 
2009). Finally, the two different H10 glycovariants ought to be analysed regarding their 
PR1A3
T84.66
MN-14
H10
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functional binding to CEA and their ADCC induction properties. For these purposes, the PhD 
thesis was structured in two parts (Figure I-4): 
 
1. Establishment of a CHO platform for high level mAb production: 
In this first part two suitable vector systems were generated and tested with the human 
H10 IgG as a model protein. Different aspects, like the choice of a suitable selection 
system and vector backbone as well as the assembly of the required expression 
cassettes for efficient IgG expression, were considered. Once suitable vector systems 
were generated, their efficiency for high level IgG production were investigated and 
further improved by MTX-mediated gene amplification of the target gene. In this 
context, different amplification strategies and a variety of cultivation conditions 
should be tested. Finally, monoclonal CHO lines were generated to maximise H10 
production levels. 
 
2. Production and analysis of two H10 glycoforms in CHO cells: 
A monoclonal, high level H10 producing CHO cell line which had been established in 
the first part of this thesis was used in this second part to produce H10 with a CHO 
specific complex N-glycan structure (H10_CHO_WT). Furthermore, this monoclonal 
cell line was led to glycoengineering by the coexpression of β1-4-N-
acetylglucosaminyltransferase III (GnTIII) in order to produce H10 bearing a bisected 
N-glycan structure (H10_CHO_GnTIII). 150 mg of both H10 glycovariants were 
produced and purified to obtain sufficient material for subsequent functional analysis. 
In a next step the specific H10 binding to the CEA antigen was detected on 
recombinant CEANA3, whole cell lysate as well as on intact cells and on human 
tissue. Since H10 is known to bind an epitope of the CEA N-domain (Hombach et al. 
2007), its cross-reactivity to NCA, whose N-domain is to approx. 80% identical to 
those of CEA, was analysed in addition (Nasu et al. 1999). Furthermore both H10 
versions were compared regarding their FcγR binding capacity as well as their 
efficiency to induce ADCC.  
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Figure I-4: Schematic diagram showing the structure of this PhD thesis. HC = heavy chain; LC = light 
chain; H10_CHO_WT = H10 with a CHO specific, complex N-glycan structure; H10_CHO_GnTIII = H10 with 
a bisected N-glycan structure. 
Vector design and cloning of two polycistronic vectors
(pAPI:H10 and pAPT:H10)
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Vector system comparison regarding…
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Cell growth and H10 production level
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II Material and methods  
II.1 Material 
II.1.1 Chemicals and consumables  
Unless otherwise stated, laboratory chemicals were purchased from BioRad (Munich), 
Fermentas (St. Leon-Rot), Gibco BRL (Eggstein), Invitrogen (Leek, Netherlands), Medac 
(Wedel), New England Biolabs (NEB) (Frankfurt am Main), Pierce (Bonn), Promega 
(Mannheim), Roche Molecular Biochemicals (Mannheim), Roth (Karlsruhe), Sigma 
(Deisenhofen), Thermo Fisher Scientific (Schwerte), Vector laboratories (Burlingame, USA). 
 
Consumable were purchased from:  
Amersham Biosciences (Munich), Becton Dickinson Bioscience (Heidelberg), Corning 
(Kaiserslautern), Eppendorf (Hamburg), GE Healthcare (Freiburg), Greiner (Solingen), 
Millipore (Eschborn), Nunc (Langenselbold), Partec (Münster), Roth, TPP (Trasadingen, 
Switzerland), Whatman (Bender & Hobein, Bruchsal). 
 
Cell culture media and additives were purchased from: 
Lonza (Basel, Switzerland), Pan Biotech (Aidenbach), Gibco BRL, Invitrogen (Leek). 
 
II.1.2 Enzymes and reaction kits  
Enzymes for restriction, ligation and dephosphorylation including required buffers and bovine 
serum albumin (BSA) were purchased from NEB. Unless otherwise stated all enzymes were 
used according to manufacturers instruction. Table II-1 lists the used reaction kits. 
 
Table II-1: Used reaction kits.  
Purpose Kit 
DNA gelextraction and PCR purifcation  NucleoSpin ExtractII (Macherey Nagel, Düren) 
Eucaryotic electrotransfection Cell Line Nucleofector Kit V (Lonza, Cologne) 
Genomic DNA extraction Nucleospin Tissue (Macherey Nagel) 
IgG labeling with DyLight549  DyLight549 Antibody Labeling Kit (Pierce, Bonn) 
NK isolation NK isolation kit (Miltenyi Biotec) 
PCR reaction Expand High Fidelity PCR System (Roche, Mannheim) 
Plasmid DNA extraction NucleoSpin Plasmid kit (Macherey Nagel) 
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II.1.3 Antibodies, ligands and antigens  
For immunological detection and analysis the following (Table II-2) recombinant antibodies 
and antigens were used: 
 
Table II-2: Used antibodies, ligands and antigens. 
Antibody Abbreviation Epitope Concentration Clonality Manufacturer 
      
Goat anti-human 
Fc-specific 
GAHFc Fc fragment 
of human HC 
0.4 mg/ml Poly. Jackson 
Immunoresearch 
(Hamburg) 
      
Goat anti-human 
Fc-specific ,  
AP conjugated 
GAHFcAP Fc fragment 
of human HC 
1.0 mg/ml Poly. Jackson 
Immunoresearch 
      
Goat anti-human 
lamda light chain,  
AP conjugated 
GAHλLCAP Human lamda 
LC  
0.2 mg/ml Poly. Sigma Aldrich  
      
Goat anti-human,  
FITC conjugated 
GAH(H+L)FITC HC and LC 1.5 mg/ml Poly. Jackson 
Immunoresearch 
      
Human 2G12;  
Produced in CHO 
cells 
2G12 gp120 0.012 mg/ml Mono. Polymun (Wien) 
      
Chimeric cPIPP; 
Produced in 
tobacco 
cPIPP hCG 
 
0.6 mg/ml Mono. Alexander Boes, 
Fraunhofer IME 
      
Ligand/Antigen Abbreviation Description Concentration Clonality Manufacturer 
      
Streptavidin,  
Cy3 conjugated 
StrepCy3 Binds to 
biotin 
1 mg/ml - Invitrogen 
      
CEANA3; 
Produced in 
DG44 cells 
CEANA3 Consists of 
the N and A3 
domain of 
human CEA 
5 mg/ml - Pascal Thom, 
Fraunhofer IME, 
Aachen 
      
High affinity 
vaiant human  
FcγRIIIa  
[Val-158];  
Produced in NS0 
cells 
FcγRIIIa Binds to 
human IgG 
0.1 mg/ml - R&D Systems 
(Wiesbaden-
Nordenstadt) 
      
HC = antibody heavy chain; LC = antibody light chain; Fc = crystallisable fragment of HC; AP = alkaline 
phosphatase; FITC = fluorescin isothiocyanate; gp120 = glycoprotein of human immunodeficiency virus type 1; 
hCG = human chorionic gonadotrophin; Cy3 = cyanine 3; Poly. = polyclonal; Mono. = monoclonal; 
FcγRIIIa = Fc gamma receptor IIIa, CD16a; Val-158 = valine at position 158. 
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II.1.4 Substrates  
Alkaline phosphatase (AP) substrate for the detection of immunoblots was generated by a 2:1 
mixture of nitro-blue tetrazolium chloride (NBT) and 5-bromo-4-chloro-3’indolyphosphate 
p-toluidine salt (BCIP) from Roche (NBT: 4421.3/BCIP: 6368.2) which was stored in 
Formamide at -20°C.  For application the NBT/BCIP solution was used 1:100 in AP-buffer. 
The AP-substrate used for ELISA was para-nitro-phenylphosphat (pNpp) from Sigma Aldrich 
which was used in a concentration of 1 mg/ml in AP-buffer.  
 
Alkaline phosphatase (AP) buffer  Tris-HCl, pH 9.6 100 mM
 NaCl 100 mM
 MgCl2 x H2O 5 mM
 
II.1.5 Bacterial strain 
For cloning and isolation of plasmid DNA the Escherichia coli strain DH5α was used. 
 
Table II-3: Used E. coli strain. 
E. coli strain Reference Genotype 
   
DH5α Ausubel et al., 1994 F
- (f80d Lac2ΔM15) Δ(LacZYA-arfF) U169end A1 rec1 
hsdR17 (rk- mk-) deo R thi- supE44 gyr A96 relA1 λ- 
   
 
II.1.6 Mammalian cell lines 
For H10 expression in mammalian cells the CHO cell line DG44 (Invitrogen) was used. 
Binding of CHO produced H10 to surface CEA was demonstrated with the cell lines 
HEK293T, HEK293T-CEA_p, MCF-7 and LS174T. The recombinant cell line 
HEK293T-CEA_p was kindly provided by Univ.-Prof. Dr. Hinrich Abken and coworkers 
(University Hospital Cologne). 
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Table II-4: Used mammalian cell lines. 
Cell line Source Cell type CEA/NCA Growth Culture medium 
      
CD DG44 Invitrogen  CHO CEA-/NCA- suspension serum free 
      
HEK293T ATCC Human embryonic kidney  CEA-/NCA- adherent serum containing 
      
HEK293T-
CEA_p 
University 
Hospital 
Cologne 
HEK293T cell line 
expressing a CEA version 
which includes the A3 and 
the N domain of CEA 
CEA+/NCA- adherent serum containing 
      
LS174T ATCC Human colorectal adenocarcinoma  CEA+/NCA+ adherent 
serum 
containing 
      
MCF-7 DSMZ Human breast adenocarcinoma CEA-/NCA+ adherent 
serum 
containing 
      
+ = positive; - = negative; CEA = carcinoembryonic antigen; NCA = non-specific cross-reacting antigen 
II.1.7 Human tissue 
Human tissue which was used for immunohistochemical (IHC) staining (III.2.2.5) was kindly 
provided by Prof. Dr. med. Nikolaus Gaßler and coworkers (University Hospital Aachen, 
Pathology). It was taken from Colon sigmoideum of a 42 year old male patient and contained 
areas of colon adenocarcinoma and normal colon tunica mucosa Sigma (NG200 Histo). 
II.1.8 Plasmids  
Following plasmids were modified for recombinant protein expression: 
• pGEX-5x-3 (GE Healthcare): The pGEX-5x-3:CEANA3 shuttle vector was generated 
by the insertion of an extended multiple cloning site (MCS) and a spacer gene 
(CEANA3) into the pGEX-5x-3 vector (III.1.1.1.1). This shuttle vector was later on 
used for the cloning of the mammalian expression vectors pAPI:H10 and 
pTRACER:GnTIII (III.1.1.1.1, III.2.1.1). 
• pIRES (Clontech): This bicistronic mammalian expression vector contains an internal 
ribosome entry site (IRES) of the Encephalomyocarditis virus (EMCV). It was used 
for the cloning of the tricistronic expression cassette of pAPI:H10 (III.1.1.1.1). 
Thereby, the partly truncated IRES (IREST) inside the pIRES expression cassette was 
completed to form a full-size IRES (IRESFS) which should allow higher expression 
levels of the downstream placed gene. 
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• pOptiVEC (Invitrogen): For recombinant protein expression in dihydrofolate 
reductase deficient (DHFR-) CHO cells this mammalian expression vector enables the 
bicistronic coexpression of the gene of interest (GOI) and the DHFR gene driven by a 
human Cytomegalo virus promoter (PCMV). The transcription of the GOI is separated 
from the DHFR auxotrophic selection marker by an IRES, allowing transcription of 
the GOI and the selectable marker on the same mRNA. Furthermore, MTX-based 
gene amplification of both genes is possible in order to accelerate GOI expression.  
• pTRACERTM-SV40 (Invitrogen):  Expression of GnTIII in the golgi apparatus of 
DG44 cells took place via this vector. Here, the GOI expression is driven by the 
Simian virus 40 promoter (PSV40), which promotes weaker expression levels in CHO 
cells compared to the commonly used PCMV (Liao and Sunstrom 2006). A pTRACER 
encoded reporter protein consisting of the fusion of a green fluorescent protein (GFP) 
gene and a zeocin-resistant gene enables the selection of transfected cells via the 
antibiotic zeocin combined with GFP fluorescence screening.   
 
Plasmid maps including feature descriptions are found in the attachment (VII.1). 
II.1.9 Oligonucleotides 
All oligonucleotide sequences are listed in the attachment (VII.2). For cloning and sequencing 
of the vector constructs pGEX-5x-3:CEANA3 (III.2.1.1), pAPI:H10 (III.1.1.1.1) and 
pAPT:H10 (III.1.1.1.2) the oligonucleotides shown in Table VII-1 and Table VII-3 were used. 
Primer used for correct GnTIIIcmyc integration into the pTRACER vector backbone (II.1.8) 
are stated in Table VII-2. 
II.1.10 Solutions, media and buffers  
Standard solutions, buffer as well as media for cultivation of bacteria were prepared according 
to standard procedures using double deionized water (ddH2O) (Ausubel 1994, Coligan 1995, 
Sambrook 2001). Solutions were filter-sterilized (0.2 μm) if necessary. Recipes of solutions, 
media and buffers are listed at the end of each method and were prepared with 1 L ddH2O. 
II.1.11 Media and supplements for the cultivation and isolation of mammalian 
cells 
In Table II-5 the serum and animal-component free cultivation media used for CHO 
suspension cultivation, regeneration and target protein production are listed. 
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Table II-5: Serum and animal-component free CHO media.  
* Except small quantities of recombinant insulin; n.k. = not known; HL = hyldrolysate; CD = chemically 
defined; Glu = L-glutamine; HT = hypoxanthine and thymidin; PR = phenol red. 
 
The following media compositions and supplements were used for the cultivation, selection 
and regeneration of DG44 cells: 
 
 
 
Complete Ex-CELL CHO medium 
(50 ml): 
Ex-CELL CHO (Sigma Aldrich) 50 ml
L-glutamine (200 mM) 4 mM
 
Selective agents: 300 µg/ml zeocin (100 mg/ml stock)  
 0.05-512 µM MTX (1 mM stock in 1x PBS) 
 
MCF-7, LS174T as well as HEK293T and HEK293T-CEA cells were cultivated in the serum 
containing “R10 medium”. 
 
“R10-medium” (500 ml): RPMI-1640 + GlutaMAX™-I (Invitrogen) 500 ml
Fetal calf serum (FCS) 10% (v/v)
 β-mercaptoethanol 50  µM
 Penicillin (5000 U)/streptomycin (5 mg/ml) 100 µg/ml
 
For the isolation of mononuclear cells from blood (II.2.2.9) Histoplaque 1077 medium (Sigma 
Aldrich) via density gradient centrifugation was used. It consists of polysucrose and sodium 
diatrizoate, adjusted to a density of 1.077 g/mL. For the regeneration of isolated peripheral 
blood mononuclear cells the serum-free X-VIVO 15 medium (Lonza) was used. 
 
 
Medium Company Protein-free HL-free CD Glu HT PR Pluronic F-68
         
CD DG44  Invitrogen + + + - + - - 
CD OptiCHO Invitrogen + + + - - + + 
Panserin C6000 PanBiotech + * - - + - + + 
Ex-CELL CHO Sigma Aldrich + - - - - + - 
CD CHO Invitrogen + + + - - - - 
HyQ SFM4CHO HyClone + - n.k. - - - + 
ProCHO5 Lonza + - - - - - + 
ProCHO4 Lonza + - - - - - + 
PowerCHO2 Lonza + + + - - - + 
         
Complete DG44 medium  CD DG44 (Invitrogen) 50 ml
(50 ml): L-glutamine (200 mM) 2 mM
 Pluronic F-68 (10% (v/v)) 0.018% (v/v)
 Anti-clumping agent 50 µl
Complete OptiCHO medium 
(50 ml): 
CD OptiCHO (Invitrogen) 50 ml
L-glutamine (200 mM) 2 mM
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II.1.12 Matrices and membranes 
For affinity purification of the human IgG H10 the protein A matrix from Pall (Dreieich) was 
used. Subsequent protein dialysis took place by a dialysis membrane tube from SpectraPor 
(Breda) with a molecular weight cut off (MWCO) of 8 kDa (II.2.3.1). HybondTM-C-
Nitrocellulose membrane (0.45μm) (GE Healthcare) and Whatman No.1 paper (Whatman) 
were used for Immunoblots (II.2.4.2).  
II.1.13 Equipment 
Autoclaves Varioklav H+P 135S (H+P Labortechnik GmbH) 
Automated documentation 
of clone regeneration  
Freedom EVO Roboter (Tecan, Mainz-Kastel) 
Cellavista Analyser  (Roche Innovatis, Bielefeld) 
Balances Precision and analytic balances; Talent Series (Satorius): 
TE6101,TE64, TE31025, TE12000  
Cell counter Cell counter CASY 1 TT (Roche Innovatis) 
Cell washer Dade Serocent (Baxter) 
Centrifuges Avanti TM J25I Centrifuge (Beckman Coulter) 
Biofuge Primo R (Heraeus) 
Biofuge Pico (Heraeus Instruments, Hanau)  
Eppendorf Centrifuge 5415D und 5415R (Eppendorf) 
Multifuge 3S-R (Heraeus) 
Electrophoresis Mini-PROTEAN 3 Electrophoresis System (BioRad) 
PROTEAN xi Cell (BioRad) 
Mini Trans-Blot SD Semi-Dry Transfer Cell (BioRad) 
Power supply Power Pack H und Basic (BioRad) 
Mini Tans-Blot cell (BioRad) 
Sub-Cell System GT (BioRad)  
Electroporator Multiporator (Eppendorf) 
Electrotransfection Nucleofector II (Amaxa Biosystems) 
ELISA ELISA Reader Synergy HT (BioTek)  
ELISA Washer Elx405 (BioTek) 
Flow Cytometry FACSCalibur (Becton Dickinson, Heidelberg) 
FACSDiVa Vantage SE (Becton Dickson) 
Fume hood mc6 fume hood (Waldner, Wangen) 
Ice machine Icematic D201 (Castel Mac) 
Incubators CO2 Incubator CB Series (Binder) 
ISF1-X CO2 incubator shaker with humidity (Kühner, Basel) 
Laminar flow hood Biowizard 2 MSC  und KR-130 (Kojair, Frankfurt am Main)  
Microscope DMIL Fluorescence Microscope (Leica, Solms) 
UltraView Vox confocal microscope (PerkinElmer, Rodgau) 
DMR Fluorescent microscope with DFC320 (Leica) 
DMRE confocal microscope with ARC lamp and TCS SP multi band 
confocal imaging spectrophotometer (Leica) 
ET-DAPI (BP 350/50) and Y3 (BP 545/40) filter cubes (Leica) 
MiliQ-water supply Aquintua LS with MemTap1, 0,2μm PES (Membra-Pure, Bodenheim) 
Mass spectrometer Ultraflex mass spectrometer (Bruker, Billerica, MA) 
PCR-Thermocycler Primus 96 Plus (MWG-Biotech, Ebersberg) 
pH-Meter Basic Meter PB-11 (Satorius, Göttingen) 
Photodocumentation „Gel Doc 1000 System“ (BioRad)  
High Performance Ultraviolet Transilluminator (BioRad) 
LAS-3000 (Fujifilm, Tokyo, Japan)  
FLA-2000 (Fujifilm, Tokyo, Japan)  
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Pipetts CellMate II (Thermo Scientific Matrix, Cheshire, UK)  
Easypet (Eppendorf) 
Multichannel Pipett Research pro (Eppendorf) 
Pipettman Starter Kit (Gilson, Bad Camberg) 
Pipettman Micro-Volume Kit (Gilson) 
Protein purifcation Äkta Explorer 10 (GE Healthcare) 
Rotors JA-10 und JA25.50 (Beckman Coulter, Krefeld)  
#3324 (Heraeus Instruments, Düsseldorf) 
Sequencing machines ABI Prism 3730 Sequencer (AME Bioscience, Toroed, Norway) 
Shaker and vortex Innova TM 4430 Incubator Shaker (New Brunswick Scientific, 
Nürtingen) 
Innova TM 4000 Incubator Shaker (New Brunswick Scientific)  
Magnetic Stirrer RCT basic (IKA, Staufen) 
Multiflask-Shaker VKS75A (Edmund Bühler GmbH, Hechingen)  
Vortex-Genie 2 G-560° (Scientific Industries, New York, USA) 
Certomat MO II (Sartorius) 
Sonication Ultrasonic homogenisers Sonoplus HD 2070 with GM 2070 
generator, ultrasonic converter UW 2070, stepped standard horn SH 
70G, titan sonotrode MS73, sound-proof box LS4/6 (Bandelin 
electronic, Berlin) 
Spectrophotometer NanoDrop Fluorospectrometer ND-1000 (NanoDrop Technologies, 
Wilmington, USA) 
Surface plasmon resonance 
detector 
Biacore T100 Instrument (GE Healthcare, Freiburg) 
Biacore 2000 Instrument (GE Healthcare) 
Thermoincubator Function Line B-12 and U-12 (Heraeus Instruments) 
Thermomixer Thermomixer Comfort (Eppendorf) 
UV-Sterilization CL-1000 Ultraviolet Crosslinker (UVP, Cambridge, UK) 
Vakuumpump MZ 2C (Vakuubrand, Wertheim) 
Vakuum-Regulator (Vakuubrand) 
Waterbath TW20 waterbath (Julabo, Seelbach) 
 
II.1.14 Software 
Codon usage analysis: Graphical Codon Usage Analyser 2.0 
(http://gcua.schoedl.de/) 
Digital image documentation: Quantity One documentation software 4.6 
(BioRad) 
Digital image processing: Adobe Photoshop CS2 (Adobe)  
Evaluation of ELISA results: KC4 3.4 (BioTek) 
Evaluation of flow cytometric data: CellQuest (Becton Dickson)  
Windows Multiple Document Interface 
software WinMDI 2.9 (The Scripps Institute, 
Flow Cytometry Core Facility) 
Evaulation of surface plasmon resonance data: BIAevaluation software 3.0 (GE Healthcare, 
Uppsala, Sweden) 
BIAEval 4.0 (GE Healthcare) 
Origin 8.1 (Origin Labs, Northhampton, MA, 
USA) 
SDS-gel evaluation: Aida Image Analyzer 4.14 (Raytest) 
Sequence analysis and primer design: Clone Manager Professional Suite 8 (SciEd8) 
Chromas 14.45 (Technelysium) 
Others Microsoft Office 2007 (Microsoft) 
Windows XP and 7 (Microsoft) 
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II.2 Methods 
II.2.1 Recombinant DNA technology  
II.2.1.1 Cultivation of E. coli  
The cultivation of E. coli took place either in liquid LB or 2x YT medium (37°C, 180 rpm) or 
on agar containing medium plates at 37°C.  
 
LB liquid medium/ agar (pH 7.4) Tryptone 1% (w/v)
 Yeast extract 0.5% (w/v)
 NaCl 0.5% (w/v)
 Agar 1.5% (w/v)
 
2x YT liquid medium/agar (pH 7.4) Tryptone 1.6% (w/v)
 Yeast extract 1% (w/v)
 NaCl 0.5% (w/v)
 Agar 1.5% (w/v)
II.2.1.2 Generation of electrocompetent E. coli  
Electrocompetent E. coli DH5α cells were generated according to Dower et al.(1988). 500 ml 
medium were inoculated with 3 ml of an over night (ON) grown E. coli culture (37°C, 
180 rpm) and cultivated for 3-4 h (37°C, 180 rpm) (II.2.1.1). When an E600nm of 0.5-0.8 was 
reached, cells were chilled on ice for 15-20 min, sedimented (16,000 g, 10 min, 4°C) and 
subsequently washed three times with sterile ice cold water and eventuelly resuspended in 
10% (v/v) glycerol, aliquoted and stored at -80°C. Suitable electrocompentent E. coli batches 
exhibited a transformation efficiency of <107 µg-1 plasmid. (Dower et al. 1988). 
II.2.1.3 Electrotransformation of E. coli  
Electrocompetent cells (II.2.1) were thawed on ice and mixed with 1 pg-100 ng plasmid DNA 
(II.2.1.5, II.2.1.10). The mixture of cells and DNA were transferred to a cooled 
electroporation cuvette (0.2 cm), electroporated (2.5 kV, 5 ms), diluted with 1 ml S.O.C. 
medium and incubated for one hour (37°C, 180 rpm). Afterwards the cell suspension was 
streaked on LB-agar selection plates and incubated ON at 37°C.   
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II.2.1.4 Generation of glycerol stocks for long-term storage of E. coli strains  
Selective antibiotic containing LB-medium was inoculated with a single, recombinant E. coli 
colony cultivated on an LB-agar plate and incubated ON (37°C, 180°C). 500 µl 40% (v/v) 
glycerol solution was mixed with 500 µl ON grown culture and was immediately stored at -
80°C. 
II.2.1.5 Isolation of plasmid DNA from E. coli 
Recombinant plasmid DNA was extracted via the NucleoSpin Plasmid kit (Macherey Nagel), 
which is based on the alkalic lysis method (Sambrook 2001). Storage of DNA took place at -
20°C. Quality and yield was determined by spectrometric measurement at 260 nm and 
280 nm according to Sambrook et al. (Sambrook 2001) by using the NanoDrop spectrometer 
(II.1.13).  
II.2.1.6 Agarose gelelectrophoresis of DNA  
For size specific DNA separation and analysis of enzymaticly digested DNA or PCR-
fragments, agarose gelelectrophoresis was done according to Sambrook et al. (Sambrook 
2001). Thereby samples were mixed with DNA sample buffer and separated in a 0.8-1.2% 
(w/v) TBE agarose gel containing 25 μg/l ethidiumbromide in an electric field (120 V, 1x 
TBE running buffer). DNA bands were visualised at 302 nm using an UV transilluminator 
(II.1.13). The DNA fragment sizes could be identified by comparison of DNA bands with 
reference bands of the 1 kb molecular marker (Roth). 
 
DNA-sample buffer Bromphenolblue 0.1% (w/v)
 Xylencyanol 0.1% (w/v)
 Glycerol 50% (w/v)
 1x TBE, pH 8.3 ad 50 ml
 
10x Tris-borate-EDTA (TBE)-  EDTA 100 mM
buffer (pH 7.5) Tris  2 M
 Acedic acid 1 M
 
TBE-agarose gel Agarose   0.8-1.2% (w/v)
 1x TBE-buffer a.d. 1000 ml
 
For the isolation of specific DNA fragments, the corresponding DNA bands were gelextracted 
using the NucleoSpin Extract II kit (Macherey Nagel) (II.1.2). Equivalent to chapter II.2.1.5 
DNA quality and yield was determined via spectrometric measurment at 260 nm and 280 nm. 
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II.2.1.7 Polymerase Chain Reaction (PCR)  
The PCR method was used for target DNA amplification, screening of transformed E .coli 
and to test whether or not an insert was integrated into a plasmid. The PCR reaction was 
performed as described by Ausubel et al.(1994) and based on Sambrook et al. (2001).  
Screening of clones as well as the verification of gene integrity in cloned plasmids was 
done with a home-made Taq-DNA Polymerase (Fraunhofer IME, Aachen). If PCR fragments 
should be used for cloning, the high fidelity Taq-DNA-Polymerase (Roche) with proof-
reading ability was used in order to reduce point mutations or deletions. The composition of 
each PCR reaction mixture is listed in Table II-6. (Sambrook 2001) (Ausubel 1994) 
 
Table II-6: Composition of PCR reaction mixture. 
Components Amount Volume 
   
10 x PCR buffer 1x 5 µl 
50 mM Mg Cl2 1.5 mM 1.5 µl 
10 mM dNTP 0.2 mM each 1 µl 
Forward-Primer   (10 pmol/μl) 10 pmol 1 µl 
Reverse-Primer (10 pmol/μl) 10 pmol 1 µl 
DNA template 10-100 ng 0.5 – 5 µl 
Taq polymerase/ High Fidelity Taq Polymerase (Roche) 2.5 U 0.5 µl 
dd H2O   ad 50 µl 
   
 
Annealing temperature (X) and DNA elongation time (Y; 1 min/kb PCR product) were 
determined by PCR simulation using the CloneManager program (II.1.14). Each PCR-
reaction was performed under following conditions:  
Initialisation:   1 min   95°C 
Denaturation:   1 min   95°C 
Annealing:  1 min   X °C     25 x  
Elongation:  Y min  72°C 
Final elongation:  10 min 72°C 
 
For each reaction a positive and a negative (no DNA template) control was run with the same 
master mix than the samples. In order to check the success of DNA amplification, 5 µl of each 
reaction was separated in a 1.2% (w/w) TBE-agarose gel (II.2.1.6). If the PCR fragments 
should be used for cloning, they were purified by gel extraction (II.2.1.6) in order to remove 
PCR template DNA from the sample. 
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II.2.1.8 Restriction enzyme digestion of DNA and cohesive end fill-in 
For cloning and analysis plasmid DNA (II.2.1.5) and PCR fragments (II.2.1.7) were digested 
with the required restriction enzymes (RE) which were purchased from NEB. RE digestion 
was performed according to the manufacturer’s manual. Only for test-digestion purposes the 
RE reaction was performed in the microwave (20 µl, 630 Watt, 20 sec). Digestion was 
checked via agarose gelelectrophoresis (II.2.1.6).   
If blunt-ends were required for cloning, cohesive ends were filled in by T4 DNA 
polymerase from NEB according to manufacturer’s protocol. All cloning steps were planned 
and simulated using the CloneManager program (II.1.14). 
II.2.1.9 Dephosphorylation and ligation of restriction enzyme digested DNA 
Religation of RE digested plasmid was avoided by dephosphorylation of the 5‘ends with calf 
intestine phosphatase (CIP) from NEB, which was done according to the manufacturer’s 
protocol. Target DNA, which should be used for cloning, was purified by gel extraction 
(II.2.1.6) with the intention to remove unwanted DNA fragments, REs and CIP. Digested 
PCR-fragments were purified by using the PCR-purification protocol of the NucleoSpin 
Extract II kit (II.1.2). Ligation with cohesive as well as blunt ends was performed in a molar 
vector:insert ratio of 1:3 which was calculated as followed:  
1
3
][
][][
][ ×∗=
vector
insertvector
insert kb
kbng
ng  
According to NEB the overall concentration of vector and insert was adjusted to 1-10 μg/ml 
for efficient ligation. RE digested DNA-fragments were ligated as stated in Table II-7 and 
incubated for 1-2 hours at room temperature (RT). In addition, a religation control was 
prepared without insert addition.  
 
Table II-7: Composition of ligation mixture. 
Components Amount Volume
   
Vector X ng 
Insert  Y ng  
NEB T4 Ligase buffer (10x) 1x 2 µl
NEB T4 Ligase (400.000 U/ml) 400 U 1 µl
dd H2O  ad 20 µl
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II.2.1.10 Dialysis of ligation samples for salt removal  
For successful electrotransformation (II.2.1.3) of 20 µl ligation samples, salts were removed 
by dialysis against ddH2O for 25 min at RT using a MF-membrane filter (Millipore). 
II.2.1.11 Sequencing of plasmid DNA  
If the test-digestion (II.2.1.8) of ligated and amplified plasmid DNA (II.2.1.9) was successful, 
the correct insert integration and sequence was analysed by sequencing. Sequencing was 
performed according to Sanger’s “chain terminating method“ (Sanger et al. 1977) using the 
ABI Prism Analyzer 3730 (AME Bioscience). Sequencing reactions were performed by Dr. 
Jost Muth (Fraunhofer IME, Aachen) and Raphael Soeur (Fraunhofer IME, Aachen). The 
composition of the sequencing reaction mixture is listed in Table II-8. Evaluation was done 
with CloneManager and SeqMan software (II.1.14). 
 
Table II-8: Composition of sequencing reaction mixture. 
Components Amount Volume
   
Forward-/Backward primer (10 pmol/μl) 20 pmol 2 µl
Plasmid-DNA 100 ng/kb plasmid X µl
dd H2O   ad 30 µl
   
II.2.1.12 Phenol-chloroform-isoamyl alcohol (PCI) and ethanol precipitation  
Prior to transfection of plasmid DNA into mammalian cells, the vector had to be linearised 
and REs as well as salts needed to be removed for succesful nucleofection (II.2.2.3). At first, 
REs were removed by phenol-chloroform-isoamyl alcohol (PCI) precipitation. For this, an 
equal volume of PCI (Roth; Roti-Phenol/C/I; 25/24/1) was added to the DNA solution. The 
sample was vigorously vortexed for 10 sec and phase seperation was done by centrifugation 
(16,000 g, 5 min, RT). The top, aqueous, DNA-containing phase was carefully removed, 
transferred to a fresh tube and mixed by vortexing with one volume of chloroform. Again the 
top, aqueous, DNA-containing phase was transferred to a new device after phase separation 
(16,000 g, 5 min, RT) and salts were removed thereafter by ethanol precipitation. The latter 
took place by mixing the DNA sample with 100% (v/v) ice cold ethanol (2.5x DNA sample 
volume) and 3 M sodiumacetate pH 5.2 (1/10 of DNA sample volume) followed by DNA 
precipitation at -80°C for 30 min. Subsequently the DNA was washed twice with 70% (v/v) 
ethanol (16,000 g, 4°C, 30 min) and was eventuelly air dried before resuspension with the 
required volume ddH2O. 
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II.2.2 Mammalian cell culture methods  
General cell culture work was performed under sterile conditions under a laminar flow hood 
(II.1.13) using sterile disposable plastic ware. 
II.2.2.1 Cultivation of mammalian cell cultures  
Cultivation of mammalian cells (II.1.6) took place in a humidified 5% (v/v) CO2 atmosphere 
at 37°C. For maintainance purposes, cells were cultured in the logarithmic growth phase and 
passaged every 3-4 days in fresh, 37°C prewarmed culture medium (II.1.11). Adherent 
growing cell lines like HEK293T and MCF-7 were detached from the culture flask surface 
with a cell scraper as soon as a confluence of 80-90% was reached. For the cultivation in 
biological replicates under standardised conditions, the cells were prepared in a master mix 
and homogeniously distributed to the different cultivation vials to provide equal starting 
conditions. 
Viable and total cell density was determined using the cell counter CASY 1 TT 
(Inovatis) and VoluPACS (Sartorius) respectively according to the manufacturer’s manual. 
Viable cell counting by trypan blue was performed according Freshney (Freshney 1987). 
II.2.2.2 Cryopreservation and thawing of mammalian cells 
For long term storage via cryopreservation, 5*105 – 1*107 viable cells were sedimented 
(200 g, 5 min, RT) resuspended in 1 ml Ibidi freezing medium (Ibidi) and transferred in 
1.8 ml cryovials. Immediately, cells were placed at -80°C and transferred the next day into a 
liquid nitrogen storage freezer. Cryopreserved cells were thawn rapidly in a 37°C water bath, 
transferred to 9 ml prewarmed cultivation medium (II.1.11). 
II.2.2.3 Transfection and generation of stable transfected DG44 cells 
According to Lonza’s recommendation, linearising of the vector before transfection increases 
the chance that it will integrate into the host cell genome without disrupting the GOI or other 
elements required for expression in mammalian cells. Therefore, plasmid-DNA for DG44 
transfection was linearised (II.2.1.8) by PvuI (pAPI:H10 (III.1.1.1.1), pAT:H10 (III.1.1.1.2)) 
or SpeI (pTRACER:GnTIII (III.2.1.1)) followed by PCI extraction, ethanol precipitation 
(II.2.1.12) and resuspension in ddH2O. A DNA concentration of 1-5 µg/µl as well as a purity 
of A260nm/A280nm > 1.8 was required for subsequent transfection procedure.  
Before transfection, DG44 cells were cultivated in the logarithmic growth phase in 
HT-supplemented CD DG44 medium (Invitrogen) and did not exceed a viable cell density of 
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1*106 cells/ml. Transfection took place by using the “Cell Line Nucleofector Kit V” (Lonza) 
and the nucleofection protocol for CHO suspension cells with the nucleofector program U-30. 
24 hours after nucleofection, transfected DG44 cells were exposed to selection pressure. If a 
DHFR-based selection system was used (pAPI:H10, pAPT:H10) this was done by passaging 
cells to HT-free (HT-), complete OptiCHO medium. For pTRACER:GnTIII transfected DG44 
cells, however, the selection process took place with 300 µg/ml zeocin. Transfected DG44 
cells were passaged every 3-4 day into fresh selection medium. Cell lines were declared as 
stably transfected when a viablity of > 90% was gained for DHFR+ selected cells or when 
ZeoR selected cells had been exposed to Zeocin for a period of two weeks. For further 
cultivation, the selection pressure was maintained in order to guarantee constant gene 
expression levels.  
II.2.2.4 MTX-mediated gene amplification 
DG44 cells, which had been stably transfected (II.2.2.3) with a DHFR containing plasmid 
(pAPI:H10, pAPT:H10), underwent a gene amplification of the transgene with the intention to 
increase the H10 production level. This was done by the stepwise exposure to increasing 
MTX concentrations within several amplification rounds (0.05 µM – 128 µM MTX). Each 
round was started by seeding a viable cell density of 2.5*105 cells/ml in 30 ml fresh, MTX 
supplemented, complete OptiCHO medium in T75 flasks. Cells were passaged every 3-4 days 
in fresh, MTX supplemented complete OptiCHO medium. When a viability of >90% was 
reached, the next amplification round was started by doubling the previously used MTX 
concentration. For the cultivation of gene amplified DG44 populations, the MTX 
concentration of the last selection round was maintained in order to avoid a decrease of target 
protein expression. 
II.2.2.5 Limiting dilution (LD) 
In order to generate monoclonal DG44 cell lines, the cell suspension of polyclonal 
populations was diluted in Panserin C6000 medium to provide a final viable cell density of 
6 cells per well in a 96-well plate with 200 µl per well.  
Since regeneration efficiency was very low with Panserin C6000, complete Ex-CELL CHO 
regeneration medium (II.1.11) was used later (III.1.3.2) on with a seeding density of 3 cells 
per 200 µl and per well. Clonal regeneration was documented by automated, microscopic 
visualisation every 3 days for 2 weeks via Cellavista (Innovatis) and Feedom EVO roboter 
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(Tecan). Thereby monoclonal cell lines could be identified by backtracking of colony 
formation. 
II.2.2.6 Flow cytometric analysis and sorting 
Flow cytometry is a high throughput method which enables the analysis and separation of 
cells according their size, granularity and fluorescence. Cells are hydrodynamically focused in 
a sheath of FACS Flow (BD) before intercepting a focused laser beam. As cells pass through 
this interrogation zone they create light scatter which is specific for their size and granularity. 
At the same time fluorescent compounds that are inside (e.g. fluorescent proteins) or attached 
to the cells (e.g. fluorochrome conjugated secondary antibodies) can be excited and emit light 
at a higher wavelength. Multiparametric information about the physical characteristics of a 
particle can be determined from the detection and analysis of both the scattered (FSC and SSC 
sensor) and fluorescent light (FL1, FL2 and FL3 sensor) (Figure II-1, Table II-9). 
  
Figure II-1: Principle of flow cytometry. Flow cytometers use the principle of hydrodynamic focusing for 
presenting cells seperately to a laser. Therefore the cell suspension sample is injected into the center of a sheath 
flow. The combined flow is reduced in diameter, forcing the cell into the center of the stream. Every cell 
passages the laser beam once at a time and scattered light as well as fluorescent light is detected by several 
sensors (modified from http://flow.csc.mrc.ac.uk). Descriptions of FSC, SSC, FL1, FL2 and FL3 sensors are 
found in Table II-9. 
 
For flow cytometric analysis the FACSCalibur (Becton Dickinson) was used with an 
excitation wavelength of 488 nm and the sensors listed in Table II-9.  
SSC sensor
FL1 sensor
FL2 sensor
FL3 sensor
cell suspension seath solution
laser beam
FSC sensor
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Table II-9: List of used sensors for flow cytometric analysis. 
Sensors Abbreviation Emission Detection of  
    
Forward scatter FSC  Event size 
Sideward scatter SSC  Event granularity 
Fluorescent sensor 1 FL1 530/30nm FITC (emission max. 519 nm) 
Fluorescent sensor 2 FL2 585/42nm  
Fluorescent sensor 3 FL3 670 nm long path PI  (emission max. 600 nm) 
    
PI = Propidium iodide 
 
Fluorescent activated sorting (FACS) of cells was done via FACSDiVa Vantage SE (BD) 
with 488 nm excitation wavelength (Enterprise II argon ion laser). For data evaluation the 
WinMDI software (II.1.14) was used. 
II.2.2.6.1 Flow cytometric analysis 
Binding characteristics of H10 to human cells was evaluated via flow cytometry 
(FACSCalibur; BD) as stated in Table II-10. Since theses cells were not used for further 
cultivation, the preperation and flow cytometric analysis of cells was done under non-sterile 
conditions. For each setup 5*105 cells were used and between every working step cells were 
washed twice with 1x PBS by using the cell washer Dade Serocent (Baxter). Considering that 
FITC is very light sensitive, the samples were kept in the dark as soon as GAH(H+L)FITC was 
applied. 
 
Table II-10: Procedure for labeling of mammalian cells for flow cytometric analysis.  
 
The major cell population, which was observed in a SSC versus (vs.). FSC dot plot, was 
gated. Dead, propidium iodide (PI) stained cells of the previously gated cell population were 
excluded from the measurement in a SSC vs. FL3 dot plot and only viable, non-PI labled cells 
were chosen for evaluation.  
10x Phosphate buffered saline  NaCl 1.37 M
(PBS) KCl 27 mM
 Na2HPO4 12 H2O 81 mM
 KH2PO4 15 mM
Working step Component Amount Volume Incubation 
Blocking BSA 1% (w/v) in 1x PBS 200 µl 10 min, 4°C 
Sample Purified antibody 5 µg in 1x PBS 200 µl 30 min, 4°C 
Detection  GAH (H+L)FITC 5 µg in 1x PBS 200 µl 30 min, 4°C 
Analysis Propidium iodide 2 µg/ml in 1x PBS 500 µl 4°C 
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II.2.2.6.2 Fluorescence activated cell sorting (FACS) 
To generate monoclonal HEK293T cell lines with elevated GOI expression levels 
(III.2.2.4.1), the initial polyclonal cell culture HEK293T-CEA_p (II.1.6) was labled with 
FITC conjugated antibodies under sterile conditions as shown in Table II-11. Subsequently, 
cells were sorted by fluorescence activated cell sorting (FACS) according to brightest FITC 
fluorescence. For each setup 5*106 - 5*107 cells were used and between every working step 
cells were washed twice with 5 ml ice cold, sterile 1x PBS by centrifugation (300 g, 5 min, 
4°C) and aspiration of liquid. Since FITC is very light sensitive, the samples were kept in the 
dark as soon as GAH(H+L)FITC was applied. 
 
Table II-11: Procedure for labeling of HEK293T-CEA_p for FACS-based monoclonal cell line generation  
 
Equivalent to chapter II.2.2.6.1, the major cell population, which was observed in a SSC vs. 
FSC dot plot, was gated. Dead, PI stained cells of the previously gated cell population were 
excluded from the measurement in a SSC vs. FL3 dot plot and only viable, non-PI labled cells 
were chosen for evaluation.  
Cells were deposited in 96-well microtiter plates filled with 200 µl R10 medium per well with 
6 cells per well for monoclonal cell line regeneration. Clonal regeneration was documented by 
automated, microscopic visualisation every 3 days for 2 weeks via Cellavista (Innovatis) and 
Feedom EVO roboter (Tecan). Thereby monoclonal cell lines could be identified by 
backtracking of colony formation. 
II.2.2.7 Procedure of whole cell extract preparation 
Thirty ml well grown LS174T, MCF-7, HEK293T (II.1.6), HEK293T_CEA.p/16 (III.2.2.4.1) 
cell cultures from a T75 flask (approx. 80-100% confluent) were pelleted (300 g, 5 min, RT) 
and resuspended in 1 ml lysis buffer (15 ml 1x PBS + 1 complete Mini, EDTA-free protease 
inhibitor tablet (Roche)). Cell disruption took place by sonication on ice using a MS73 
sonotrode (Bandelin) (65% power, 9 cycles, 4x 1 min). Eventually, cell fragments were 
removed by centrifugation (10,000 g, 4°C, 30 min) and the whole cell extract was stored at 
-20°C until use.  
Working step Component Amount Volume Incubation 
Sample HEK293T-CEA_p (II.1.6) 50 µg in RPMI 2 ml 30 min, 4°C 
Detection  GAH (H+L)FITC 50 µg in RPMI 2 ml 30 min, 4°C 
Analysis Propidium iodide 2 µg/ml in 1x PBS 2 ml 4°C 
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II.2.2.8 Nomenclature of H10 producing DG44 cells 
H10 producing DG44 cells were named according to the nomenclature shown in Table II-12. 
 
Table II-12: Nomenclature of H10 producing DG44 cells 
Name Description 
  
DG44_H10I_x.p 
DG44_H10T_x.p 
 
 
DG44_H10I_x.m 
DG44_H10T_x.m 
 
DG44 cells were transfected with the H10 encoding, tricistronic 
double IRES vector pAPI:H10 or the bicistronic Tandem vector 
pAPT:H10. The resulted polyclonal (p) cell culture was gene 
amplified by stepwise MTX concentration increments until x µM 
MTX was reached. If monoclonal cell lines were isolated from 
this polyclonal culture (e.g. by LD) the p in the cultures name is 
replaced by the clone number (m). 
Example: polyclonal cell line DG44_H10T_4.p (III.1.1.2.1), 
                monoclonal cell line DG44_H10I_64.5 (III.1.3.1) 
  
DG44_H10T_x.m_y.p Monoclonal DG44_H10T_x.m cell lines were gene amplified by 
stepwise MTX concentration increments from x µM MTX until 
y µM MTX. After the amplification procedure each cell contains 
different plasmid copy numbers inside its genome resulting in a 
polyclonal culture (p).  
Example: DG44_H10T_0.119_8.p (III.1.3.2) 
  
DG44_ H10I_x.m_GnTIII.p 
 
DG44_ H10I_x.m_GnTIII.n 
DG44_H10I_x.m cells were overtransfected with the GnTIII 
encoding vector pTRACER:GnTIII resulting in a polyclonal 
culture (p). If monoclonal cell lines were isolated from this 
polyclonal culture (e.g. by LD) the p in the cultures name is 
replaced by the clone number (n). 
Example: DG44_H10I_64.5_GnTIII.8 (III.2.1.2) 
  
 
If different cell cultures which had been transfected with the same vector (e.g. pAPI:H10) but 
were exposed to different MTX concentrations (e.g. 0, 4 and 8 µM MTX), their names were 
written as a summarised form (e.g. DG44_H10I_0/4/8.p) instead of stating each cell line 
separately (e.g. DG44_H10I_0.p, DG44_H10I_4.p, DG44_H10I_8.p).  
II.2.2.9 Separation of peripheral blood mononuclear cells (PBMC) from blood and 
isolation of natural killer (NK) cells 
The isolation of PBMC and NK cells was performed at the University of Surrey (Guildford, 
UK) by Dr. Catherine Riley. Blood was taken from a healthy donor and placed into a tube 
with heparin. Following this the peripheral blood mononuclear cells (PBMCs) were separated 
using the so called Ficoll gradient centrifugation. For this fresh blood was briefly diluted at a 
ratio of 1:1 with serum free RPMI1640 (Sigma Aldrich) containing penicillin and 50 μg 
streptomycin (Sigma Aldrich) and 2 mM glutamax-I (Invitrogen), layered onto 15 ml of 
Histopaque 1077 (Sigma Aldrich) and centrifuged (690 g, 25 min, RT). Centrifugation in this 
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high density medium causes the PBMCs to form a distinct layer at the plasma-interface which 
can be transferred into a fresh tube containing 10 ml of serum free RPMI1640 using a Pasteur 
pipette. The sample was then centrifuged again (690 g, 10 min, RT). The supernant was 
removed, the cells counted (II.2.2.1) and then NK cells isolated using Miltenyi Biotec NK 
isolation kit (II.1.2).   
II.2.2.10 ADCC assay 
The ADCC assays were performed at the University of Surrey (Guildford, UK) by Dr. 
Catherine Riley using purified H10_CHO_WT (III.2.1.3.1) and H10_CHO_GnTIII 
(III.2.1.3.2). The effector cells used were isolated NK cells (II.2.2.9). NK cells were 
resuspended in X-VIVO 15 media (Lonza) containing penicillin and 50 μg streptomycin 
(Sigma Aldrich) and 2 mM glutamax-I (Invitrogen), counted in trypan blue (II.2.2.1) and 
adjusted to give 2.5*106 cells/ml. Serial dilutions were performed in a 96-well round 
bottomed plate, which gave a range of effector:target cell ratios from a maximum of 100:1 to 
a minimum of 3:1. If there was a shortage of cells they were adjusted to give 
1.25*106 cells/ml so the top effector:target cell ratio was 50:1. Each dilution was set up in 
triplicate for statistical purposes. 
The target cells used were HEK-293T-CEA_16 cells (III.2.2.4.1), which had either 
been pulsed with 20 µg/ml of antibody or left untreated for 1 h at 37°C in 5% CO2. The cells 
were then centrifuged (400 g, 3 min, RT), counted in trypan blue (II.2.2.1) and resuspended at 
a concentration of 2.5*104 cells/ml. 
Hundred μl target cell suspension was added to the previously diluted effector cells in 
the 96-well plates to give a final volume of 200 μl/well. The cells were incubated at 37°C in 
5% CO2 for 4 h after which 50 μl of CytoTox-Glo reagent (Promega) was added to each well. 
The plates were then left at RT for 15 min. Following this 100 μl of supernant was removed, 
placed into a white walled flat bottomed 96-well plate and the luminescence measured to 
determine the degree of cell death. The CytoTox-Glo reagent is a luminogenic peptide 
substrate (Alanyl-alanyl-phenylalanyl-aminoluciferin; AAF-Glo) which is cleaved by “dead-
cell proteases” that are released from cells that have lost their membrane integrity and 
therefore allows measurement of cell killing. Effector cells were set up alone with media as a 
control to remove any background cell death of the effectors. For calculation of cell killing a 
maximum and spontaneous release of “dead-cell proteases” were set up. The maximum 
release consisted of 100 μl of target cells plus 80 μl of X-VIVO 15 media and 20 μl of 10% 
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Triton-X whereas the spontaneous release consisted of 100 μl of target cells plus 100 μl of 
X-VIVO 15. Cytotoxicity was calculated according to the following formula: 
 
Cytotoxicity [%] = [(experimental - spontaneous release)/(maximum - spontaneous release)] x 100 
 
P-values, for the determination of the statistical relevance of the results, were calculated 
according to the Student-t test calculator from the physics department of the College of Saint 
Benedict and Saint John’s University (http://www.physics.csbsju.edu/stats/t-test.html). 
II.2.3 H10 purification and labeling  
II.2.3.1 Purification of H10 via Protein A affinity chromatography 
For affinity chromatography purification of H10 antibody from culture supernatant a protein 
A matrix (Pall) and an Äkta purifier (GE Healthcare) were used (III.1.1.3.1, III.2.1.3.1, 
III.2.1.3.2). Prior to purification, the culture supernatant was adjusted to pH 8 to enable 
optimal conditions for antibody binding to protein A. Additionaly particles were removed 
from the culture supernatant as well as from required buffers and solutions by 0.22 µm 
filtration. In order to wash the Protein A matrix and equilibrate it to pH 7, it was washed with 
10 column volumes (CV) washing buffer (15 ml/min, RT). Culture supernatant loading, the 
removal of unspecifically bound components (10 CV washing buffer) and the subsequent H10 
elution procedure (approximately 5 CV elution buffer) took place at a flow rate of 10 ml/min 
at RT. Elution fractions were immediately neutralised with 1 M TrisHCl pH 9.6.  
 
II.2.3.2 Buffer exchange of protein solutions 
A buffer exchange of purified H10 (III.2.1.3) was done either by dialysis, using a dialysis 
membrane tube with a MWCO of 8 kDa (SpectraPor, III.2.1.3.1), or by a PD10 desalting 
column (Amersham Biosciences, III.2.1.3.2). Both buffer exchange procedures were 
performed according to manufacturer’s manual. Microbial contaminations of purified, buffer 
exchanged proteins were avoided by sterile filtration (0.22 µm) and subsequent storage in 
500 µl aliquots at -20°C. 
Washing buffer, pH 7.0  Tri sodium citrate dihydrate 50 mM
 pH adjustment with  50 mM citric acid monohydrate 
Elution buffer, pH 3.5 Citric acid monohydrate 50 mM
 pH adjustment with  50 mM tri sodium citrate dihydrate 
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II.2.3.3 Conjugation of H10 with biotin or DyLight549 
For immunohistochemical analysis (IHC; II.2.4.5.2) of the H10 antibody binding to CEA in 
human tissue, the H10 antibody, bearing a complex CHO N-glycan structure 
(H10_CHO_WT; III.2.1.3.1), was labled via NHS-ester coupling either with biotin (indirect 
IHC) or DyLight549 (direct IHC). For an efficient labeling reaction, it was required to remove 
Tris from the protein sample. Therefore the Tris-Glycine storage buffer of the H10_CHO_WT 
sample was removed by dialysis against 1x PBS using a dialysis membrane tube with a 
MWCO of 8 kDa (SpectraPor, II.2.3.2). 
Biotin labeling was done with NHS-PEG4-Biotin (Thermo Scientific) according to the 
manufacturer’s manual. DyLight549, which has a similar spectrum like Cy3 (DyLight549 
Ex/Em: 562/576; Cy3 Ex/Em: 550/570), was conjugated to H10_CHO_WT by using the 
DyLight549 Antibody Labeling kit (Pierce). However, the manufacturer’s protocol was 
slightly changed, since the H10 precipitates in 50 mM sodium borate labeling buffer (pH 8.5). 
Instead, the labeling reaction was performed in 1x PBS (pH 7.4) using a DyLight549 reagent 
and an incubation time of 2 h at RT. Labeling efficiency of DyLight549 was determined via 
spectrophotometric measurement and calculation according to the Pierce manual. 
II.2.4 Proteinchemical and immunological methods 
II.2.4.1 SDS-Polyacrylamide gelelectrophoresis (SDS-PAGE) and Coomassie staining  
Proteins were separated by sodium-dodecyl-sulfate-polyacrylamide-gelelectrophoresis 
(SDS-PAGE). Discontinous SDS-polyacrylamid gels, consisting of a 4% (w/v) stacking gel 
and a 10% or 12% (w/v) seperating gel, were prepared according to Laemmli (Laemmli 1970) 
whereas 4-20% (w/v) gradient gels were purchased from Pierce. The composition of 
discontinuous SDS polyacrylamid gels is stated in Table II-13.  
 
Table II-13: Composition of two discontinuous SDS polyacrylamid gels consisting of a 4% (w/v)  stacking 
gel and a 10% or 12% (w/v) separation gel.  
Total acrylamide-bisacrylamide monomer concentration (T) = 4%; cross linker concentration (C) = 2.7%. 
Components Stacking gel (4%) Seperation gel (10%) Seperation gel (12%) 
    
H2O 3.625 ml 2.78 ml 2.115  ml 
1M TrisHCl (pH 6.8)  625 μl   
1M TrisHCl (pH 8.8)   3.75 ml 3.75  ml 
30% (v/v) Polyacrylamide 830 μl 3.33 ml 4 ml 
10% (w/v) SDS 50 μl 100 µl 100 µl 
TEMED 5 μl 10 µl 10 µl 
20% (w/v) APS 15 μl 30 µl 30 µl 
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Protein samples were mixed with the required sample buffer depending on whether non-
reducing or reducing sample conditions were required. For non-reducing conditions samples 
were additionally denatured for 5 min at 99°C before loading onto the gel. Electrophoretic 
protein seperation took place in Mini-Protean-chambers (BioRad) with 180 V for 1 h in 1x 
Tris-Glycine-SDS-running buffer for discontinous gels and for 4-20% (w/v) grandient gels 
with 150 V for 45 min in 1x Tris-HEPES-SDS running buffer. PageRuler prestained protein 
ladder (Fermentas) served as a molecular marker. 
Protein staining was performed according to Fairbanks Coomassie blue staining 
(Fairbanks et al. 1971). For this, the SDS-gel was boiled in a microwave using Fairbanks A 
solution (900 Watt), cooled down for 5 min and subsequently boiled with Fairbanks B, C and 
D for 1 min each. Fairbanks D exposure was repeated until the gel’s background was 
completely destained and protein bands were clearly visible. Eventually, gel documentation 
took place with LAS-3000 (Fujifilm). The composition of the Fairbanks solutions A-D are 
shown in Table II-14. 
 
Table II-14: Composition of Fairbanks solutions A, B, C and D. 
Components Fairbanks A Fairbanks B Fairbanks C Fairbanks D 
     
Coomassie brilliant blue R250 0.005% (w/v) 0.005% (w/v) 0.002% (w/v)  
Acedic acid 10% (v/v)  10% (v/v) 10% (v/v) 
2-propanol 25% (v/v) 10% (v/v)   
  
 
HC:LC ratio as well as protein purity was evaluated with Aida Image Analyzer v.4.14 
software (II.1.14) according to the band’s pixel intensity of Coomassie stained gels 
(III.1.1.2.3, III.2.1.3.1, III.2.1.3.2).  
 
5x reducing  SDS-PAGE  
sample buffer 
TrisHCl pH 6.8 62.5 mM
Glycerol 30% (w/v)
 Bromphenol blue 0.05% (w/v)
 SDS   4% (w/v)
 β-mercaptoethanol 10% (w/v)
 
2x non-reducing  SDS-PAGE 
sample buffer 
TrisHCl pH 7.0 200 mM
Glycerol 15% (w/v)
 Bromphenol blue 0.05% (w/v)
 SDS   6% (w/v)
 
10x Tris-glycine-SDS   
running buffer  
Tris 250 mM (w/v)
Glycine 1.92 M (v/v)
 SDS 1% (w/v)
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10x Tris-HEPES-SDS   
running buffer  
Tris 250 mM (w/v)
HEPES 1 M (v/v)
 SDS 1% (w/v)
II.2.4.2 Immunoblot analysis 
SDS-PAGE separated proteins (II.2.4.1) were transferred to a HybondTM-C nitrocellulose 
membrane (0.45 μm, Millipore) via tank blot using transfer buffer and a Mini Trans-Blot 
Electrophoretic Transfer Cell (BioRad) (4°C, 100 V/gel, 90 min). Specific detection of target 
proteins was done as stated in Table II-15 and Table II-16. 
Table II-15: Immunoblot for HC and LC detection of a human antibody. Blocking and antibody solutions 
were incubated for 1 h at RT. Between all working steps membranes were washed three times with PBST for 
5 min. 
Working step Component Concentration/dilution 
Blocking Skim milk 3% (w/v) in 1x PBS 
Detection antibody  GAHFcAP and GAHλLCAP 0.33 µg/ml and 0.07 µg/ml in 1x PBS 
Substrate NBT/BCIP 1:100 in  AP buffer 
 
Table II-16: Immunoblot for CEA detection. Blocking and antibody solutions were incubated for 1 h at RT. 
Between all working steps membranes were washed three times with PBST for 5 min. 
Working step Component Concentration/dilution 
Blocking Skim milk 3% (w/v) in 1x PBS 
1st  antibody  H10_CHO_WT (III.2.1.3.1) 23 µg/ml in 1x PBS  
2nd antibody  GAHFcAP 0.33 µg/ml in 1x PBS 
Substrate NBT/BCIP 1:100 in  AP buffer 
 
II.2.4.3 Enzyme linked immuno sorbent assay (ELISA) 
Quantification and functional analysis of H10 was performed via capture ELISA according to 
Engvall and Perlham 1971 (Clark and Adams 1977, Engvall and Perlman 1971). The assays 
took place in high-binding 96-well microtiter plates as listed in Table II-17 and Table II-18. 
1xPBS was used for background signal substraction. H10_CHO_WT (2.3 mg/ml, III.2.1.3.1) 
served as a standard for H10 quantification (Table II-17) and cPIPP (II.1.3) as an isotype 
control for the characterisation of H10-antigen binding (Table II-18, III.2.2.1). 
PBST 1x PBS 
 Tween 20 0.05% (v/v)
  
Transfer buffer TrisHCl, pH 8.3 25 mM
 Glycine 192 mM
 Methanol 20% (v/v)
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Table II-17: Capture ELISA for H10 quantification. Antibody, blocking and sample dilutions were incubated 
for 1h at RT. Between all working steps ELISA plates were washed three times with 300 µl per well PBST using 
the ELISA Washer Elx405. 
Working step Component Concentration/dilution Volume/well 
Coating GAHFc 0.73 µg/ml in coating buffer  100 µl 
Blocking Skim milk 2% (w/v) in 1x PBS 300 µl 
Sample  Culture supernatant or purified antibody 1:2 serial dilution in 1x PBS  100 µl 
Detection antibody  GAHλLCAP 0.04 µg/ml in 1x PBS 100 µl 
Substrate pNpp 1 mg/ml in AP buffer 100 µl 
 
Table II-18: Capture ELISA to characterise the H10-antigen binding. Antibody, blocking and sample 
dilutions were incubated for 1h at RT. Between all working steps ELISA plates were washed three times with 
300 µl per well PBST using the ELISA Washer Elx405. 
Working step Component Concentration/dilution Volume/well 
Coating CEANA3 5 µg/ml in 1x PBS 100 µl 
Blocking Skim milk 2% (w/v) in 1x PBS 300 µl 
Sample  Purified antibody 1:2 serial dilution in 1x PBS  100 µl 
Detection antibody  GAHFcAP 0.2 µg/ml in 1x PBS 100 µl 
Substrate pNpp 1 mg/ml in AP buffer 100 µl 
 
II.2.4.4 Surface plasmon resonance (SPR) based quantification and analysis 
Antibody quantification as well as CEANA3 (II.1.3) and FcγRIIIa (II.1.3) binding studies 
were performed by surface plasmon resonance (SPR) spectroscopy on a Biacore T100 or 
Biacore 2000 instrument (Biacore, GE Healthcare, Freibung) using HBS-EP running buffer. 
Protein A (> 4000 response units (RU)) or protein G (> 3000 RU) was coupled via N-ethyl-
N′-(3-dimethylaminopropyl)carbodiimide (EDC) / N-hydroxysuccinimide (NHS) ester 
(25 µg/ml) in coupling buffer onto a CM5-rg sensor chip (GE Healthcare) using the amine 
coupling kit (GE Healthcare). Accordingly, CEANA3 was aldehyde coupled as described by 
Abraham et al. (1995). Protein samples were diluted in HBS-EP running buffer and injected 
at a flow rate of 30 µl/min (sample volume: 200 µl; injection volume of 90 µl). Assays were 
performed at 25°C if not otherwise stated and surfaces were regenerated by a 1 min pulse with 
30 mM HCl (30 µl/min). Binding curves were evaluated using BIAevaluation software 3.0 or 
BIAEval 4.0 (GE Healthcare).  
Coating buffer  Na2CO3 15 mM
 NaHCO3 35 mM
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CHO produced 2G12 (II.1.3) and H10_CHO_WT (III.2.1.3.1) served as an standard for 
antibody quantification. The equilibrium dissociation constant (eqKD) for FcγRIIIa binding 
studies was obtained by plotting the steady-state response reached at the equilibrium against 
the ligand concentration and fitted using origin software (Origin Labs, Northhampton, MA, 
USA). (Abraham et al. 1995) 
 
II.2.4.5 Immunofluorescence staining 
Immunofluorescence staining is a technique for the detection of a specific target on fixed cells 
(II.2.4.5.1) or tissue sections (II.2.4.5.2) via the target-specific binding of a fluorescent dye 
conjugated detection antibody. There are two major types of immunofluorescence staining 
methods: the direct immunofluorescence staining (II.2.4.5.2), where the primary antibody is 
labeled with a fluorescence dye, and the indirect immunofluorescence staining in which a 
secondary antibody or ligand is conjugated with a fluorochrome which specifically binds to a 
primary antibody (II.2.4.5.1, II.2.4.5.2). Immunofluorescence stained samples were examined 
under the DMIL fluorescence microscope (Leica) or UltraView Vox confocal microscope 
(PerkinElmer). 
II.2.4.5.1 Immunofluorescence staining of fixed cells 
Visualisation of the specific H10 binding on adherent, fixed cells was performed via the 
indirect immunofluorescence staining technique. 5*105 cells/ml (500 µl/well) were sown in 
8-well chamber slides (Lab-TekII Chamber Slide-System, Nunc) and cultivated for 48 h at 
37°C and 5% CO2. Direct immunofluorescence staining was performed as stated in Table 
II-19. Cells were washed twice with 800 µl 1x PBS between every working step. Considering 
that FITC is very light sensitive, the samples were kept in the dark as soon as GAH(H+L)FITC 
was applied.  
 
 
 
 
 
HBS-EP running buffer, pH 7.4 NaCl 150 mM
 HEPES 1 mM
 EDTA 3 mM
 Tween 20 0.05% (v/v)
Coupling  buffer, pH 4.25  Sodium acetate 10  mM
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Table II-19: Direct immunofluorescence staining on fixed mammalian cells. 
Working step Component Concentration/dilution Volume/well Incubation 
Cell fixation Paraformaldehyde 4% (w/v) in 1x PBS 200 µl 10 min, RT 
Blocking BSA 3% (w/v) in 1x PBS 300 µl 1 h, RT 
Sample  Purified antibody 20 µg in 1x PBS  200 µl ON, 4°C 
Detection antibody  GAH(H+L)FITC 3 µg/ml in 1x PBS 200 µl 1h, RT 
Dapi = 4’,6-Diamidin-2’-phenylindoldihydrochloride 
 
The chambers were removed from the microscope slide according to manufacturer’s manual 
and 50-75 µl of 4’,6-Diamidin-2’-phenylindoldihydrochloride (Dapi) containing mounting 
medium (VECTASHIELD) was immediately applied to the cells and subsequently covered 
with a coverslip. 
II.2.4.5.2 Immunofluorescence staining of tissue sections (immunohistochemistry) 
The tissue specific binding of H10 was analysed by immunofluorescence staining of human 
tissue cryosections (II.1.7) via immunohistochemistry (IHC). However, the commonly used 
indirect IHC protocol using a murine detection antibody followed by a secondary, fluorescent 
dye labled anti-mouse antibody could not be used here, since H10 as well as the tissue are 
human. Therefore two immunofluorescence-based IHC protocols were developed during this 
thesis: an indirect IHC assay using biotin conjugated H10 (II.2.3.3, II.2.3.2) and StrepCy3 as 
well as a direct IHC assay using H10 conjugated to DyLight549 (II.2.3.3).  
For each protocol 7 µm thick, freshly sliced cryosections from -80°C frozen tissue 
blocks (II.1.7) were used, which were placed on a glass microscope slide and air dryed ON at 
RT. Slides were acetone fixed by incubation in pre-chilled acetone for 10 min at -20°C and 
were subsequently dryed for 20 min at RT until residual acetone evaporated completely. 
Thereafter, tissue sections were encircled on the microscope slide with a liquid blocker pen 
(SCI Science). From now on the slides were kept in liquid all the time and were placed in a 
humidity chamber for all incubation steps in order to maintain the tissue’s quality.  
The specific immunofluorescence staining steps of the developed indirect and the 
direct IHC protocols are shown in Table II-20 and Table II-21. The tissue was washed 3x for 
5 min with 1x PBS between every working step. Negative controls were always washed 
seperately to avoid cross contamination. Since Cy3 and DyLight549 are very light sensitive, 
the samples were kept in the dark as soon as StrepCy3 or H10DyLight549 was applied. Eventually, 
nuclei staining took place by the application of Dapi containing mounting medium 
(VECTASHIELD) as described in chapter II.2.4.5.1. 
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Table II-20: Indirect immunofluorescence staining of human tissue using the human, biotin conjugated 
H10 antibody. All component dilutions were performed in HAMA-ELISA dilution reagent (Medac). 
Working step Component Concentration Volume/section Incubation 
Blocking NHS 10% (v/v)  300 µl 30 min, RT 
Sample  H10Biotin 1 µg/ml  300 µl 1 h, RT 
Detection  StrepCy3 5 µg/ml  300 µl 30 min, RT 
NHS = normal horse serum (Vector laboratories) 
 
Table II-21: Direct immunofluorescence staining of human tissue using the human, DyLight549 
conjugated H10 antibody. All component dilutions were performed in HAMA-ELISA dilution reagent 
(Medac). 
Working step Component Concentration Volume/section Incubation 
Blocking NHS 10% (v/v)  300 µl 30 min, RT 
Sample/detection  H10DyLight549 4 µg/ml  300 µl 1 h, RT 
NHS = normal horse serum (Vector laboratories) 
II.2.5 Matrix assisted laser desorption/ionisation (MALDI) glycopeptide 
analysis 
The N-glycan structure of glycopeptides was analysed by Matrix Assisted Laser 
Desorption/Ionisation (MALDI) at Plant Research International (Wageningen, NL) by Dr. 
Maurice Henquet. HC and LC from purified antibodies were separated on a reducing, 
denaturing SDS-PAGE gel (II.2.4.1). The HC was excised from the gel, treated with trypsin 
and the peptide mixture was desalted using C18 zip-tip (Millipore). The purified 
(glyco)peptide mixture was dissolved in ddH2O and spotted onto a stainless-steel MALDI 
target plate. Samples spotted onto MALDI plate were overlaid with an equal volume of 
dihydroxybenzoic acid (DHB, 2 mg/mL 30% (v/v) ACN with 0.1% (v/v) TFA) and allowed 
to dry at air at room temperature. Positive-ion MALDI-TOF spectra were recorded on an 
Ultraflex mass spectrometer (Bruker) fitted with delayed extraction and a nitrogen laser 
(337 nm). A maltodextrin series was used as an external molecular weight standard. Spectra 
were generated from the sum of at least 1000 laser pulses. The glycans on the glycopeptides 
were subsequently deduced by subtracting the mass of the predicted tryptic glycopeptide 
(EEQYNSTYR; 1188.5 Da) from the observed masses of the glycopeptides. 
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III Results  
The treatment of cancer via immunotherapy using specific monoclonal antibodies has 
significantly developed during the last decades and represents a promising approach to 
support currently available cancer therapies (Schuster et al. 2006, Murphy 2010). In particular 
the use of IgGs, which are specific for CEA-positive tumors have been shown to have a 
significant potential in tumor targeting and destruction (Wong et al. 2006, Li et al. 2008, 
Liersch et al. 2005, Zbar et al. 2005). In the frame of this work the human full-size anti-CEA 
IgG1 H10 was introduced as a possible alternative for cancer immunotherapy. Therefore it 
was produced in CHO cells, optimised by glycoengineering and eventually characterised 
regarding its CEA specific binding and effector functions. Accordingly, the PhD thesis was 
structured in two parts: 
1. Establishment of a CHO production platform for high level mAb production (III.1) 
2. Production and analysis of two H10 glycoforms in CHO cells (III.2) 
III.1 Establishment of a CHO platform for high level monoclonal 
antibody production 
High level IgG production in CHO cells requires the establishment of a suitable expression 
vector system (III.1.1), a variety of production optimisation steps (III.1.2) as well as the 
development of an efficient strategy for the isolation of monoclonal high producer cell lines 
(III.1.3). In this chapter the stepwise development of a monoclonal antibody production 
platform, using the DHFR deficient CHO cell line DG44 (II.1.6), is described. 
III.1.1 Establishment and comparison of two polycistronic vector systems  
The first step for high level IgG production in DG44 cells is the establishment of an efficient 
vector system, which enables the production of functional, fully assembled IgG. This chapter 
describes the development of two polycistronic vector systems (III.1.1.1) which were 
compared regarding their effect on cell growth and their IgG production characteristics 
(III.1.1.2.1), the extracellular ratio of antibody heavy chain (HC) and light chain (LC) 
(III.1.1.2.3), the most suitable MTX concentration (III.1.1.2.1) and the ability to produce 
functional IgG (III.1.1.3). The human IgG1 H10 was used here as a model antibody to 
demonstrate the performance of each vector system. 
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III.1.1.1 Vector design and cloning 
For high level IgG production in DG44 cells an efficient mammalian expression vector, 
providing a strong promoter as well as a balanced HC and LC expression, is required. In 
addition, a selection system is needed which enables the stable genomic integration of the 
plasmid followed by the possibility to undergo gene amplification of the GOI to further 
increase target protein production. In order to fulfill these requirements the two polycistronic 
DG44 expession vectors pAPI:H10 (III.1.1.1.1) and pAPT:H10 (III.1.1.1.2) were generated. 
They both derived from the mammalian expression vector pOptiVEC-TOPO (II.1.8) which 
contains the strong PCMV promoter in its target protein expression cassette, permitting high 
expression levels in CHO cells (Cacciatore et al. 2010). Moreover, this plasmid enables 
efficient, yield-improving MTX-based gene amplification by linking the GOI via an IRES 
sequence with the DHFR selectable marker.  
For time, cost and efficiency purposes the expression cassettes for antibody LC and 
HC were placed on the same plasmid. This eliminates the need to select with two different 
selection systems and should avoid that either antibody LC or HC are produced in an 
inbalanced extent, which in turn might lead to yield loss of the assembled IgG (Strutzenberger 
et al. 1999). For cloning of the tricistronic vector pAPI:H10 and the bicistronic-tandem vector 
pAPT:H10 recombinant DNA-technology methods, as described in chapter II.2.1, were used. 
III.1.1.1.1 Tricistronic vector pAPI:H10  
The challenge was to link antibody LC and HC expressions with those of the DHFR 
selectable marker to ensure that high selection pressure always induces high LC and HC 
expression without selecting for DHFR only. For this purpose LC, HC and DHFR were linked 
by IRES elements creating a tricistronic construct. It is known that in CHO cells the gene, 
placed downstream of an IRES sequence, is expressed 2-16 times lower compared to a cap-
dependent gene (Mizuguchi et al. 2000). In addition it is described that a LC over HC excess 
in the endoplasmatic reticulum (ER) is favorable for increased rate of monoclonal antibody 
folding and assembly (Bertolotti et al. 2000, Schlatter et al. 2005). Furthermore, Li et al. 
(2007) described a HC:LC ratio of 1:3 - 1:5 gained with a LC-IRES-HC expression cassette 
which is in the optimal range for high level IgG production in CHO cells (Schlatter et al. 
2005). For these reasons the expression cassette for the tricistronic vector pAPI:H10 was 
constructed in the sequence order LC-IRES-HC-IRES-DHFR. Moreover, the positioning of 
the selectable marker at third position should lead to a reduction of DHFR expression level 
and consequently an increase of selection pressure. In turn, the chance for the selection of 
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clones with highly expressional active plasmid integration loci and for those exhibiting high 
copy numbers of the tricistronic expression cassette would be increased. 
For the cloning of the tricistronic expression cassette of pAPI:H10, a shuttle vector 
(pGEX-5x-3:CEANA3) needed to be constructed first. This was done by the insertion of a 
multiple cloning site (MCS) (BamHI, XhoI, NcoI, XbaI, EcoRI, NotI) and a spacer gene 
(CEANA3) into the pGEX-5x-3 vector (II.1.8, Figure III-1). The MCS insertion was 
performed by PCR amplification of CEANA3 from pTRA:CEANA3 using the primer F/B 
CEANA3 (II.1.9), followed by the cloning of the resulting PCR fragment into the pGEX-5x-3 
vector via BamHI and NotI RE digestion. H10_LC and H10_HC, including human lamda LC 
leader (λ leader) and human HC variable (VH) leader (VH leader), were inserted from 
pTRA:H10_LC and pTRA:H10_HC into the previously cloned pGEX-5x-3:CEANA3 shuttle 
vector by NcoI and XbaI RE digestion and subsequent ligation. Next, H10_LC and H10_HC 
were inserted from this intermediate vector into the bicistronic pIRES vector (II.1.8) via XhoI 
and EcoRI. Considering that the pIRES vector contains only a truncated IRES element 
(IREST), which according to Invitrogen reduces the expression level of the downstream 
placed gene in a higher extent than the full-size IRES sequence (IRESFS), the IREST was filled 
up via PCR to form an IRESFS. This was done with the primer F XhoI-EcoRI-IRES and B 
NcoI-IRESFS (II.1.9) as well as the pIRES vector as a template. The resulted fragments and 
the previously cloned pGEX-5x-3:H10_HC vector were digested with XhoI and NcoI and 
subsequently ligated to form pGEX-5x-3:IRESFS-H10_HC. In a next cloning step the 
intermediate vector pIRESII:H10 was formed by the ligation of PciI and NotI digested 
IRESFS-H10_HC fragment into the pIRES:H10_LC vector. Furthermore, the LC-IRESFS-HC 
sequence, including their specific human leader sequences, were PCR amplified from 
pIRESII:H10 using the primer F XhoI-Kozak-lamda_leader as well as B XbaI-H10_HC 
(II.1.9). By this, the Kozak sequence GCC GCC ACC ATG G was inserted which should 
increase the GOI expression level 10-fold according to Lonza 
(http://www.lonza.com/group/en/products_services/Custom_Manufacturing/mammalian/gene
expressions/faq_s/question_3.html). The resulting PCR fragment was inserted by TOPO 
cloning into the Invitrogen pOptiVEC-TOPO vector according to the manufacturer’s manual 
resulting in the final expression construct pAPI:H10 (Figure III-1). Finally, the tricistronic 
expression cassette of the cloned pAPI:H10 vector was checked by sequencing (II.2.1.11), 
confirmed to exhibit the correct sequence. pAPI:H10 was finally used for H10 expression in 
DG44 cells (III.1.1.2.1). 
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III.1.1.1.2 Bicistronic tandem vector pAPT:H10 
In addition to pAPI:H10 (III.1.1.1.1), the bicistronic tandem vector pAPT:H10 was cloned. 
Here again the purpose was to gain a HC:LC expression ratio similar to those described by 
Schlatter et al. (2005) as the most suitable for IgG expression in stably transfected CHO cells. 
In order to increase the level of HC expression compared to those gained by pAPI:H10 
(III.1.1.1.1), HC and LC were placed on two separate expression cassettes. However, the 
DHFR selectable marker is linked to the HC by an IRES element creating a direct correlation 
between IgG expression, selection pressure and the extent of gene amplification. 
The cloning of pAPT:H10 started by the insertion of a Kozak sequence 5’ of the λ- and VH-
leader of LC and HC gene via PCR (Figure III-2). For this, the primer 
F XhoI-Kozak_λ_leader and B XbaI-H10_LC as well as F XhoI-Kozak_VH_leader and 
B XbaI-H10_HC (II.1.9) were used, respectively, including pTRA:H10_LC and 
pTRA:H10_HC as a template. Both resulted DNA fragments were inserted into the 
pOptiVEC-TOPO vector (II.1.8) by TOPO cloning, creating the intermediate plasmids 
pOptiVEC:H10_LC and pOptiVEC:H10_HC. For the removal of IRES-DHFR, the former 
vector was digested by HpaI and PmeI and subsequently religated. In a final step, the created 
LC expression cassette, lacking the IRES-DHFR sequence, was inserted into the 
pOptiVEC:H10_HC vector by PCR amplification via the primer F SspI-PCMV and B SspI-PA 
(II.1.9) followed by SspI digestion and subsequent ligation to form the final vector pAPT:H10 
(Figure III-2). The sequences of LC and the bicistronic HC expression cassette were finally 
checked by sequencing and pAPT:H10 was eventually used for H10 exression in DG44 cells 
(III.1.1.2.1). 
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Figure III-2: Cloning of the bicistronic expression vector APT:H10. Restriction enzyme recognition sites and 
primer which were used for the next cloning steps are highlighted in orange. H10_LC = lambda light chain of the 
human H10 antibody; H10_HC = heavy chain of the human H10 antibody; DHFR = dihydrofolate reductase; 
PCMV = human cytomegalovirus promoter; IRESFS = full-size internal ribosome entry site of the 
encephalomyocarditis virus; PA = polyadenylation site; Kozak = Lonza recommended Kozak sequence; 
λ leader = human lamda LC leader sequence; VH leader = human leader sequence of the heavy-chain variable 
region (VH). Each cloning step is described in the text and detailed cloning procedure protocols as well as the 
corresponding plasmids are stated in chapter II.2.1 and II.1.8. 
III.1.1.2 Comparison of the tricistronic and bicistronic-tandem vector system  
After successful cloning of the tricistronic vector pAPI:H10 and the bicistronic tandem vector 
pAPT:H10 (III.1.1.1), their suitability regarding high level H10 accumulation was analysed. 
For this, both vector systems were compared regarding the most suitable MTX concentration 
for high level IgG yields (III.1.1.2.1), their influence on cell growth and IgG production levels 
(III.1.1.2.3) and their HC:LC ratio of the produced IgGs (III.1.1.2.1). 
III.1.1.2.1 Comparision of H10 expression levels in the presence of various MTX  
                        levels  
DG44 cells were transfected with linearised pAPI:H10 (III.1.1.1.1) and pAPT:H10 
(III.1.1.1.2) vectors (II.2.2.3), respectively. After the cultivation for two weeks in HT- 
selective, complete OptiCHO medium (II.1.11) stable DG44_H10I_0.p and DG44_H10T_0.p 
pTRA:H10_LC
H10_LCλ leader
pTRA:H10_HC
H10_HCVH leader
F XhoI-Kozak-λ leader B XbaI-H10_LC
PCR
pAPT:H10
PCMV PAH10_LCλ leader H10_HCVH leaderKozak IRESFS DHFR
TOPO cloning
pOptiVEC-TOPO
PCMV PAIRESFS DHFR
TOPO cloning site
F XhoI-Kozak_VH leader B XbaI-H10_HC
PCR
TOPO cloning
H10_LCλ leaderKozak Kozak H10_HCVH leader
pOptiVEC:H10_LC
PCMV PAIRESFS DHFRH10_LCλ leaderKozak
pOptiVEC:H10_HC
PCMV PAIRESFS DHFRKozak H10_HCVH leader
SspIHpaI PmeI
pOptiVEC:H10_LC w/o DHFR
PCMV PAH10_LCλ leaderKozak
HpaI + PmeIF SspI-PCMV B SspI-PA
PCMV PAH10_LCλ leaderKozak
SspI SspI
PCR
SspI
PA PCMV
SspISspI
Kozak
DG44_H10I_0.p and DG44_H10T_0.p = Polyclonal (p) pAPI:H10 (H10I) and pAPT:H10 (H10T) transfected 
DG44 cells, which were cultivated without MTX (0 µM) and thereby did not underwentgene amplification. 
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cell cultures were generated. Since both vectors originated from the vector pOptiVEC (II.1.8), 
which is part of the OptiCHO Express kit (Invitrogen), the gene amplification protocol of this 
kit was used as a guideline (II.2.2.4). In this manual MTX-mediated gene amplification was 
described only for MTX concentration up to 4 µM. Since the use of MTX concentrations 
higher than that had been already described in literature (Kingston et al. 2002), the target 
protein yield could theoretically be enhanced with MTX concentrations higher than 4 µM. In 
order to test this hypothesis and to identify the optimal MTX concentration for the highest 
possible yield, the DG44_H10I_0.p and DG44_H10T_0.p polyclonal DG44 cultures were 
exposed stepwise to higher MTX levels from 50 nM to 512 µM and 128 µM MTX, 
respectively (II.2.2.4). The resulted gene amplified, polyclonal cultures (DG44_H10I/T_x.p) 
were subsequently compared regarding their H10 production. This was done by their 
cultivation under standardised conditions in the presence of their corresponding MTX 
concentration (2.5*105 cells/ml seeding density, 30 ml complete OptiCHO medium + MTX, 
T75 cell culture flasks, 5 days). H10 in the culture supernatant was quantified by ELISA 
(II.2.4.4) or SPR analysis (Protein G chip, II.2.4.4). Two different quantification methods 
were used here, because due to higher sample throughput over time the quantification method 
ELISA was replaced by SPR analysis.The results are shown in Figure III-3.  
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Figure III-3: Determination of the optimal MTX concentration for high level H10 production in 
pAPI:H10 and pAPT:H10 transfected, gene amplified DG44 cell cultures. pAPI:H10 (A and B) and 
pAPT:H10 (C and D) transfected (II.2.2.3), gene amplified DG44 cells were cultivated under standardised 
conditions in the presence of  their specific MTX concentration (2.5*105 cells/ml seeding density, 30 ml 
complete OptiCHO medium + MTX,  T75 cell culture flasks). Culture supernatants were taken 5 dpi and the 
H10 concentration was determined by capture ELISA  (II.2.4.4) with the detection antibodies GAHFC 
(0.73 µg/ml) and GAHλLCAP (0.04 µg/ml) (A) and by SPR analysis (II.2.4.4) using a protein G chip (B, C, D). 
Error bars represent the standard deviations gained from technical triplicates.  
 
The results in Figure III-3 (A and C) show a clear H10 yield increase in the culture 
supernatant with increasing exposure to MTX, which was observed for both vector systems. 
However, the highest H10 yield was reached with different MTX concentrations: 64 µM for 
the pAPI:H10 and 8 µM for the pAPT:H10 vector system. Increasing MTX concentrations 
beyond this optimum resulted in no further H10 yield increase (Figure III-3 B and D). In case 
of the tricistronic pAPI:H10 vector, a decline of yield was observed with increasing MTX 
concentration beyond this optimum. In contrast to this remained the expression level of 
pAPT:H10 transfected cells, which were cultivated with MTX concentrations higher than 
8 µM, in the range of those cultivated between 4-8 µM MTX. These observations as well as 
the identified, optimal MTX concentration for high level H10 production could be confirmed 
by the repetition of this assay with the cultures DG44_H10I_0/4/32/64/128.p as well as 
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DG44_H10T_0/4/8/64/128.p and an elongation of the cultivation period from 5-12 days (data 
not shown). Differences in the H10 production level, like observed by the comparison of the 
cultures at 4 and 64 µM MTX, were assay dependent (SPR, ELISA) and also occurred due to 
biological fluctuations of mammalian cells. 
III.1.1.2.2 Growth and production characteristics 
In order to analyse whether or not the presence of the vector as well as the initial selection in 
HT- medium has an effect on cell growth, the non MTX cultured DG44_H10I_0.p and 
DG44_H10T_0.p cells (II.2.2.7) as well as non-transfected, wild type (WT) DG44 cells, 
which served as a reference, were compared regarding their growth characteristics. In 
addition, the influence of MTX on cell growth was observed by viable cell density 
comparison of the genomic amplified polyclonal cell cultures DG44_H10I_4/32/64/128.p as 
well as DG44_H10T_4/32/64/128.p. At least two weeks before, all compared cell cultures had 
been adapted from complete OptiCHO medium to Panserin C6000 production medium. 
OptiCHO medium requires, according to the manufacturer Invitrogen, a CO2 concentration of 
8% to achieve an optimal pH of 7.4. Cultivation at lower CO2 concentration would thereby 
result in a pH increase and in turn in a reduced cell growth. Since cultivation at 8% CO2 was 
not possible in the cell culture lab, cells were adapted from OptiCHO medium to 
Panserin C6000, which requires a CO2 concentration of 5% only.  
For growth comparison cells were cultivated in biological triplicates under 
standardised conditions (5*105 cells/ml seeding density, 10 ml Panserin C6000, T25 cell 
culture flasks, 12 days). WT DG44 cells were cultivated in the presence of HT since they 
were DHFR- (I.1.1). Viable cell density was measured every day in technical triplicates using 
the CASY cell counter (II.2.2.1). Figure III-4 shows the resulting growth curves. 
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Figure III-4: Growth comparison of pAPI:H10 and pAPT:H10 transfected DG44 cells before and after 
gene amplification. DG44_H10I_4/32/64/128.p as well as DG44_H10T_4/32/64/128.p cells were cultivated in 
biological triplicates under standardised conditions (5*105 cells/ml seeding density, 10 ml Panserin C6000 
medium, T25 cell culture flasks, 12 days). WT DG44 cells were used as a reference cell line and were cultivated 
in the presence of HT. Viable cell density was measured every day by CASY cell counting (II.2.2.1). Error bars 
represent the standard deviation of technical and biological triplicates. Dpi = days post inoculation. 
  
As shown in Figure III-4, DG44_H10I_0.p as well as DG44_H10T_0.p exhibit similar growth 
characteristics compared to WT DG44 cells. This indicates that the presence of the pAPI:H10 
and pAPT:H10 vector as well as the HT depletion in the medium does not have an effect on 
cell growth. Equivalent to this, MTX concentrations until 4 µM MTX had no effect on cell 
growth neither on pAPI:H10 nor on pAPT:H10 transfected cell lines. However, the cell 
growth was reduced with increasing MTX concentrations from 4-128 µM. This effect was 
even more intense in pAPI:H10 than in pAPT:H10 transfected cells. The here stated results 
were confirmed by a repetition of this assay (data not shown). 
For production comparison purposes of both vector systems the DG44_H10I_4.p and 
DG44_H10T_4.p polyclonal cultures, which exhibit similar cell growth characteristics, were 
compared regarding H10 accumulation in the production medium. This comparative 
production assay took place in biological triplicates under standardised conditions 
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(5*105 cells/ml seeding density, 10 ml Panserin C6000 medium + 4µM MTX, T25 cell culture 
flasks, 12 days). Samples were taken in the mid-exponential growth phase (5 days post 
inoculation (dpi)), the beginning of the stationary phase (8 dpi) and the death phase (12 dpi). 
H10 accumulation in the medium was quantified via SPR analysis (Protein G chip, II.2.4.4), 
viable cell density was determined by CASY cell counting (II.2.2.1) and the IgG appearance 
in the culture supernatant was analysed on a Coomassie stained 4-20% (w/v) PAA-SDS 
gradient gel (II.2.4.1). The results are shown in Figure III-5. 
           
 
Figure III-5: Comparison of DG44_H10I/T_4.p cells regarding H10 production level, viable cell density 
and H10 assembly. DG44_H10I_4.p and DG44_H10T_4.p were cultivated for 12 days under standardised 
conditions (5*105 cells/ml seeding density, 10 ml Panserin C6000 medium + 4µM MTX, T25 cell culture flasks) 
in biological triplicates. Samples were taken and analysed at 5 dpi (mid exponential growth phase), 8 dpi 
(beginning of stationary phase) and 12 dpi (death phase). The H10 concentration of each sample was determined 
by SPR analysis using a Protein G chip (A; II.2.4.4). Viable cell density determination of the selected sample 
points took place by CASY cell counting (B; II.2.2.1). The specific productivity was determined according to the 
viable cell density and the H10 concentration shown in A and B (D). The culture supernatant was analysed by 
separating 20  µl culture medium of DG44_H10I_4.p (lane 1) and DG44_H10T_4.p (lane 2) under non-reducing 
conditions by SDS-PAGE using a 4-20% (w/v) SDS-PAA gradient gel followed by protein band visualisation 
via Coomassie staining (D; II.2.4.1). LC2 = lambda LC dimer, dpi = days post inoculation, M = PageRuler 
prestained protein marker (Fermentas).  
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The SPR results in Figure III-5 (A) demonstrate that the H10 concentration in the medium of 
cell line DG44_H10T_4.p is 2-2.5 times higher compared to those of DG44_H10I_4.p. Since 
the viable cell densities of both cell cultures at each taken sample point were comparable, the 
possibility that this difference might result from lower DG44_H10I_4.p cell densities can be 
excluded (Figure III-5; B). The specific productivity of both tested cell cultures decreased 
with increasing cultivation time (Figure III-5; C). Highest productivities of pAPI:H10 or 
pAPT:H10 transfected cells were 3 pg/cell/day and 6.5 pg/cell/day, respectively, as calculated 
from Figure III-5 A and B. Analysis of culture supernatant from DG44_H10I_4.p and 
DG44_H10T_4.p by SDS-PAGE (Figure III-5; D) confirmed, the SPR quantification results 
(Figure III-5;A) showing a more intense band of the full-size, assembled H10 at approx. 
150 kDa in the DG44_H10T_4.p culture supernatants compared to those of DG44_H10T_4.p. 
In addition, it is noticable that there is a significant LC excess in form of a Lambda LC dimer 
(LC2) detectable at 50 kDa (Elkabetz et al. 2008). Moreover, the LC2 band intensity in 
relationship to the full-size IgG band in the DG44_H10T_4.p samples is much stronger 
compared to those found in the DG44_H10I_4.p supernatants. This indicates that there is a 
larger LC excess produced by pAPI:H10 transfected DG44 cells compared to pAPT:H10 
transfected cells. In order to verify this assumption, the HC:LC ratio of the culture 
supernatant, produced by DG44_H10I_4.p and DG44_H10T_4.p, was further analysed 
(III.1.1.2.3).  
III.1.1.2.3 HC:LC ratio determination 
Immuoblots, 2D-PAGE and ELISA are currently the methods of choice for extracellular 
HC:LC ratio determination (Schlatter et al. 2005, Li et al. 2007b). Since these methods are 
time and cost intensive an alternative system, using Coomassie stained SDS-gels from which 
the protein band’s pixel intensity was evaluated by Aida evaluation software (II.1.14), was 
used here. However, the suitability of this method needed to be tested first because the 
identification of HC and LC bands requires to be very precise and reproducible.  
As a first step the protein bands of HC and LC as well as assembled IgG in the culture 
supernatant of H10 producing DG44 cells in a Coomassie stained needed to be identified via 
immunoblot analysis. For this the H10 secreting cell line DG44_H10I_4.p (III.1.1.2.1) was 
used as a model system and 15 µl of its culture supernatant was separated under reducing and 
non-reducing conditions on a 10% (w/v) SDS-PAA gel. Subsequently, protein bands were 
visualised by Coomassie staining (II.2.4.1) and in addition antibody HC and LC bands were 
identified by immunoblot via the detection antibodies GAHFcAP and GAHλLCAP (II.2.4.2). The 
results are shown in Figure III-6. 
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Figure III-6: Identification of H10 bands from a Coomassie stained SDS-PAA gel via immunoblot analysis. 
15 µl of serum-free culture supernatant from DG44_H10I_4.p cell culture were separated under non-reducing 
and reducing conditions on a 10% (w/v) SDS-PAA gel. Protein bands were visualised by Coomassie staining 
(II.2.4.1). For the identification of HC, LC, LC-dimer (LC2) as well as assembled IgG bands via immunoblot, 
proteins were transferred to a nitrocellulose membrane (100 V, 90 min) and target protein bands were 
specifically visualised with GAHFCAP (0.33 µg/ml) or GAHλLCAP (0.07 µg/ml) according to the protocol 
described in chapter II.2.4.2. NBT/BCIP substrate was incubated for 5 min. LC2 = LC dimer, M = PageRuler 
prestained protein marker (Fermentas), r. = reducing conditions, n.r. = non-reducing conditions.  
 
As shown in Figure III-6 distinct protein bands of the culture medium sample can be 
visualised on Coomassie stained SDS-PAA gels under reducing and non-reducing conditions. 
Additionaly, the most intense protein bands could be identified as H10 HC, LC, LC dimer 
(LC2) and assembled H10 via immunoblot analysis. Since these bands are clearly visible on a 
Coomassie stained SDS-gel without any contaminating proteins it is possible to allocate them 
to the corresponding proteins without the need to prepare immunoblots. 
In order to compare the HC:LC ratio of H10 in the culture supernatant of pAPI:H10 
and pAPT:H10 transfected DG44 cells, the polyclonal cell cultures DG44_H10I_4.p and 
DG44_H10T_4.p were used as model cultures. Both polyclonal populations were cultivated in 
triplicates, under standardised conditions (2.5*105 cells/ml seeding density, 10 ml 
Panserin C6000 medium + 4 µMTX, T25 cell culture flask, 12 days). Twenty µl culture 
supernatant was taken 5, 8 and 12 dpi and separated by SDS-PAGE on a 4-20% (w/v) SDS-
PAA gradient gel under reducing conditions. Three µg protein A purified H10_CHO_WT 
(III.2.1.3.1) were used as a positive control. Protein bands were visualised by Coomassie 
staining (II.2.4.1). Each gel was digitised (LAS-3000, Fujifilm, II.1.13) and the band pixel 
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intensity was evaluated with Aida Image Analyzer software (II.1.14). According to the peak 
integral of the antibody HC and the LC band, the extracellular HC:LC ratio was calculated. 
Since the HC (55 kDa) exhibits approximately the double weight of the LC (25 kDa), 
theoretically twice as many Coomassie molecules can stain the HC protein. This would result 
in a twice as intense HC protein band in a Coomassie stained SDS-PAA gel if a molar HC:LC 
ratio of 1:1 is present. For this reason the peak integral of the total pixel intensity per kDa was 
used for the calculation of the extracellular HC:LC ratio of H10 using the following formula:  
HC:LC ratio = (peak integral HC/55kDa) / (peak integral LC/25kDa)  
The HC:LC ratios of H10 in the culture supernatants of the samples as well as of the 
H10_CHO_WT positive control were determined in technical triplicates. Examples of the 
generated Coomassie stained SDS-PAA gels as well as the extracellular HC:LC results are 
shown in Figure III-7. 
  
 
Figure III-7: Extracellular HC:LC ratio of H10 during the cultivation process of DG44_H10I/T_4.p. 
DG44_H10I_4.p and DG44_H10T_4.p were cultivated in triplicates under standardised conditions 
(2.5*105 cells/ml seeding density, 10 ml Panserin C6000 medium + 4 µMTX, T25 cell culture flasks). Culture 
supernatants were taken 5, 8 and 12 dpi and 20 µl were separated by SDS-PAGE using a 4-20% (w/v) SD-SPAA 
gradient gel. Protein bands were visualised by Coomassie staining (II.2.4.1, A). Three µg protein A purified 
H10_CHO_WT (III.2.1.3.1) was used as a control and was separated equivalently to the samples (A). The 
HC:LC ratio of H10 in the culture supernatants as well as in the positive control was determined in triplicates via 
the total pixel intensity of the HC and LC band using the Aida evaluation software (II.1.14). Shown are examples 
of Coomassie stained SDS-PAA gels (A) which were used for HC:LC evaluation (B). Error bars represent the 
standard deviations gained from biological and technical triplicates. M: PageRuler prestained protein marker 
(Fermentas). 
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The Coomassie stained SDS-PAA gels shown in Figure III-7 (A) showed that the lowest 
background of contaminating proteins in the culture supernatant was present in those samples 
harvested 5 dpi and increased within the cultivation process. As expected, the extracellular 
HC:LC ratio of the protein A purified controls H10_CHO_WT was approx. 1 (HC:LC = 2:2) 
(Figure III-7, B), demonstrating that the evaluation procedure is reliable. The evaluated H10 
HC:LC ratio of DG44_H10I_4.p culture supernatant was around 0.5 (2:4) which indicated a 
LC excess of two LC molecules per assembled IgG in the culture supernatant. In contrast, the 
H10 HC:LC ratio in the culture supernatant of DG44_H10T_4.p was approximately 0.8 
(2:2.5) indicating an excess of one LC molecules per assembled two IgG only. Furthermore, 
the extracellular HC:LC ratio of H10 in the culture supernatant of DG44_H10I_4.p remained 
relatively constant during the entire cultivation process, whereas those of DG44_H10T_4.p 
decreased slightly during cultivation. 
In order to analyse whether or not the extracellular HC:LC ratio of H10 remains 
constant with increasing rounds of MTX-mediated gene amplification the culture supernatants 
of DG44_H10I_4/32/64/128.p as well as DG44_H10T_4/8/16/32/64/128.p cell cultures were 
analysed. For this, each polyclonal cell culture was cultivated under standardised conditions 
(2.5*105 cells/ml seeding density, 10 ml Panserin C6000 medium + 4 µMTX, T25 cell culture 
flasks, 5 days). The extracellular HC:LC ratio 5 dpi was determined in technical triplicates as 
described above by SDS-PAGE (II.2.4.1) followed by Aida evaluation (II.1.14). An example 
of the Coomassie stained SDS-gels as well as the HC:LC ratio of H10 in the culture 
supernatant is shown in Figure III-8. 
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Figure III-8: Extracellular HC:LC ratio of H10 with increasing gene amplification rounds of pAPI:H10 
and pAPT:H10 transfected DG44 cell cultures. DG44_H10I_4/32/64/128.p and 
DG44_H10T_4/8/16/32/64/128.p were cultivated under standardised conditions with the required MTX 
concentration (2.5*105 cells/ml seeding density, 10 ml Panserin C6000 medium + MTX, T25 cell culture flasks, 
5 days). Twenty µl of each culture supernatant was separated in triplicates by SDS-PAGE using a 4-20% (w/v) 
gradient SDS-gel followed by protein visualisation via Coomassie staining (II.2.4.1, A). Three µg of Protein A 
purified H10_CHO_WT (III.2.1.3.1) served as a control. According to the total pixel intensity of the HC and LC 
band, the HC:LC ratio was determined using the Aida evaluation software (II.1.14). Error bars represent the 
standard deviations gained from technical triplicates. M: PageRuler prestained protein marker (Fermentas), 
N.d. = Not determined. 
 
As shown in Figure III-8 (A), there is a quite low background of contaminating proteins in the 
serum-free culture supernatant. Furthermore, it could be demonstrated that the extracellular 
HC:LC ratio does not significantly alter during MTX based gene amplification in pAPI:H10 
transfected DG44 populations and remained relatively constant within a range of 0.41-0.45 
(2:4.5 – 2:5) (Figure III-8, B). In contrast to this, the HC:LC ratio of pAPT:H10 transfected 
DG44 populations was fluctuating between 0.59 and 0.78 (2:2.5 – 2: 3.5). In particular with 
MTX concentrations higher than 16 µM a decrease in HC:LC ratio from approx. 0.8 to 0.6 
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was observed. However, the gained ranges for both vector systems are comparable with those 
evaluated in the previous assay shown in Figure III-7.  
The results demonstrate that the vector pAPT:H10 allows a more efficient IgG 
assembly compared to pAPI:H10. In addition, the previous observation that higher IgG levels 
can be achieved with pAPT:H10 transfected DG44 cells compared to pAPI:H10 could be 
confirmed (Figure III-5). However, pAPI:H10 provides a more stringent coupling of HC and 
LC compared to pAPT:H10 since HC:LC level in the culture supernatant were less 
fluctuating. 
III.1.1.3 Functional comparison of H10 derived from tricistronic and bicistronic-tandem 
vector system 
As shown in chapter III.1.1.2, the tricistronic vector pAPI:H10 as well as the bicistronic-
tandem vector pAPT:H10 are suitable for the production of assembled IgG in DG44 cells. 
Whether or not the produced IgGs are functional was tested in a next step by using purified 
H10 from DG44_H10I_4.p and DG44_H10T_4.p culture supernatant which was analysed 
regarding its antigen specific binding. 
III.1.1.3.1  Small-scale H10 production, purification and quantification 
H10 was produced by DG44_H10I_4.p and DG44_H10T_4.p cell cultures in 50 ml 
Panserin C6000 production medium supplemented with 4 µM MTX (T75 flask). Culture 
supernatant was harvested when cells entered the death phase (8 dpi). Cells were subsequently 
removed by centrifugation, H10 in the culture supernatant was purified via protein A affinity 
chromatography (II.2.3.1) and its concentration in the load and elution fraction was quantified 
by SPR analysis (protein G; II.2.4.4). Twohundred ng H10 of each purification fraction were 
separated on a 4-20% (w/v) SDS-PAA gradient gel (II.2.4.1) and H10 fragments were 
visualised by immunoblot using GAHλLCAP and GAHFcAP detection antibodies and NBT/BCIP 
substrate (II.2.4.2, Figure III-9). 
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Figure III-9: Immunoblot analysis of H10 produced by pAPI:H10 and pAPT:H10 transfected, gene 
amplified DG44 cells before and after protein A purification. DG44_H10I_4.p as well as DG44_H10T_4.p 
were cultivated until the beginning of death phase in 50 ml Panserin C6000 production medium, which was 
supplemented with 4 µM MTX. H10 in the culture supernatant was purified via protein A affinity 
chromatography (II.2.3.1). Load and elution fractions of each batch, containing 200 ng assembled H10, were 
separated by SDS-PAGE under reducing and non-reducing conditions using a 4-20% (w/v) gradient SDS-gel 
(II.2.4.1). H10 was subsequently transferred to a nitrocellulose membrane (100 V, 90 min) and visualised by 
immunoblot analysis via GAHFcAP (0.33 µg/ml) and GAHλLCAP (0.07 µg/ml) detection antibodies (1h) as well as 
NBT/BCIP substrate (II.2.4.2).  M = PageRuler prestained protein marker  (Fermentas), r. = reducing conditions, 
n.r. = non-reducing conditions, LC2 = Light chain dimer. 
 
The immunoblot analysis (Figure III-9) showed that the LC excess in form of LC monomers 
(LC) and dimers (LC2), which are in particular visible in the non-reducing load fractions, 
could be removed by protein A affinity chromatography in both purification batches as 
demonstrated by comparison with the elution fractions. 
III.1.1.3.2  Functional analysis 
In order to test whether or not the two protein A purified H10 batches, derived from the 
tricistronic (pAPI:H10) and the bicistronic tandem (pAPT:H10) vector system, were 
functionally active (III.1.1.3.1), they were analysed by flow cytometry regarding their specific 
binding to CEANA3. For this purpose the recombinant cell line HEK293T-CEA_16 was 
used. This monoclonal cell line had been generated by single-cell sorting of the polyclonal 
HEK293T-CEA population (II.1.6) via FACS as part of this thesis (III.2.2.2). As a negative 
control HEK293T wild type (WT) cells were used, which do not express CEA on their cell 
surface (II.1.6). The flow cytometric analysis was performed as described in chapter II.2.2.6.1 
using 5 µg of each protein A purified H10 batches as well as GAH(H+L)FITC as secondary 
antibody. The chimeric IgG1 cPIPP was used as an isotype control and to exclude unspecific 
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binding of the used antibodies. Figure III-10 shows the flow cytometric results.   
 
Figure III-10: Flow cytometric analysis of purified H10 produced via the tricistronic or bicistronic-tandem 
vector system, respectively. Shown are FL1 histogram overlays of live-gated HEK293T WT (A; II.1.6) and 
HEK293T-CEA_16 (B; III.2.2.4.1) cell cultures, which had been labled with 5 µg protein A purified, 
DG44_H10I_4.p and DG44_H10T_4.p produced H10 (III.1.1.3.1)  as well as 3 µg GAH(H+L)FITC. Five µg cPIPP 
IgG1 served as an isotype negative control. HEK293T WT cells were used to monitor non-CEA specific cell 
binding. Dead cells were excluded from flow cytometric analysis by PI addition with a final concentration of 
2 µg/ml. Detailed procedure protocols are described in chapter II.2.2.6.1. 
 
As demonstrated in Figure III-10, H10 produced with both vector systems induced a 
significant, almost identical shift of HEK293T-CEA_16 cells indicating that CEA is 
specifically bound. In contrast to this, almost no shift was visible with the CEA-negative 
HEK293T WT control demonstrating that the observed shifts on CEA-positive HEK293T-
CEA_16 cells are not due to unspecific antibody binding. These results show that the 
tricistronic (pAPI:H10) as well as the bicistronic tandem vector system (pAPT:H10) are 
suitable for the production of functional IgG. Since the shifting of both H10 versions is almost 
identical, it can be assumed that there is no difference between both vector systems with 
respect to production of functional IgG. 
III.1.2 Optimisation of production conditions 
The two vector systems for high level production of IgGs had been successfully established 
(III.1.1). In a next step the H10 yield was further increased by the optimisation of production 
conditions. Therefore, different CHO media (III.1.2.1), the cultivation in the absence of MTX 
(III.1.2.2) as well as different cultivation vessels for up-scaling purposes (III.1.2.3) were 
tested.  
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III.1.2.1 Medium testing  
There are several CHO production media currently on the market which all promise to boost 
recombinant protein production yield. For further IgG production improvement the media 
CD CHO, CD OptiCHO, CD DG44, HyQ SFM4CHO, Panserin C6000, PowerCHO2, 
ProCHO4, ProCHO5 and RPMI (II.1.11) were tested using the DG44_H10I_4.p polyclonal 
cell line as a model. Standardised cultivation of DG44_H10I_4.p took place in biological 
triplicates in a 12-well plate (2.5*105 cells/ml seeding density, 3 ml medium supplemented 
with the recommended L-glutamine concentration). Since the specific productivity was shown 
to be the highest in the exponential growth phase (III.1.1.2.2, Figure III-5), the medium was 
harvested at 5 dpi in order to note differences in the volumetric productivity. H10 was 
quantified from the culture supernatant by capture ELISA (II.2.4.3) in triplicates using the 
coating antibody GAHFC and the detection antibody GAHλLCAP (II.1.3) (Figure III-11). 
 
Figure III-11: Testing of CHO cultivation media to boost the H10 production level. DG44_H10I_4.p was 
used as a model cell culture and was cultivated under standardised conditions in biological triplicates 
(2.5*105 cells/ml seeding density, 3 ml medium per well of a 12-well plate) using the media CD CHO, CD 
OptiCHO, CD DG44, HyQ SFM4CHO, Panserin C6000, PowerCHO2, ProCHO4, ProCHO5 and RPMI. All 
tested media were supplemented with the recommended L-glutamine concentration. Culture supernatants were 
taken 5 dpi and the H10 concentration was determined by capture ELISA in triplicates with the coating antibody 
GAHFC (0.73 µg/ml) and the detection antibody GAHλLCAP (0.04 µg/ml) (II.2.4.3). Error bars represent the 
standard deviations gained from technical and biological triplicates. 
 
According to the manufacturer the media CD CHO, RPMI and CD DG44 (23-38 µg/ml) are 
specialised for cell culture maintainance and promoted a 1.6-2.6 fold lower H10 yield 
compared to the production media HyQ SFM4CHO, ProCHO5, ProCHO4, Panserin C6000 
and PowerCHO2 (55-60 µg/ml H10) (Figure III-11). Only the CD OptiCHO production 
medium, which was used for the gene amplification process, mediated a production level of 
29 µg/ml and was thereby in the range of the maintainance media. However, it has to be noted 
that the optimal CO2 concentration of 8%, which is necessary for the pH of the medium, could 
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not be provided here due to limited lab space and since all media in the lab, including the 
others tested here, required a concentration of 5%. The highest H10 yield of approximately 
60 µg/ml was documented with PowerCHO2 followed by Panserin C6000. For 
pharmaceutical large-scale production PowerCHO2 would be recommended, since it is, in 
contrast to Panserin C6000, chemically defined. For smaller lab scales, however, 
Panserin C6000 was chosen as the most suitable DG44 production medium because it is 
cheaper compared to PowerCHO2 and in addition it is a “ready to use” medium, 
supplemented with glutamine and phenol red.  
III.1.2.2 Long-term cultivation in the presence and absence of MTX 
Besides the effect of yield increase gained by MTX-mediated gene amplification (III.1.1.2.1), 
it was also observed that MTX reduces the cell growth (III.1.1.2.1). Based on these results it 
would have been expected that the cultivation of the generated cell cultures in the absence of 
MTX lead to a production increase due to higher cell densities. To analyse this hypothesis, the 
polyclonal cell culture DG44_H10I_64.p as well as the low and high producing monoclonal 
cell lines DG44_H10I_64.14 and DG44_H10I_64.5, which had been generated by LD from 
DG44_H10I_64.p (III.1.3.1), were cultivated in the presence and absence of MTX for a 
period of 102 days. For this, the cells were passaged every 3-4 days in a fresh T25 cell culture 
flask with a seeding density of 1*105 cells/ml in 5 ml Panserin C6000 medium with and 
without 64 µM MTX. At the end of each passaging cycle the viable cell density was 
determined by CASY cell counting (II.2.2.1) and the H10 concentration in the culture 
supernatant was evaluated via SPR quantification (II.2.4.4). The results of this assay are 
shown in Figure III-12. 
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Figure III-12: Comparison of a polyclonal cell cultures and two monoclonal cell lines regarding viable cell 
density, H10 yield and specific productivity in the presence and absence of MTX over a period of 
102 days. The initial polyclonal population DG44_H10I_64.p as well as the derived monoclonal cell lines 
DG44_H10I_64.14 (low producer) and DG44_H10I_64.5 (high producer) (III.1.3III.1.2.3) were cultivated in the 
presence and absence of 64 µM MTX for a period of 102 days. Every 3-4 days cells were passaged in a T25 cell 
culture flask with a seeding density of 1*105 cells/ml in fresh Panserin C6000 medium supplemented with or 
without 64 µM MTX. At the end of each passaging cycle, the viable cell density was determined by CASY cell 
counting (II.2.2.1) and the H10 concentration of in the culture supernatant was determined via SPR analysis 
(protein G chip, II.2.4.4). Specific productivity was calculated according to the viable cell densities and H10 
concentrations shown. Trendlines point out the tendency of viable cell density, H10 concentration and 
productivity development within time. dpi = days post inoculation. 
 
According to the data in Figure III-12 it is noticable that the H10 concentration in the culture 
supernatant as well as the specific productivity from all three tested cell cultures decreased 
with increasing passaging cycles in the absence of MTX. Along with this, the cell 
proliferation is enhanced as demonstrated according to increasing viable cell densities within 
time. Interestingly, the latter was also examined for the cultivation with MTX 
supplementation, however to a lower extent. Besides this observation, the gained results in the 
presence of MTX are quite different between the polyclonal culture DG44_H10I_64.p and the 
monoclonal cell lines DG44_H10I_64.14 and DG44_H10I_64.5. The H10 concentration in 
the culture supernatant of the polyclonal culture as well as its specific productivity decreases 
constantly during cultivation time whereas there was a consistent increase of H10 
concentration in both monoclonal cell lines observed. Importantly the specific productivity of 
the monoclonal cell line DG44_H10I_64.14 remained constant for the whole cultivation 
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period. In contrast, the productivity of the DG44_H10I_64.5 cell line decreased similar to the 
polyclonal mother population DG4_H10I_64.p. 
To summarise, the cultivation in the absence of MTX is not a suitable tool for yield 
improvement. Longer cultivation periods of monoclonal cell lines however result in an 
increase of H10 yield by a factor of 1.2-1.6 due to elevated cell growth. 
III.1.2.3 Cultivation vessel testing for large-scale protein production 
In the previous experiments the cultivation of H10 producing DG44 cells took place 
exclusively in either micotiter plates or cell culture flasks in volumes of max. 50 ml. The 
switch to an agitating system, as implemented in industrial processes, is an important step for 
target protein production at a larger scale. Therefore different cultivation vessels enabling a 
shaken cultivation and production process has been tested. Again, the polyclonal population 
DG44_H10I_4.p served as a model cell culture (III.1.1.2.1). It was cultivated in biological 
triplicates under standardised conditions (7*104 cells/ml seeding density, 
75 ml Panserin C6000 medium + 4 µM MTX, 17 days) using 250 ml square shaped glas 
bottles (Schott) as well as 250 ml polycarbonate, vented caps Erlenmeyer flasks with and 
without baffles (Corning). In order to guarantee sufficient gas exchange, the square bottle’s 
lids were opened by 1/3 of a turn and fixed with autoclaving tape. The filling volume of 30%, 
a rotational diameter of 25 mm as well as the shaking speed of 130 rpm was recommended by 
Muller et al. (2005) and Corning, respectively. Cultivation took place on a Certomat MO II 
orbital shaker (Sartorius) (II.1.13) which was placed inside the CO2 incubator. Viable cell 
density, PCV and H10 concentration in the culture supernatant was analysed at 6, 11 and 
17 dpi (Figure III-13). 
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Figure III-13: Cultivation vessel testing for large-scale protein production in a shaking system. 
DG44_H10I_4.p was cultivated under standardised conditions (7*104 cells/ml seeding density, 75 ml 
Panserin C6000 medium + 4 µM MTX, 130 rpm, 25 mm rotational diameter) in biological triplicates using 
250 ml square glas bottles as well as 250 ml polycarbonate, vented cap Erlenmeyer flasks with baffle as well as 
without baffle. The H10 concentration (A, ELISA using GAHFC (0.73 µg/ml) and GAHλLCAP (0.04 µg/ml) 
(II.2.4.3)), the viable cell density (B, CASY cell counting, II.2.2.1), the PCV (C, VoluPAC packed cell volume 
determination, II.2.2.1) and the specific productivity (D) were determined 6, 11 and 17 dpi. Error bars represent 
the standard deviations gained from biological and technical triplicates. dpi = days post inoculation; 
PCV = packed cell volume.  
 
As shown in Figure III-13 (A), the cell culture cultivated in Erlenmeyer flasks without baffle 
(Ew/ob) and square bottles achieved an average H10 yield of 60 µg/ml. However, 30% lower 
H10 concentrations were reached by the use of Erlenmeyer flasks with baffles (Ewb). The 
highest viable cell density of 7*105 cells/ml could be documented for the culture in Ew/ob 
(Figure III-13 B). Regarding the PCV approximately the same total cell density was reached 
with every device at 17 dpi, whereas the PCV increase until 11 dpi remained at approximately 
0.2% in cultures of square bottles and Erlenmeyer flasks with baffles (Figure III-13 C). The 
specific productivity was found to be the highest in Erlenmeyer flasks with baffles (Figure 
III-13 D). 
In summary, square bottles and Ew/ob are most suitable for the production of H10 in 
suspension adapted DG44 cells. Since glass square bottles are reusable compared to the 
polycarbonate Erlenmeyer flasks and since they are in addition very space-saving, which is in 
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particular important for up-scaling purposes, they were used later on for large-scale 
H10_CHO_WT production (III.2.1.3.1).  
III.1.3 Establishment of an efficient gene amplification procedure  
There are two gene amplification strategies known for MTX-mediated gene amplification 
which have been described in chapter I.1.3: The pool strategy and the individual clone 
strategy. Once a high producing polyclonal cell culture is established via gene amplification, 
monoclonal cell lines have to be generated in order to isolate high producer and to provide a 
more stable expression level over a long cultivation period, as demonstrated in chapter 
III.1.2.2. For the generation of a suitable, high level IgG producing cell culture, the pool and 
the individual clone strategy were compared here. 
III.1.3.1 Pool strategy 
Via the pool strategy polyclonal cell cultures undergo gene amplification from which 
monoclonal high producers can be isolated. Previously this strategy was already used for the 
generation of DG44_H10I_64.p and DG44_H10T_8.p (III.1.1.2.1). In a next step, these high 
producing polyclonal cultures were used for monoclonal cell line generation by LD (II.2.2.5). 
For this, six cells per well were sawn in five 96-well plates using Panserin C6000 medium 
supplemented with 64 or 8 µM MTX, respectively. In general, 4-6 clones per 96-well plate 
could be regenerated. Subsequent screening of monoclonal cell lines by the cultivation under 
standardised conditions (2.5*105 cells/ml seeding density, 1 ml Panserin C6000 medium + 
64 µM / 8 µM MTX, 24-well plate, 5 days) followed by SPR-based H10 quantification 
(protein G chip, II.2.4.4) of the culture supernatants, lead to the identification of two high 
producers (Figure III-14). As a reference the corresponding initial populations were analysed 
equivalently. 
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Figure III-14: Screening of monoclonal cell lines. Monoclonal cell lines were generated by LD (II.2.2.5) from 
the polyclonal populations DG44_H10I_64.p (A) and DG44_H10T_8.p (B). The regenerated clones as well as 
their corresponding initial cultures were cultivated under standardised conditions (2.5*105 cells/ml seeding 
density, 1 ml Panserin C6000 medium + 64 µM / 8 µM MTX, 24-well plate, 5 days) and H10 in the culture 
supernatant was subsequently quantified by SPR analysis (protein G chip, II.2.4.4).  
 
Twenty-two clones from DG44_H10I_64.p and 32 from DG44_H10T_8.p could be generated 
by LD whereas the high producing monoclonal cell lines DG44_H10I_64.5 (94 µg/ml H10) 
and DG44_H10T_8.25 (100 µg/ml) could be identified (Figure III-14). In both cases the yield 
of the monoclonal cell lines has been significantly improved, compared to their polyclonal 
initial population. Noticeable, the majority of the generated monoclonals exhibited lower H10 
yields compared to their initial culture (55% of DG44_H10I_64.p and 78% of 
DG44_H10T_8.p). 
III.1.3.2 Individual clone strategy 
The individual clone strategy is performed equivalent to the pool strategy, but with the 
difference that monoclonals are selected before gene amplification and that only monoclonal 
high producers are exposed to MTX inducing gene amplification. Since the bicistronic tandem 
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vector strategy had previously turned out to be the most suitable for high level IgG 
production, the individual clone strategy was proceeded only with the bicistronic tandem 
vector system (III.1.1.2.1). 
DG44_H10T_0.p (III.1.1.2.1) was used as an initial culture from which monoclonal, 
high producer were generated by LD (II.2.2.5). This time the LD procedure was modified, 
however, only three cells per well were sown in 96-well microtiter plates and the serum-free 
EX-CELL CHO clone regeneration medium (II.1.10) was used. In addition clonal 
regeneration was automatically documented using the Freedom Evo roboter (Tecan) which 
transferred the microtiter plates into the Cellavista documentation machine via plate specific 
bar codes. By this, pictures of each well were taken every 2-3 days allowing the backtracking 
of colony formation and the identification of wells in which only one cell regenerated. 
Thereby wells containing monoclonal cell lines could be identified. Two weeks after cell 
seeding, each well was supplemented with 200 µl Panserin C6000 medium. Wells containing 
cell colonies could be identified two weeks later via colour change of the pH indicator phenol 
red and by microscopic analysis. From 56 microtiter plates, 1320 clones regenerated with an 
average regeneration efficiency of 10-20 clones per 96-well plate. The H10 concentration of 
the culture supernatant from recovered wells four weeks after seeding was determined by SPR 
quantification (protein G chip, II.2.4.4) and is shown in Figure III-15. 
 
  
Figure III-15: Screening of clones which were generated by LD from DG44_H10T_0.p initial culture. 
Monoclonal cell lines were generated by LD (II.2.2.5) from the initial culture D44_H10T_0.p (III.1.1.2.1) by 
seeding three cells per well in 56 96-well plates using EX CELLCHO regeneration medium (II.1.11). Cultivation 
took place in a microtiter well incubator at 37°C and 5% CO2. Clonal regeneration was documented automaticaly 
every 2-3 days via a Freedom Evo roboter (Tecan) which transferred microtiter plates according to their 
individual bar codes into the Cellavista documentation machine (Innovatis). Two weeks after seeding 200 µl 
Panserin C6000 medium was added to each well. The culture supernatant of wells containing regenerated clones 
(1320 in total) was taken two weeks later and H10 was quantified by SPR analysis (protein G chip, II.2.4.4). 
Shown are the H10 concentrations of the culture supernatants four weeks after sowing, which were determined 
by SPR quantification (A). In addition, the clonal production distribution is shown in a histogram (B). 
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A large amount of regenerated clones (43%) exhibited no detectable H10 production (Figure 
III-15, A and B). Moreover, the groups of H10 producers diminished with increasing H10 
concentration in the culture supernatant (Figure III-15, B). Clones producing between 0.35 
and 0.9 mg/ml H10 under the given conditions were declared as high producer. The clonality 
of these 135 clones was checked by backtracking of the colony generation process of each 
clone, which had been documented by Cellavista previously. Approximately 35% of tested 
clones were eventually identified as polyclonal, 62% as monoclonal and the rest could not be 
allocated. Using this improved LD procedure with EX-CELL CHO regeneration medium, it 
was possible to increase the efficiency of clone regeneration from 4-6 clones (III.1.3.1) to 
10-20 clones per plate and to identify their clonality via automated documentation of cell 
growth in each well. 
In order to compare the production level of the 70 monoclonal high producers with 
those of the DG44_H10T_0.p initial culture, they were cultivated under standardised 
conditions (2.5*105 cells/ml seeding density, 1 ml PowerCHO2 medium + 4 mM L-
glutamine, 24-well plates, 7 days). Culture supernatant was harvested after 7 days and 
analysed by SPR quantification (Protein G chip, II.2.4.4). The results are shown in Figure 
III-16. 
 
Figure III-16: Comparison of product yield between DG44_H10T_0.p initial culture and monoclonal, high 
producers. DG44_H10T_0.p polyclonal, initial cultures as well as 70 of their monoclonal, high producing 
progenies were cultivated in biological duplicates under standardised conditions (2.5*105 cells/ml seeding 
density, 1 ml PowerCHO2 medium + 4 mM L-glutamine, 24-well plates, 7 days). Shown are the H10 
concentrations in the culture supernatant at 7 dpi as determined by SPR (Protein G chip, II.2.4.4). 
Blue = DG44_H10T_0.p initial culture; red = clones which were chosen for gene amplification.  
 
Compared to the DG44_H10T_0.p initial polyclonal culture the selected monoclonals show a 
yield increase of 2.6-10 fold. Red highlighted clones were chosen for further gene 
amplification rounds (Figure III-16). On purpose, also low and medium producers were 
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selected, to analyse whether or not there is a correlation between the production level before 
and after the gene amplification process.  
Gene amplification of chosen clones took place in a ISF1-X incubator shaker (Kühner, 
II.1.13) using 50 ml bioreactor tubes (TPP) (10 ml PowerCHO2 medium + 4 mM L-glutamine 
+ MTX, 180 rpm, 50 mm rotational diameter). Since it was already demonstrated that 8 µM 
MTX is the most suitable concentration for the bicistronic tandem vector system (III.1.1.2.1), 
intermediate cultures were not kept. Instead, cells were exposed to increasing MTX 
concentrations by using the same filter tube for the whole gene amplification procedure until 
8 µM MTX was reached. MTX-mediated gene amplification took place as described in 
chapter II.2.2.4. 
In order to compare the expression levels of the resulted polyclonal 
DG44_H10T_0.m_8.p cell lines, they were cultivated under standardised conditions in 
biological duplicates (1*105 cells/ml seeding density, 10 ml complete PowerCHO2 medium + 
8 µM MTX, filter tube 50 bioreactors, 180 rpm, 50 mm rotational diameter, 20 days). H10 in 
the culture supernatant at 5, 10, 14 and 20 dpi were quantified by SPR-analysis (protein G 
chip, II.2.4.4). The results are shown in Figure III-17. 
 
 
Figure III-17: Comparison of H10 accumulation between gene amplified DG44_H10T_0.m_8.p polyclonal 
cultures. The previously selected monoclonal cell lines DG44_H10T_0.m (Figure III-16) were gene amplified 
until MTX concentrations of 8 µM were achieved (II.2.2.4). The corresponding gene amplified 
DG44_H10T_0.m_8.p polyclonal cultures were cultivated in biological dublicates under standardised conditions 
(1*105 cells/ml seeding density, 10 ml PowerCHO2 medium + 4 mM L-glutamine + 8 µM MTX, filter tube 50 
bioreactors, 180 rpm, 50 mm rotational diameter, 20 days). Shown are the average H10 concentrations in the 
culture supernatant 5, 10, 14 and 20 dpi as determined by SPR (protein A chip, II.2.4.4). Error bars represent the 
standard deviations of biological duplicates. 
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There was no correlation between the H10 yield of non-amplified clones and the 
corresponding amplified, polyclonal cultures observable (Figure III-17). In addition, some 
amplified cultures even produced levels in the range of the non-amplified culture. The highest 
H10 concentration of 335 µg/ml was measured in the culture supernatant of the 
DG44_H10T_0.119_8.p culture at 20 dpi.  
Due to time limitations, the generation of monoclonal cell lines could not be 
performed in the frame of this thesis. In chapter III.1.4, a direct comparison of the expression 
levels achieved with both strategies is demonstrated.  
III.1.4 Summary of improvement steps 
The cloning of two polycistronic vectors (III.1.1.1), the optimisation of MTX-based gene 
amplification (III.1.1.2.1), the identification of a suitable CHO production medium (III.1.2.1) 
and the testing of different gene amplification strategies (III.1.3) enabled the establishment of 
a production platform for efficient IgG production. The different improvement steps achieved 
in this thesis were verified by a final comparison assay in which the best H10 producing 
cultures of each improvement step were cultivated under standardised conditions. In this 
context, the tricistronic vector system and the bicistronic tandem vector system were directly 
compared. In addition, a direct comparison of cultures, derived from gene amplification via 
the pool strategy and via the individual clone strategy, was conducted.  
For the comparison of the tricistronic and the bicistronic tandem vector system, the 
polyclonal cultures DG44_H10I_0/4/64.p and DG44_H10T_0/4/8.p (III.1.1.2.1) as well as the 
monoclonal cell lines DG44_H10I_64.5 and DG44_H10I_8.25 (III.1.3.1) were used. These 
cell cultures had been generated according to the pool strategy (III.1.3.1), which had been 
documented to be less time intensive and to result in higher antibody yields under the given 
amplification conditions (III.1.3). The comparative cultivation took place under standardised 
conditions (2.5*105 cells/ml seeding density, 10 ml Panserin  C6000 medium + MTX,  T25 
flasks, 5 days) using Panserin C6000 medium, which had been shown as most suitable for 
high level IgG production (III.1.2.1). The H10 concentration in the collected culture 
supernatants was analysed via SPR quantification (protein G chip, II.2.4.4) and is shown in 
Figure III-18:. 
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Figure III-18: Production improvement by the use of an efficient production medium, gene amplification 
and the generation of monoclonal cell lines.  The cell lines DG44_H10I_0/4/64.p, DG44_H10I_64.5 (A) as 
well as DG44_H10T_0/4/8.p and DG44_H10T_8.25 (B) were cultivated under standardised conditions for 5 
days using the production medium Panserin C6000 which was supplemented with the required MTX 
concentration (2.5*105 cells/ml seeding density, 10 ml Panserin  C6000 + MTX,  T25 flasks). H10 in the culture 
supernatant was quantified by SPR technology (protein G chip, II.2.4.4). Error bars represent the standard 
deviations gained from biological and technical triplicates. 
 
The highest H10 yield improvement between 410 fold and 480 fold has been achieved by 
gene amplification (Figure III-18:). A minor impact on product yield, however, had the 
generation of monoclonal cell lines. Only 1.5 times or no yield improvement could be shown 
in this example. However, this factor depends on the number of clones which are screened, as 
for the individual clone strategy (Figure III-16). Confirming the results of chapter III.1.1.2.2 
(Figure III-5), it could be demonstrated here that 1.7 fold higher H10 yields could be achieved 
with the bicistronic vector system pAPI:H10 compared to the tricistronic vector system 
pAPT:H10.  
The monoclonal cell line DG44_H10I_64.5 (III.1.3.1, Figure III-14) was used for 
large scale H10 production (III.2). To characterise this production cell line regarding maximal 
achievable H10 level and specific productivity in a batch process, an independent timecourse 
in biological replicates was performed with this cell line (1*105 cells/ml seeding density, 
10 ml complete PowerCHO2 medium + 64 µM MTX, filter tube 50 bioreactors, 180 rpm, 
50 mm rotational diameter, 22 days). Yields of up to 312 µg/ml H10 could be documented 
and a specific productivity of 23 pg/cell/day was evaluated according to the slope of growth 
and production curves in the exponential growth phase (data not shown). 
 To determine which gene amplification strategy (pool or individual clone strategy) is 
most suitable for high H10 production, the polyclonal cultures DG44_H10T_8.p and 
DG44_H10T_0.119_8.p, which had been generated via the pool (III.1.1.2.1, III.1.3.2) and the 
individual clone strategy (III.1.3.2), respectively, were cultivated under standarised conditions 
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in biological duplicates (2.5*105 cells/ml seeding density, 10 ml complete PowerCHO2 
medium + 8 µM MTX, filter tube 50 bioreactors, 180 rpm, 50 mm rotational diameter, 22 
days). Viable cell densities and H10 concentrations were determined via CASY cell counting 
(II.2.2.1) and SPR analysis (protein A chip, II.2.4.4), respectively (Figure III-19). 
 
   
Figure III-19: Comparison of best producers generated by gene amplification using the pool or the 
individual clone strategy, respectively.  The polyclonal cell line DG44_H10T_8.p was generated by gene 
amplification via the pool strategy from the polyclonal culture DG44_H10T_0.p (III.1.3.1). In contrast to this, 
the polyclonal culture DG44_H10T_0.119_8.p originated from the monoclonal cell line DG44_H10T_0.119, 
which had been gene amplified via the individual clone strategy (III.1.3.2). These two gene amplified, polyclonal 
cultures were cultivated under standardised conditions (1*105 cells/ml seeding density, 10 ml complete 
PowerCHO2 medium + 8 µM MTX, filter tube 50 bioreactors, 180 rpm, 50 mm rotational diameter, 22 days). 
Shown are the average viable cell densities (A) and H10 concentrations of the culture supernatants as quantified 
by SPR technology (protein G chip, II.2.4.4) (B). Error bars represent the standard deviations gained from 
biological duplicates. 
 
Two fold higher maximal viable cell densities and production levels were achieved with 
DG44_H10T_8.p (4.5*106 cells/ml; 554 µg/ml) compared to DG44_H10T_0.119_8.p 
(2*106 cells/ml; 304 µg/ml) (Figure III-19 A and B). As soon as the death phase was reached, 
cells started to aggregate, making it impossible to determine viable cell densities at time 
points later than 12 dpi. Specific productivities of 25 pg/cell/day and 15 pg/cell/day, 
respectively, were determined according the slope of growth and production curves in the 
exponential growth phase (Figure III-19 A and B). Based on theses results, gene amplification 
via the pool strategy resulted in a two fold higher H10 yield compared to cultures generated 
via the individual clone strategy.  
 In summary, up to 2.5 fold higher H10 yields were reached by antibody HC:LC 
improvement using the bicistronic tandem vector pAPT:H10 (III.1.1.2.2). Furthermore, gene 
amplification resulted in a yield improvement of up to 480 fold (III.1.1.2.1, III.1.4). In this 
context the pool strategy was shown to be two fold more effective compared to the individual 
clone strategy (III.1.3.2, III.1.4). Moreover, antibody yields were elevated up to two fold by 
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the use of the serum-free CHO production media Panserin C6000 and PowerCHO2 instead of 
the commonly used OptiCHO medium (III.1.2.1). In this thesis the highest H10 yield of 
554 µg/ml with a specific productivity of 25 pg/cell/day was obtained with the pAPT:H10 
transfected, gene amplified, polyclonal culture DG44_H10T_8.p in a normal batch process 
using PowerCHO2 medium (III.1.4, Figure III-19). As previously shown, this yield is very 
likely to be significantly improved up to 10 fold by the isolation of high producing clones via 
LD (III.1.3.2) and up to 1.6 fold by long-term cultivation of the resulting monoclonal high 
producer in the exponential growth phase (III.1.2.2).  
According to the results of all optimisation steps (III.1) a final protocol for the 
generation of high level IgG producing monoclonal DG44 cultures was composed and is 
shown in Figure III-20. Based on this protocol gene amplified monoclonal high producers can 
be generated within 4 – 6.5 months. Optional a selection for fast growing subclones can be 
performed subsequently which takes additional 5 – 5.5 months. 
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Figure III-20: Decision tree for the generation of high level IgG producing DG44 cultures established 
according to the cell line optimisation steps in this thesis. Grey boxes = process steps; green diamonds = 
questions how to continue; blue boxes = final production cell cultures; bold = required time; orange = name of 
the final production cell culture; grey arrows = expected yield improvement as determined in this work. 
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III.2 Production and analysis of two H10 glycoforms in CHO cells 
In the 2nd part of the PhD thesis, the anti-CEA specific human H10 antibody was produced in 
DG44 cells with two different N-glycan structures (III.2.1) followed by the functional 
analysis of both H10 versions regarding its CEA binding characteristics (III.2.2) and its ability 
to activate effector functions (III.2.3). For the production of H10 the previously established 
CHO production platform was used for high level H10 production (III.1). Considering that at 
this time point the more efficient bicistronic tandem vector pAPT:H10 had not been cloned 
yet, the tricistronic vector pAPI:H10 was used here for H10 production (III.1.1.1). 
III.2.1 Production and purification of H10 bearing a complex or a bisected 
N-glycan structure 
Umana et al. (1999) described that ADCC induction efficiency of a CHO produced IgG can 
be improved by glycoengineering. In order to generate an IgG with such enhanced effector 
functions, an H10 version bearing a bisected N-glycan structure (H10_CHO_GnTIII) should 
be produced in DG44 cells and afterwards compared with a non-glycoengineered H10 version 
exhibiting a complex CHO glycoform (H10_CHO_WT).  
For this purpose, both H10 variants have been produced and purified in a larger scale 
to provide sufficient material for its subsequent functional characterisation (III.2.2). 
H10_CHO_WT was produced by the previously generated, monoclonal cell line 
DG44_H10I_64.5 (III.1.3.1) whereas the generation of an H10_CHO_GnTIII producing 
monoclonal cell line is described in this chapter. The flow scheme in Figure III-21 gives an 
overview of the production cell lines cell line generation, the glycoengineering procedure as 
well as the large-scale H10_CHO_WT and H10_CHO_GnTIII production and purification 
process.  
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Figure III-21: Flow chart for the generation of high level H10 producing, monoclonal DG44 cell lines 
producing a complex or a bisected N-glycan structure, respectively. Wild type DG44 cells (WT DG44) were 
nucleofected (II.2.2.3) with the tricistronic H10 expression vector pAPI:H10 (III.1.1.1.1) and after two weeks 
selection in hypoxanthine and thymidine deficient medium, a stable polyclonal, H10 secreting cell culture was 
generated (DG44_H10I_0.p; III.1.1.2.1). Eleven gene amplification rounds of the tricistronic expression cassette 
(III.1.1.2.1) lead to the high producing polyclonal DG44 cell line DG44_H10I_64.p (III.1.1.2.1). Subsequent LD 
(II.2.2.5) and screening of generated clones by SPR quantification (II.2.4.4) lead to the isolation and 
identification of the monoclonal, high producing cell line DG44_H10I_64.5 (III.1.3), which was used for the 
large-scale production of H10 bearing a complex CHO N-glycan structure (H10_CHO_WT; III.2.1.3.1). 
Subsequently, the DG44_H10I_64.5 monoclonal cell line was overtransfected with the pTRACER:GnTIII vector 
(III.2.1.1), which encodes the β 1-4-N-acetylglucosaminyltransferase III (GnTIII). After two weeks of selection 
with the antibiotic zeocin, stable polyclonal H10 and GnTIII transgenic cell cultures developed, from which the 
monoclonal DG44_H10I_64.5_GnTIII.8 was isolated by LD and identified as high producer by subsequent SPR-
based screening. This cell line was used for large-scale production of H10 with a bisecting N-glycan structure 
(H10_CHO_GnTIII; III.2.1.3.2), which was purified, like H10_CHO_WT, from the culture supernatant of a 
large-scale batch via protein A affinity chromatography. Grey boxes = process steps; blue boxes = final 
production cell lines and expected glyco structures; orange = name of the corresponding DG44 cell line. 
III.2.1.1 Cloning of pTRACER:GnTIII  
By the insertion of the β1-4-N-acetylglucosaminyltransferase III (GnTIII) into the inner golgi 
membrane of DG44_H10I_64.5 cells (III.1.3), secretory proteins should feature a glycan 
pattern with a branching N-acetylglucosamine (Gn) in their complex CHO N-glycan structure. 
The CHO expressed, human GnTIII gene, including their leader and membrane anchor, were 
synthetically produced and codon optimised for Nicotiana tabacum by the company Geneart. 
According to the Graphical Codon Usage Analyser 2.0 software (Geneart) the codon 
optimisation for N. tabacum does not critically influence the relative adaptiveness in CHO 
(Cricetulus griseus) so that the same cDNA can be used for GnTIII expression in both 
organisms. 
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For GnTIII expression, the mammalian expression vector pTRACER-SV40 (II.1.8) was used. 
This vector enables moderate expression of GnTIII via its SV40 promoter, which is known to 
induce a weaker expression in CHO cells compared to the commonly used CMV promoter 
(Liao and Sunstrom 2006). A low expression rate is desired here, since GnTIII overexpression 
is known to inhibit cell growth (Umana et al. 1999a). As a first cloning step the GnTIII 
cDNA, including a 5’ attached cmyc tag, was cloned into pGEX-5x-3 by double digestion of 
pTRA:GnTIII with BspHI/XbaI as well as double digestion of the shuttle vector 
pGEX-5x-3:CEANA3 (III.1.1.1.1) with NcoI/NotI followed by the ligation of the resulting 
fragments to form the intermediate vector pGEX-5x-3:GnTIII. Double digestion with BamHI 
led to the excision of a GnTIIIcmyc fragment, which was subsequently blunt ended by T4 
DNA polymerase and eventually ligated in the PmeI double digested pTRACER vector for 
the generation of the final vector pTRACER:GnTIII. All described cloning steps are shown in 
Figure III-22. Finally, the sequence of GnTIIIcmyc was verified by sequencing (III.1.1.2.1). 
 
 
Figure III-22: Cloning of the mammalian expression vector pTRACER:GnTIII. Restriction enzyme 
recognition sites which were used for the next cloning steps are highlighted in orange. 
GnTIII = β1-4-N-acetylglucosaminyltransferase III; cmyc = cmyc tag; CEANA3 = N and A3 domain of the 
carcinoembryonic antigen, which was used as a spacer gene sequence here; PSV40 = Simian virus 40 promoter; 
PA = polyadenylation site. Each cloning step is described in the text and detailed cloning procedure protocols are 
stated in chapter II.2.1. 
III.2.1.2 Generation of glycoengineered monclonal DG44 cell lines producing H10 with a 
bisecting N-glycan structure  
H10 with a bisecting N-glycan structure was generated by coexpression of the 
glycosyltransferase GnTIII in H10 expressing DG44 cell lines. For this, the monoclonal 
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H10_CHO_WT high producer DG44_H10I_64.5 (III.1.3) was overtransfected with the 
linearised pTRACER:GnTIII vector (III.2.1.1). After the extablishment of a stable polyclonal 
cell culture (II.2.2.3), monoclonal cell lines were generated (DG44_H10I_64.5_GnTIII) via 
LD (II.2.2.5) and subsequently analysed regarding their GnTIII expression.  
As the detection of GnTIII in the cell lysate of DG44_H10I_64.5_GnTIII.n monoclonals was 
not successful by immunoblot or ELISA via its cmyc tag (data not shown), the genomic 
integration of GnTIII including its cmyc tag was checked by PCR (II.2.1.7). For this genomic 
DNA, which had been extracted from DG44_H01I_64.5_GnTIII clones using the Macherey 
Nagel Nucleospin Tissue kit (II.1.2), was used as a template and the GnTIII and cmyc specific 
primer F-GnTIII and B-GnTIII (Table VII-2). Agarose gelelectrophoresis separated PCR 
products, including the non template negative control and pTRACER:GnTIII positive control, 
showed that all twelve tested monoclonal DG44_H10I_64.5_GnTIII cell lines contained the 
GnTIII gene with attached cmyc tag integrated in their genome (Figure III-23). 
 
Figure III-23: PCR in order to check genomic integration of GnTIII and the presence of a cmyc tag. 
Genomic DNA was extracted from generated DG44_H10I_64.5_GnTIII clones using the Macherey Nagel 
Nucleospin Tissue kit (II.1.2) and GnTIII gene including its cmyc tag was amplified by PCR (II.2.1.7) using the 
GnTIII specific primer F-GnTIII and the cmyc specific primer B-GnTIII (Table VII-2). A sample without 
template and one with pTRACER:GnTIII template served as a negative and positive control, respectively. 
Shown is an ethidium bromide stained, 1.2%  (w/v) agarose gel (30 min, 120 V) in which 10 µl of each PCR 
sample were separated (II.2.1.6). 1kb = 1kb molecular marker (Roth). 
 
Besides genomic integration of GnTIIIcmyc, the H10 expression levels in the culture 
supernatant of DG44_H10I_64.5_GnTIII cell lines (Panserin C6000 + 64 µM MTX + 
300 µg/ml Zeocin, 6-well plate) were checked by SPR quantification using a protein G chip 
(II.2.4.4). The production levels of the twelve tested clones vairied between 26 µg/ml and 
86 µg/ml of H10. H10 glycovariants of the identified four highest producer, clone 1 
(79.62 µg/ml H10), clone 4 (83.02 µg/ml H10), clone 8 (85.94 µg/ml H10) and clone 14 
(70.53 µg/ml H10), were purified in a small-scale of 50 ml culture supernatant by protein A 
affinity chromatography (II.2.3.1). Their N-glycan structure was subsequently analysed by Dr. 
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Maurice Henquet at Plant Research International (Wageningen, NL) using MALDI 
glycopeptide analysis (II.2.5). Glycananalysis results are shown in Table III-1. 
Table III-1: MALDI determined N-glycan structure of DG44_H10I_64.5_GnTIII clone 1, 4, 8 and 14 
produced H10. 
Glycoform abbreviation 
 
Glycoform Clone 1 
[%TIC]
Clone 4 
[%TIC]
Clone 8 
[%TIC] 
Clone 14
[%TIC] 
Gn2M3 9.2 % 8.1 % 7.8 % 5.3% 
Gn2FM3 25.2 % 19.3 % 21.1 % 20.3 % 
GalGn2FM3 14.5 % 22.5 % 18.2 % 15.0 % 
Gal2Gn2FM3 1.3 % 5.2 % 2.8 % 0.8 % 
Gn3FM3 19.2 % 10.9 % 14.5 % 21.0 % 
GalGn3FM3 20.2 % 22.5 % 24.5 % 30.3 % 
Total amount of bisecting N-glycans 39.4 % 33.4 % 39.0 % 51.3 % 
TIC = mass spectrometry total ion current = amount of N-glycanstructure in percent; Gn = N-acetylglucosamin 
(square); M = mannose (circle); Gal = galactose (star); F = 1.6-alpha fucose (triangle); highlighted sections = 
bisected N-glycan structures 
 
The tested clones 1, 4, 8 and 14 produced H10 with bisected N-glycan structures in a range of 
33-51 %. However, there were problems with the fragmentation during LC-ESI-QTOF, 
leading to lower percentage of bisecting N-glycan structure as expected. Therefore, the 
N-glycan analysis needed to be repeated with the H10_CHO_GnTIII final batch which was 
eventually used for functional characterisation (III.2.2). Since there was not much difference 
between the total levels of bisected N-glycan structures of clone 1, 8 and 14, the highest H10 
producer clone 8 (DG44_H10I_64.5_GnTIII.8) was chosen for large scale H10_CHO_GnTIII 
production (III.2.1.3.2). 
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III.2.1.3 H10_CHO_WT and H10_CHO_GnTIII large-scale production and purification  
In order to provide sufficient H10 material of the same quality for functional characterisation 
(III.2.2), H10_CHO_WT as well as H10_CHO_GnTIII were produced in large-scale with the 
aim to provide 200 mg purified H10 of each version (III.2.1.3.1, III.2.1.3.2). For the 
production of H10_CHO_WT and H10_CHO_GnTIII, the monoclonal cell lines 
DG44_H10I_64.5 (III.1.3) and DG44_H10I_64.5_GnTIII.8 (III.2.1.2) were used, 
respectively.  
III.2.1.3.1 Production of H10_CHO_WT in square bottles 
As demonstrated in chapter III.1.2.3, square bottles (Schott) turned out to be efficient 
cultivation vessels for recombinant H10 production in a scalable process. In addition, 
Panserin C6000 was tested as suitable medium for the production of high levels of 
recombinant proteins (III.1.2.3). Therefore they were chosen for the final batch production of 
H10_CHO_WT in DG44 cells. A preculture of DG44_H10I_64.5 cells was staticly expanded 
in square bottles using the Certomat MO II shaker (Sartorius) and Panserin C6000 medium 
+ 64 µM MTX production medium (25 mm rotational diameter, 130 rpm). After scale-up and 
adaptation to shaking conditions, cells were sedimented, resuspended in 2.1 L fresh, 
prewarmed Panserin C6000 medium + 64 µM MTX and distributed homogeneously to seven 
1 L sterile square bottles (300 ml/bottle) with a seeding density of 3*105 viable cells/ml. 
Homogeneous seeding was checked and confirmed by CASY cell counting (II.2.2.1). 
Production took place according to Muller et al. (2005) with a recommended shaking speed of 
130 rpm and a filling volume of 30% as well as a rotational diameter of 25 mm. To guarantee 
sufficient gas exchange, the bottle’s lids were opened one-quarter of a turn and fixed with 
autoclaving tape. Eight days after seeding the phenol red pH indicator containing culture 
medium had turned bright yellow and the viable cell density had droped from a viable cell 
density of approximately 3*106 cells/ml to 7*105 cells/ml, indicating that the death phase was 
already reached as confirmed by microscopic analysis. Subsequently the culture medium was 
harvested and cells were removed by centrifugation followed by the purification of H10 from 
the culture supernatant via protein A affinity chromatography (II.2.3.1). Since there was as 
well a big culture volume left from the scale-up process (1.8 L), H10 from this pre-batch was 
purified as well in parallel and was finally pooled with the elution fraction of the square bottle 
batch. For storage purposes the pooled elution fraction was dialysed against 1x PBS and was 
filtrated (0.22 µm). A 2nd buffer exchange against TrisGlycin buffer (95.2 mM glycine, 
47.6 mM Tris; pH 7) was done using a dialysis membrane tube followed by sterile filtration of 
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the sample (0.22 µm) (II.2.3.2). H10 amounts of all purification fractions were quantified by 
SPR analysis (protein G chip; II.2.4.4) and are shown in Figure III-24. (Muller et al. 2005) 
 
Figure III-24: Large-scale H10_CHO_WT production and purification. Large-scale H10_CHO_WT 
production took place by the cultivation of the monoclonal, high producing cell line DG44_H10I_64.5 (III.1.3) 
with  a seeding density of 3*105 cells/ml in seven 1L square bottles filled with 300 ml Panserin C6000 medium + 
64 µM MTX each (180 rpm, 25 mm rotational diameter). Eight dpi the culture supernatant (2.1 L) was harvested 
and purified via protein A affinity chromatography (II.2.3.1). In parallel, the culture supernatant from the scale 
up process (1.8 L) was protein A purified and the elution fractions of both purification batches were finally 
pooled. For storage purposes the pooled elution fraction was dialysed against 1x PBS and filtrated (0.22 µm). 
Subsequently, a 2nd buffer exchange against TrisGlycin buffer took place followed by sterile filtration (0.22 µm). 
Both dialysis steps took place by using a dialysis membrane tube with a MWCO of 8 kDa (II.2.3.2, II.2.3.1). 
Shown are the total H10 amounts of each purification step from both production batches, which were determined 
by SPR quantification using a protein A chip (II.2.3.1).  
 
Approximately 264 mg H10 were present in the total loaded culture supernatant of both 
production batches (scale-up batch: 99 mg; square bottle batch: 165 mg) and approximately 
9% yield was lost during the purifcation process leading to a final H10 yield of 240 mg (scale-
up batch: 90 mg; square bottle batch: 150 mg) (Figure III-24). Further yield loss was observed 
after dialysis against 1x PBS followed by filtration (9%) and after buffer exchange against 
TrisGlycine including subsequent sterile filtration (26%). Eventually, 160 mg protein A 
purified H10_CHO_WT (2.3 mg/ml) with a recovery rate of 61% could be generatated from 
3.9 L medium with a purity of 94.4% as determined by Aida Image Analyzer evaluation 
(II.1.14) (data not shown). 
III.2.1.3.2 Production of H10_CHO_GnTIII in a two-compartment bioreactor 
The large-scale H10_CHO_GnTIII production took pace in a CELLine CL1000 (Sartorius) 
disposable two-compartment bioreactor, which is already successfully used at the IME for 
high level antibody production with hybridoma cell cultures. This cultivation device consists 
of a 1 L upper medium reservoir and a lower cell cultivation compartment which is seperated 
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by a semi-permeable membrane with a 10 kDa MWCO. The membrane allows the exchange 
of cultivation medium between the two compartments, but higher molecular weight molecules 
secreted by the proliferating cells are retained within the lower cell compartment. This 
technique enables the achievement of very high cell densities and in turn very high 
recombinant protein concentrations in a very small volume. 
For high level H10_CHO_GnTIII production the previously generated clone 
DG44_H10I_64.5_GnTIII.8 (III.2.1.2) was used as a production cell line and was cultivated 
in a CELLine CL1000 using 1 L Panserin C6000 medium supplemented with 64 µM MTX, 
300 µg/ml Zeocin and according to the Sartorius’s manual as well with additional 4 mM 
L-glutamine and 4.5 g/L D-glucose. Seeding density in the lower compartment was 
2.5*106 cells/ml and cells were passaged ever 11 days according to the manufacturer’s 
manual. Immediately after harvest of the culture supernatant in the lower reservoir, cells were 
removed by centrifugation and the supernatant was subsequently stored at 4°C until H10 
purification (II.2.3.1). After four passaging cycles in total 76 ml culture supernatant was 
collected and purified by protein A affinity chromatography (II.2.3.1). Immediately after 
H10_CHO_GnTIII elution a buffer exchange against TrisGlycine storage buffer, using a 
PD10 desalting column, took place followed by sterile filtration (0.22 µm) (II.2.3.2). SPR 
quantified (protein G chip; II.2.4.4) H10 amounts of each culture supernatant and purification 
fraction are shown in Figure III-25. 
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Figure III-25: Large-scale H10_CHO_GnTIII production and purification. Large-scale H10_CHO_GnTIII 
production took place by the cultivation of the monoclonal, high producing cell line DG44_H10I_64.5_GnTIII 
(III.2.1.2) in a CELLine CL1000 using 1 L Panserin C6000 medium supplemented with 64 µM MTX, 300 µg/ml 
Zeocin, 4 mM L-glutamine and 4.5 g/L D-glucose. Seeding density in the lower compartment was 
2.5*106 cells/ml and cells were passaged every 11 days for 4 cycles. Every harvesting cycle the culture 
supernatant in the lower compartment was collected. Pooled culture supernatants (load fraction) were finally 
purified via protein A affinity chromatography (II.2.3.1) and the elution fraction was filtered (0.22 µm). 
Subsequently a buffer exchange of the elution fraction against TrisGlycin buffer, using a PD10 desalting column, 
was performed followed by sterile filtration (0.22 µm) (II.2.3.2). Shown are the total H10_CHO_GnTIII 
amounts of each production and purification fraction, which were determined by SPR quantification using a 
protein G chip (II.2.3.1).  
 
As shown in Figure III-25 the production level of each CELLine supernatant batch was quite 
constant between 56 and 66 mg H10 per harvesting cycle (56-66 µg/ml). Thereby 
approximately the same H10 concentration as previously measured during the 
H10_CHO_WT production process in square bottles (~ 73 mg/L) (III.2.1.3.1) was achieved. 
Approximately 23% H10_CHO_GnTIII was lost during protein A affinity chromatography 
purification. However, no H10 loss could be observed in the elution fraction after filtration 
(0.22 µm) as well as after PD10 column based buffer exchange. From 4 L cultivation 
medium, 198 mg protein A purified H10_CHO_GnTIII (9.9 mg/ml) was obtained with a 
recovery rate of 80% and a purity of 94.80% as determined by Aida Image Analyzer 
evaluation (II.1.14) (data not shown). 
III.2.1.4 N-glycan analysis 
To verify the expected glycan patterns of H10_CHO_WT (III.2.1.3.1) and H10_CHO_GnTIII 
(III.2.1.3.2), aliquots of the final batches were analysed by MALDI glycopeptide analysis 
(II.2.5), which was performed by Dr. Maurice Henquet at Plant Research International 
(Wageningen, NL). Glycan analysis results are shown in Table III-2. 
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Table III-2: N-glycan structures of H10_CHO_WT and H10_CHO_GnTIII determined by MALDI 
glycopeptides analysis.  
Glycoform abbreviation 
 
Glycoform H10_CHO_WT
[%TIC] 
H10_CHO_GnTIII 
[%TIC] 
Gn2M3 1.1 %  
Gn2FM3 54.7 % 16.6 % 
GalGn2FM3 39.8 % 12.7 % 
Gal2Gn2FM3 4.4 %  
Gn3FM3  31.2 % 
GalGn3FM3  39.6 % 
 
TIC = mass spectrometry total ion current = amount of N-glycanstructure in percent; Gn = N-acetylglucosamin 
(square); M = mannose (circle); Gal = galactose (star); F = 1.6-alpha fucose (triangle); highlighted sections = 
bisecting N-glycan structures 
 
As shown in Table III-2 the H10_CHO_WT sample shows the expected CHO N-glycan 
structure whereas there were large amounts of bisecting N-glycan structures (70.8 %) detected 
in the H10_CHO_GnTIII sample, demonstrating that GnTIII is functional and adds a 
branching N-acetylglucosamin (Gn) to the normal CHO N-glycan structure.  
III.2.1.5 Stability of H10 at -20°C 
The maintainance of H10 stability over time is very important in order to perform a variety of 
functional assays with working material of the same quality (III.2.2). Therefore, purified 
H10_CHO_WT (III.2.1.3.1) and H10_CHO_GnTIII (III.2.1.3.2) glycovariants were stored in 
aliquots of 500 µl at -20°C for long term storage. The degree of H10 degradation within a 
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storage period of 5.5 month at -20°C was checked on a Coomassie stained 10% (w/v) 
SDS-gel with 5 µg H10_CHO_WT examplarily (Figure III-26). 
 
Figure III-26: Long term storage of H10_CHO_WT at -20°C. Five µg of protein A purified H10_CHO_WT 
(III.2.1.3.1) after different storage periods at -20°C (before freezing; storage for 1 day; 3.5, 4.5 and 5.5 months at 
-20°C) were separated on a 10% (w/v) SDS gel via SDS-PAGE under reducing (r.) and non-reducing (n.r.) 
conditions. Protein bands were stained with Coomassie blue (II.2.4.1). M = PageRuler prestained protein marker 
(Fermentas). 
 
The Coomassie stained SDS-gels in Figure III-26 show that there is no visible disassembly of 
H10_CHO_WT during a freezing period of 5.5 months. This indicates that a storage at -20°C 
degree is suitable for long term quality conservation. For each functional characterisation 
assay (III.2.2) a new aliquot of H10_CHO_WT and H10_CHO_GnTIII was thawed and used 
immediately. 
III.2.2 Characterisation of the H10 binding to CEA 
After successful production, protein A purification and the verification of the expected 
N-glycan structures, the final H10_CHO_WT (III.2.1.3.1) and H10_CHO_GnTIII batches 
(III.2.1.3.2) were characterised regarding their functional and specific binding to the CEA 
antigen. 
III.2.2.1 Functional binding of H10 to recombinant CEANA3  
With the intention to analyse and compare the functional binding of both H10 glycovariants 
(III.2.1) to the CEA antigen, a capture ELISA was performed using recombinant CEANA3 
(1:1000) for coating and GAHFcAP for the detection of 150 ng captured H10 (II.2.4.3). 
Hundred-fifty ng cPIPP was used as a negative isotype control for this assay. All samples 
were analysed in technical triplicates. While ELISA is referred to as a black box method, the 
H10_CHO_WT and H10_CHO_GnTIII binding was further monitored by SPR analysis 
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(II.2.4.4). H10_CHO_WT (2.3 µg/ml) and H10_CHO_GnTIII (8.9 µg/ml) were applied on a 
protein A (8082 RU) and CEANA3 (12306 RU) captured CM5-rg sensorchip with a flow rate 
of 30 µl/min and a contact time of 5 min. The relative activity of both H10 glycovariants to 
CEANA3 was evaluated according to the RU ratio of captured H10 by CEANA3 and 
protein A (B-D). Results of capture ELISA and SPR analysis are shown in Figure III-27. 
                
  
Figure III-27: ELISA and SPR reactivity of H10_CHO_WT and H10_CHO_GnTIII to recombinant 
CEANA3. Capture ELISA (II.2.4.3) was performed by coating 5 µg/ml CEANA3 in a high binding 96-well 
microtiter plate, capturing of H10_CHO_WT (III.2.1.3.1) and H10_CHO_GnTIII (III.2.1.3.2), respectively, in a 
1:2 serial dilution followed by the detection with GAHFcAP (1:5000 in 1x PBS) and pNpp substrate (1mg/ml in 
AP-buffer). Absorbance was measured at 405 nm (E405nm) 30 min after substrate addition. cPiPP was used as 
isotype negative control (A). The relative activity of both H10 glycovariants to CEA was determined by SPR 
analysis (II.2.4.4). H10_CHO_WT (2.3 µg/ml) and H10_CHO_GnTIII (8.9 µg/ml) were applied on a protein A 
(8082 RU) and CEANA3 (12306 RU) captured CM5-rg sensorchip with a flow rate of 30 µl/min and a contact 
time of 5 min. Shown are the corresponding sensograms on protein A (B) and CEANA3 (C) and the calculated 
relative activity of H10 to CEA (D).  
 
Almost identical binding characteristics of both H10 glycovariants to CEANA3 were obtained 
by capture ELISA, whereas the isotype negative control cPIPP showed no signal at 405 nm. 
(Figure III-27; A). In particular the slopes in the linear regions of H10_CHO_WT (0.0424) 
and H10_CHO_GnTIII (0.0444) were very similar. These results were confirmed by SPR 
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analysis resulting in a relative antigen binding activity of 70% or 60%, respectively (Figure 
III-27;, D). Taken together, both glycovariant versions show very similar binding properties 
against recombinant, CHO produced CEANA3 in ELISA and SPR analysis. This indicates 
that their different N-glycosylation profiles have no significant influence on antigen binding. 
III.2.2.2 Specific detection of CEA in human cell extract  
H10 binding was demonstrated for NiNTA purified, recombinant CEANA3 without the 
presence of other contaminating proteins (III.2.2.1). In order to visualise its specific binding 
to non-purified, full-size CEA, an immunoblot using whole cell lysate of human cell lines was 
performed. As described in chapter I.2.4 H10 is known to bind an epitope in the N-domain of 
CEA. Since this N-domain amino acid sequence is approximately 80% identical with those of 
the non-specific cross reactive antigen (NCA) (Nasu et al. 1999), the cross-reactivity to this 
CEA-familiy member was also tested.  
Whole cell extract from 30 ml culture volume with 80-100% cell confluence was 
prepared from following cell lines: HEK293T (CEA-/NCA-), HEK293T-CEA_16 
(CEA+/NCA-),  MCF-7 (CEA-/NCA+), LS174T (CEA+/NCA+) (Blumenthal et al. 2005a), 
which had been cultivated in FCS-containing R10 medium (II.2.2.7). CEANA3 served as a 
positive control to demonstrate the suitability of this assay for specific CEA detection. FCS 
was used as a negative conrol to exclude unspecific binding of H10 to serum components. All 
samples were separated by SDS-PAGE and subsequently an immunoblot was performed 
using H10_CHO_WT and GAHFcAP for CEA detection (II.2.4.2). Immunological results are 
shown in Figure III-28. 
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Figure III-28: Immunological analysis of CEA-specific H10 binding in human whole cell lysate. Whole cell 
lysate of HEK293T (CEA-/NCA-), MCF-7 (CEA-/NCA+), LS174T (CEA+/NCA+) was prepared by 
sonification (II.2.2.7). Cell extract as well as the positive (CEANA3) and the negative control (FCS) were 
separated by SDS-PAGE under reducing conditions using a 10% (w/v) SDS-PAA gel (II.2.4.1). Proteins that 
were bound by H10 were visualised by immunoblot via H10_CHO_WT (23 µg/ml, III.2.1.3.1, 1h) and GAHFcAP 
(0.33 µg/ml, 1h) detection antibodies as well as NBT/BCIP substrate (II.2.4.2) (A, B, C). Unspecific GAHFcAP 
binding was excluded by the incubation with GAHFcAP (0.33 µg/ml) only (D). Lane 1-4: 15 µl whole cell lysate 
from cells which had been cultivated in FCS containing R10 medium. Lane 1: HEK293T, Lane 2: 
HEK293T-CEA_16; Lane 3: MCF-7; Lane 4: LS174T; Lane 5: 1 µl CEANA3 (II.1.3); Lane 6: 15 µl FCS; 
M = PageRuler prestained protein marker (Fermentas). 
 
Figure III-28 demonstrates that H10 is capable of binding full-size CEA (~ 200 kDa) in whole 
cell lysate of CEA-positive LS174T cells as well as recombinant, purified CEANA3 
(45-60 kDa). The CEA variant, which had been expressed by HEK293T-CEA_16 cells, was 
also detected as a band of approximately 50-60 kDa. While full-size CEA and the 
recombinantly expressed CEA variant were detected as a separate band, CEANA3 had a quite 
blurred appearance. Since partly deglycosylated, CHO produced CEANA3 is recognised as a 
distinct band by the H10 antibody (personal communication Tamar Ziehm, Fraunhofer IME, 
Aachen), this was probably due to glycosylation heterogeneities. Besides the detected CEA, 
there were non-identified bands in all cell lysate samples detected at 35 and 110 kDa, which 
became even more intense with increasing substrate incubation time (Figure III-28, B). Since 
there were no bands detected in the FCS sample, these bands were cell specific and did not 
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result from cross-reactivity with FCS. In addition, a cross-reactivity of the GAHFcAP detection 
antibody as a reason for these non-identified bands was excluded because no signal was 
observed by the incubation of the immunoblot with the detection antibody only (Figure 
III-28, C). Since there were no bands at approx. 50 and 90 kDa in the cell lysate of NCA 
positive MCF-7 and LS174T cell lines detectable (Figure III-28, A), which would correspond 
to the size of NCA-50/90 (Kuroki et al. 1994), it was assumed that H10 does not cross-react 
with this CEA familiy member. To verify this, the H10 binding to MCF-7 cells was 
additionaly analysed by flow cytometry as shown in chapter III.2.2.4.2. 
III.2.2.3 Localisation of H10 binding on fixed cells 
In chapter III.2.2.2 CEA was successfully detected by H10_CHO_WT in LS174T cell extract. 
Now the binding localisation on intact CEA-positive cells was determined by 
immunoflorescence (II.2.4.5.1). For this CEA-positive LS174T as well as CEA-negative 
HEK293T cells (II.1.6) were grown on chamber slides until a confluence of approx. 80% was 
reached. Cells were subsequently fixed by 4% (w/v) paraformaldehyde and incubated with 
20 µg H10_CHO_WT (III.2.1.3.1) or H10_CHO_GnTIII (III.2.1.3.2), respectively, followed 
by the secondary antibody GAH(H+L)FITC in 1X PBS. Cell nuclei were stained with Dapi by 
coverliping cells with Dapi containing mounting medium. Immunofluorescent, confocal 
images were taken with an UltraView Vox confocal microscope using a Dapi and a GFP filter 
and were overlayed. Detailed protocol descriptions are stated in chapter II.2.4.5.1 and 
immunofluorescent images are shown in Figure III-29. 
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Figure III-29: Immunofluorescent images of paraformaldehyde fixed human cells to demonstrate specific 
H10 binding on the cell surface of CEA-positive cells. CEA-negative HEK293T cells and CEA-positive 
LS174T coloncarcinoma cells (II.1.6) were fixed on chamber slides with 4% (w/v) paraformaldeyde when a 
confluence of approximately 80% was reached. Subsequently they were incubated with 20 µg H10_CHO_WT 
(III.2.1.3.1) or H10_CHO_GnTIII (III.2.1.3.2), respectively. Bound H10 was detected by the secondary antibody 
GAH(H+L)FITC (3 µg/ml). Dapi staining of cell nuclei took place by coverliping cells with Dapi containing 
mounting medium (II.2.4.5.1). 20 µg cPIPP with GAH(H+L)FITC as well GAH(H+L)FITC only served as negative 
controls. Immunofluorescent images were taken with an UltraView Vox confocal microscope (II.1.13) and 
1000x magnification. Shown are overlays of immunofluorescent images of Dapi (405 nm excitation) and FITC 
fluorescence (488 nm excitation, 203 ms exposure time). Detailed protocol descriptions are stated in chapter 
II.2.4.5.1. 
 
As shown in Figure III-29 only CEA-positive LS174T cells, which had been incubated with 
H10_CHO_WT or H10_CHO_GnTIII, respectively, exhibited a green fluorescence on its cell 
surface. No fluorescence was, however, visible on CEA-negative HEK293T cells. 
Additionally, there is no cross reactivity of the GAH(H+L)FITC detection antibody and no 
binding of unspecific antibodies of the same isotype as demonstrated with cPIPP. These 
results demonstrate that H10 binding takes place on the cell surface of CEA-positive cells 
only.  
III.2.2.4 Flow cytometric analysis of H10  
In the previous chapter III.2.2.3 it was shown that only CEA-positive cells were bound by 
H10. However, only paraformaldehyde fixed, dead cells in low quantities were observed in 
this assay. For the verification of these results on living cells and in a higher throughput, 
H10_CHO_WT (III.2.1.3.1) and H10_CHO_GnTIII (III.2.1.3.2) binding was analysed by 
flow cytometry. It was tested whether the binding of both H10 glycovariants was indeed due 
to their specificity to cell surface bound CEA and not due to unspecific attachment on 
mammalian cells. 
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III.2.2.4.1 Generation of a monoclonal HEK293T-CEA cell line producing elevated    
                        levels of CEANA3  
The CEA-expressing coloncarcinoma cell line LS174T (II.1.6) was used in chapter III.2.2.2 
for full-size CEA detection. However, this cell line growths in large cell aggregates which can 
only be dissolved by excessive resuspension, leading in turn to cell death or the formation of 
heterogenous subpopulations due to the resulting shear forces. This property made them 
extremely difficult for the use in flow cytometric analysis since this method requires the 
presence of single, living cells. For these reasons the recombinant, CEA variant producing 
cell line HEK293T-CEA_p (II.1.6), which exhibits less cell aggregation, was used as an 
alternative cell line for H10 flow cytometric analysis. Though, this cell line was polyclonal 
and showed a quite heterogeneous CEA expression as observed by flow cytometric analysis 
(Figure III-30, A). A homogeneous monoclonal HEK293T-CEA cell line, producing high 
level of CEA on the cell surface, was generated by FACS-based screening and sorting 
(II.2.2.6.2). For this 1*106 cells of the initial, polyclonal HEK293T-CEA population were 
labled with 50 µg H10_CHO_WT (III.2.1.3.1) and subsequently with 50 µg GAH(H+L)FITC. 
Dead cells were excluded by PI addition. Three % of the brightest fluorescent cells in the FL1 
fluorescent chanel were sorted with 3 cells/well in five 96-well plate with 200 µl R10 medium 
per well (II.2.2.6.2). After two weeks of cultivation at 37°C and 5% CO2, 41 clones 
regenerated successfully. Subsequently 5*105 cells of each clone were labled with 5 µg 
H10_CHO_WT and 3 µg GAH(H+L)FITC and screened by flow cytometry according to the 
brightest FITC fluorescense (II.2.2.6.1). Thereby the monoclonal, CEA high producer 
HEK293T-CEA_16 was identified, which exhibits a homogenous, high level CEA expression 
(Figure III-30).  
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Figure III-30: Flow cytometric analysis of the initial polyclonal population HEK293T-CEA_p and the 
monoclonal cell lines HEK293T-CEA_16. 5*105 cells of the initial polyclonal HEK293T-CEA_p population 
and the monoclonal cell line HEK293T-CEA_16, which arose from the former by FACS-based sorting 
(II.2.2.6.2), were labled with 5 µg H10_CHO_WT (III.2.1.3.1) and 3 µg GAH(H+L)FITC. Dead cells were excluded 
from flow cytometric analysis by PI addition with a final concentration of 2 µg/ml (II.2.2.6.1). Shown are 
SSC vs. FL1 dot plot diagrams of both live-gated cell cultures (A) as well as a FL1 histogram overlay whereas 
GAH(H+L)FITC labled HEK293T-CEA_p without H10_CHO_WT were used as a negative control (B). Detailed 
protocol descriptions are stated in chapter II.2.2.6.1 and II.2.2.6.2. 
 
Figure III-30 demonstrates that the high level CEANA3 producing cell line 
HEK293T-CEA_16 could be successfully seperated from the initial polyclonal 
HEK293T-CEA_p population by FACS-based sorting and subsequent flow cytometric 
screening. The distribution pattern of this clone in a dot plot and histogram diagram was, 
compared to the initial culture, quite homogenous, indicating that the generated 
HEK293T-CEA_16 cell line is indeed monoclonal. Furthermore the staining lend to FL-1 
shift of almost 104. 
III.2.2.4.2 Flow cytometric analysis of H10 glycovariants on HEK293T-CEA cells 
The generated, CEA high producing HEK293T-CEA_16 cell line (III.2.2.4.1) was used for 
high throughput, flow cytometric binding characteristics of H10_CHO_WT (III.2.1.3.1) or 
H10_CHO_GnTIII (III.2.1.3.2), respectively. NCA cross-reactivity of both H10 variants was 
tested with the NCA positive cell lines MCF-7 (II.1.6) Equivalent to the previous chapter 
(III.2.2.4.1) 5*105 cells were labled with H10_CHO_WT or H10_CHO_GnTIII, respectively, 
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as well as GAH(H+L)FITC and were subsequently analysed by flow cytometry according to their 
FITC fluorescence intensity (II.2.2.6.1). As a negative control cell line HEK293T WT (II.1.6) 
was used to monitor unspecific H10 binding on mammalian cells. In addition non-CEA 
related IgG binding as well as unspecific GAH(H+L)FITC cell attachment was excluded by 
cPIPP isotype negative control. Overlays of the resulting FL1 histograms are shown in Figure 
III-31. 
 
Figure III-31: Flow cytometric analysis of H10_CHO_WT and H10_CHO_GnTIII reagarding CEA 
specificity and unspecific binding to CEA-negative cells. Shown are FL1 histogram overlays of live-gated 
HEK293T WT (A; CEA-/NCA-; II.1.6), MCF-7 (B; CEA-/NCA+; II.1.6)  and HEK293T-CEA_16 (C; 
CEANA3+/NCA-; III.2.2.4.1) cell cultures, which had been labled with 5 µg H10_CHO_WT (III.2.1.3.1) or 
5 µg H10_CHO_GnTIII (III.2.1.3.2), respectively, as well as 3 µg GAH(H+L)FITC. cPIPP served as an isotype 
negative control. HEK293T WT cells were used to monitor non-CEA specific cell binding. Dead cells were 
excluded from flow cytometric analysis by PI addition with a final concentration of 2 µg/ml (II.2.2.6.1). Detailed 
protocol descriptions are stated in chapter II.2.2.6.1. 
 
As shown in Figure III-31 there is no unspecific binding of H10_CHO_WT and 
H10_CHO_GnTIII on CEA-negative HEK293T WT cells detectable (A). Furthermore no 
significant shift was observed on NCA positive MCF-7 cells (B) supporting the results from 
chapter III.2.2.2 that H10 does not cross-react with NCA. In addition the cPIPP isotype 
control was negative for all tested cell cultures, showing that the detected shift of 
H10_CHO_WT and H10_CHO_GnTIII on HEK293T-CEA_16 cells is in fact CEA-specific 
(Figure III-31 C). In summary, both H10 glycovariants specifically bind CEA on 
CEA-positive, living cells without cross reacting with NCA. 
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Microscopic analysis of the cells, using a DMRE confocal microscope (Leica) (II.1.13), 
confirmed the results of the flow cytometric analysis (Figure III-31) and furthermore 
demonstrated that the H10 antibody is not internalised within an incubation period of 5 h (data 
not shown). 
III.2.2.5 Specific binding of H10 to CEA-positive tissue  
The specific H10 binding to single cells could be already demonstrated (III.2.2.3, III.2.2.4.2). 
Next, the specific CEA detection in human tissue should be analysed by 
immunohistochemistry (IHC) (II.2.4.5.2) using H10_CHO_WT (III.2.1.3.1) as a model. In 
addition, it should be tested whether or not there are differences regarding CEA accumulation 
levels between human coloncarcinoma and normal colon mucosa. However, a suitable IHC 
assay had to be developed first because at this time there was no suitable protocol available 
for the use of a human antibody, like H10, on human tissue. The IHC protocol had to 
overcome the problem to detect endogenous human immunoglobulin in the human tissue 
besides recombinant, human H10 bound to CEA. For a suitable human on human IHC method 
several strategies were tested.  
The first approach was to detect CEA in the human tissue via biotin-conjugated H10 
(H10Biotin, II.2.3.3) which was in turn detected by an avidin-biotin-HRPO complex (ABC) 
using the ABC staining kit (Pierce). This method, however, resulted in very high background 
signals in the treated tissues, which could not be removed by an avidin-biotin blocking 
solution (VectorLaboratories) or excessive blocking with NHS (data not shown). Since avidin 
based detection methods are known for high unspecific signals, (Kumar and Rudbeck 2009), 
an avidin independent system was required.  
As a second method an indirect immunoflorescent-based IHC method was evaluated. 
For this, H10Biotin was detected through a Cy3 fluorescent dye conjugated to streptavidin 
(StrepCy3, II.1.3). In this context paraffin embedded tissue was found to be unsuitable because 
of its high autofluorescence when observed with the required Cy3 filter. Even with a variety 
of tested pre-treatment procedures, including proteinase K digestion and heat induced paraffin 
removal in the presence of citric buffer, this background could not be reduced (data not 
shown). Eventually, acetone fixed cryosections turned out to be the most suitable tissue for 
immunofluorescent purposes since there was no background fluorescence detectable. This 
indirect IHC method using H10Biotin and StrepCy3 (5 µg/ml) was optimised further by different 
blocking periods with NHS and several H10Biotin concentrations. Finally, a blocking period of 
30 min and a H10Biotin concentration of 1 µg/ml was found to lead to best results (II.2.4.5.2).  
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In parallel to this method, a direct immunofluorescent-based IHC approach with DyLight549 
fluorescent dye conjugated to H10 was tested and optimised. For this, H10 was labled with 
DyLight549 via NHS-ester conjugation (II.2.3.3). An optimal tissue blocking period of 
30 min and a H10DyLight549 concentration of 4 µg/ml turned out to be most suitable for this 
assay (II.2.4.5.2). Examples of immunofluorescent images from indirect and direct human on 
human IHC are shown in Figure III-32. 
 
Figure III-32: Immunofluorescent images of aceton fixed human cryosections to demonstrate the specific 
binding of the human H10 antibody using indirect and direct IHC methods. Human cryosections (7 µm) 
were acetone fixed, incubated with H10Biotin (1 µg/ml) and StrepCy3 (5 µg/ml) for indirect IHC (II.2.4.5.2) and 
H10DyLight549 (4 µg/ml) for direct IHC (II.2.4.5.2), respectively. Sections without antibody and StrepCy3 treatment 
as well as with StrepCy3 only were used as a negative control. Dapi staining of cell nuclei was performed by 
covering cells with Dapi containing mounting medium. Immunofluorescent images were taken with a DMR 
fluorescent microscope (Leica) (II.1.13) and 200 x magnification. Shown are overlays of pictures taken with a 
ET-DAPI filter cube (Leica; BP 350/50 nm) for Dapi fluorescence emission and a Y3 filter cube (Leica; 
BP 545/40 nm) for Cy3 fluorescence emission. Exposure times with Cy3 filter were 394.7 ms and 1.2 sec for the 
indirect IHC and 3.1 sec for the direct IHC images. Detailed protocol descriptions are stated in chapter II.2.4.5.2. 
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H10Biotin and H10DyLight549 specifically bound to CEA in human cryosections. CEA could be 
localised at the luminal surface of epithelia and goblet cells in the normal colon mucosa. In 
contrast to this, CEA distribution in coloncarcinoma tissue was shown to be non-polarised and 
it accumulated to higher levels in the cancer specific luminal tissue enclosements. 
The indirect IHC turned out to be the most sensitive strategy because even low 
exposure times of around 400 ms and small amounts of H10Biotin (> 1 µg/ml) lead to sufficient 
fluorescent signals. In contrast to this, high exposure times of more than 3 sec and 
H10DyLight549 amounts (< 5 µg/ml) were necessary to detect CEA specifically in human 
cryosections. However, there is a constant fluorescence background of StrepCy3 present which 
becomes visible by microscopic observation as well as exposure times higher than 1.2 sec. 
This indicates that StepCy3 is unspecifcally bound by tissue components.  
Taken together, two IHC protocols had been developed which were both suitable to 
detect a human antibody bound to its antigen on a human tissue. If high sensitivities for CEA 
detection are required, the indirect IHC is the most suitable approach and if no unspecific 
StrepCy3 background is acceptable the direct IHC is the method of choice. 
III.2.3 Characterisation of the ability of H10 to activate effector responses  
The specific binding of H10 to the cell surface of CEA positive cells could be demonstrated in 
chapter III.2.2. This is an essential requirement to mediate ADCC-induced cell killing of 
CEA-positive target cell exclusively. In this chapter the correlation of antigen density on the 
target cell and the efficiency to induce ADCC will be tested (III.2.3.1). In addition, the 
affinity of the glycovariants H10_CHO_WT and H10_CHO_GnTIII for FcγRIIIa were 
analysed to evaluate the ADCC induction (III.2.3.2). 
III.2.3.1 ADCC 
The efficiency of H10_CHO_WT (III.2.1.3.1) to induce ADCC mediated target cell killing, 
was tested by the performance of an in vitro ADCC assay. All ADCC assays (II.2.2.10), 
including PBMC and NK isolation (II.2.2.9) were performed by Dr. Catherine Riley at the 
University of Surrey (Guildford, UK). 
In order to analyse whether or not the CEA density on the cell surface has an impact 
on the degree of ADCC mediated cytotoxcity, the polyclonal HEK293T-CEA_p population 
(II.1.6), exhibiting a relatively low CEA density on its membrane, and the monoclonal CEA 
high producer HEK293T-CEA_16 (III.2.2.4.1) were used as target cells (T). NK cells, which 
had been isolated from human blood were used as effector cells (E). For both ADCC assays 
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NK from the same donor were used. H10_CHO_WT was used in a concentration of 20 µg/ml 
and E:T ratios of 50, 25 and 12.5 were tested. In parallel the same setup was performed 
without antibody as a negative control. P-values were determined to specify the significance 
of the ADCC result. The smaller the p-value, the more statistically relevant is the difference 
observed between the results gained with H10 and those with no antibody. The significance 
niveau is set to 0.05, meaning that p-values above this level indicate that the ADCC results 
are statistically irrelevant (Bender and Lange 2001). The results are shown in Figure III-33. 
 
 
Figure III-33: H10_CHO_WT mediated ADCC with HEK293T-CEA.p or HEK293T-CEA_16 cells, 
respectively, as a target. Shown are the ADCC mediated cytotoxcities with natural killer (NK) cells as effector 
cells (E) and HEK293T-CEA.p (A) as well as HEK293T-CEA_16 (B), respectively, as target cells (T). NK cells 
had been isolated from blood of donor M (II.2.2.9). ADCC was performed as stated in chapter II.2.2.10 with 
20 µg/ml H10_CHO_WT (III.2.1.3.1) and with no antibody as a negative control. Error bars represent technical 
triplicates. P-values specify the statistical significance of the ADCC result. The significance niveau is set to 0.05 
according to Bender and Lange 2001. ADCC results with p-values above this niveau are statistically irrelevant. 
Black p-values = statistically relevant results; grey p-values = statistically irrelevant results.  
 
The results shown in Figure III-33 demonstrate that H10_CHO_WT is capable of inducing 
target cell killing via ADCC. An antibody induced cytotoxcity of 19-36% was achieved with 
HEK293T-CEA_p cells and 42-54% with HEK293T-CEA_16 cells. This indicates that the 
CEA density on the cell surface is crucial for the degree of cytotoxicity and that 
HEK293T-CEA_16 cells, due to their higher antigen levels, are more suitable for ADCC 
induction than its polyclonal initial culture.  
Due to time limitations, the comparative ADCC assay of the H10 glycovariants 
H10_CHO_WT and H10_CHO_GnTIII (III.2.1.3.2) could not be performed in the frame of 
this thesis. Alternatively, their affinities to the FcγRIIIa were compared via SPR-analysis 
(III.2.3.2) which gave an indication of the expected ADCC induction efficiency.  
 
 
 
0
20
40
60
80
100
50 25 13
C
yt
ot
ox
ic
ity
 [%
]
E:T ratio
H10_CHO_WT
no antibody
p = 0.011
p = 0.140
p = 0.539
0
20
40
60
80
100
50 25 13
C
yt
ot
ox
ic
ity
 [
%
]
E:T ratio
H10_CHO_WT
no antibodyp = 0.001 p = 0.001
p = 0.001
A  B 
III Results  100 
 
III.2.3.2 Affinity of the two H10 glycovariants to FcγRIIIa  
The interaction of the antibody Fc region with the low-affinity receptor FcγRIIIa, expressed 
on the cell surface of NK cells, monocytes and granulocytes, plays an essential role on ADCC 
induction (Robertson and Ritz 1990). Enhanced binding affinity to Fc receptors has been 
described to efficiently reduce the antibody concentration necessary to induce target cell lysis 
(Schuster et al. 2006). H10_CHO_GnTIII (III.2.1.3.2), which had been modified by the 
insertion of a bisected N-glycan structure (III.2.1.2), was compared via SPR technology with 
its non-glycoengineered counterpart H10_CHO_WT (III.2.1.3.1) regarding their FcγRIIIa 
binding affinity.  
Only a minor RU difference of 7% was observed by direct immobilisation of H10 
samples to the sensor chip surface upon FcγRIIIa application (described by Ferrara et al. 
(2006b)) compared to indirect H10 sample capture via protein A (data not shown).Since the 
latter, protein A based method was more convenient for the testing of a range of different 
antibodies under comparable conditions, this setup was chosen for comparative analysis of 
both H10 glycovariants. H10_CHO_WT (1050-1060 RU) and H10_CHO_GnTIII (890-
900 RU) were captured onto a protein A surface, respectively (30 µl/min, 90 sec, 15°C). 
Serial dilution (1:2) of human FcγRIIIa (II.1.3) were applied starting with 600 nM in HBS-EP 
running buffer (30 µl/min, 300 s, 15°C). Finally the H10 sample was dissociated from the 
chip surface by HBS-EP running buffer injection for 600 s. Overlays of the normalised 
sensograms are shown in Figure III-34. (Ferrara et al. 2006b)  
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Figure III-34: Kinetic analysis of H10_CHO_WT and H10_CHO_GnTIII to the human FcγRIIIa. 
H10_CHO_WT (1050-1060 RU) and H10_CHO_GnTIII (890-900 RU) were bound to a protein A coupled 
CM5-rg sensor chip. Subsequently, FcγRIIIa was applied in serial dilutions (1:2) from 600 nM until 0.586 nM. 
Shown is an overlay of blank substracted, normalised sensogram curves of serial FcγRIIIa dilutions on a 
H10_CHO_WT (light blue) and H10_CHO_GnTIII (dark blue) captured sensor chip. RU in the stationary phase 
correlate with the concentration of applied FcγRIIIa. The binding curves were fitted to a simple monovalent 
interaction model and the parameters determined were eqKD = 640 nM for H10_CHO_WT and eqKD = 675 nM for 
H10_CHO_GnTIII. RU = response unit. 
 
The normalised sensogram curves of H10_CHO_WT and H10_CHO_GnTIII are almost 
identical, which indicates similar binding characteristics to FcγRIIIa (Figure III-34). A 
temperature of 15°C was chosen for this setup in order to reduce the amount of recombinant 
FcγRIIIa protein. Temperatures of 37°C, however, did not result in significant eqKD 
differences (data not shown).The deduced equilibrium dissociation constant (eqKD) was 
marginally higher for the glycoengineered H10_CHO_GnTIII variant (eqKD = 675 nM) 
compared to the non-glycoengineered H10_CHO_WT version (eqKD = 640 nM). Thus, it can 
be concluded that the affinity of H10_CHO_WT to FcγRIIIa increased only insignificantly by 
the insertion of a bisected N-glycan structure. 
Since the FcγRIIIa is the main inducer of ADCC (Shibata-Koyama et al. 2009), this in 
vitro assay might predict the expected ADCC response in vivo. However, this still needs to be 
confirmed by a comparative cell-based ADCC assay using H10_CHO_GnTIII and 
H10_CHO_WT. The SPR spectroscopic results shown here indicate that no significant ADCC 
induction efficiency increase can be expected with the glycoengineered H10_CHO_GnTIII.  
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IV Discussion 
There were two major aims of this PhD thesis. First, the establishment of a CHO platform for 
monoclonal antibody production (III.1) and second, the medium-scale production and analysis 
of the human full-size anti-CEA IgG1 H10 (III.2).  
In the first part two polycistronic vector systems have been generated and were shown 
to be suitable for efficient recombinant production of full-size IgGs in CHO cells (III.1.1). 
Furthermore, cultivation conditions (III.1.2) and gene amplification strategies (III.1.3) for 
high level H10 production have been established. Those activities resulted in a production 
improvement of over 400-fold (III.1.4).  
The second part of this thesis comprised the production of two H10 variants, bearing a 
complex and a bisected N-glycan structure, respectively (III.2.1). The latter glycoform had 
been described to induce ADCC with a higher efficiency than the normal CHO complex 
glycoform (Umana et al. 1999b). Both H10 versions were therefore analysed regarding its 
binding characteristics to CEA (III.2.2) and its efficiency to induce ADCC (III.2.3, III.2.3.1). 
H10 was shown to specifically bind to CEA without cross-reacting with the CEA-family 
member NCA (III.2.2.2, III.2.2.4.2). However, cross-reactivity with non-CEA proteins in the 
cell extract of human cells was found (III.2.2.2). These proteins could be identified as 
intracellular proteins, since no cross-reactivity with intact non-CEA expressing cells was 
demonstrated (III.2.2.4.2). Importantly, H10 was shown to induce ADCC-mediated cell 
killing of CEA-positive, human cells (III.2.3.1). In this context the glycoengineered H10 
version, bearing a bisected N-glycan structure, was shown to have a similar affinity to the 
FcγRIIIa (III.2.3.2), indicating no improved ADCC induction compared to the non-
glycoengineered H10 version. 
IV.1 Establishment of a CHO platform for monoclonal antibody 
production 
In this thesis a CHO production platform for monoclonal antibody expression has been 
sucessfully established. The first challenge was the design of mammalian expression vectors 
which are suitable for high level IgG production (III.1.1). Two polycistronic vectors 
(pAPI:H10 and pAPT:H10) have been cloned (III.1.1.1) and tested for this purpose and were 
shown to allow correlated expression of the antibody HC and LC as well as the DHFR 
selectable marker (III.1.1.2.3). Furthermore, significant increase in H10 yield could be 
achieved via gene amplification using both vector systems (III.1.1.2.1). As a conclusion, both 
vector systems are suitable for high production of functional IgG (III.1.1.3) whereas the use of 
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the bicistronic tandem vector pAPT:H10 resulted in a two fold higher IgG accumulation in the 
culture medium compared to the tricistronic vector pAPI:H10 (III.1.1.2.2).  
The next challenge was to further optimise the production conditions (III.1.2). A 
suitable production media for serum-free CHO cultivation (III.1.2.1) as well as suitable 
cultivation vessels for upscaling purposes under shaking conditions (III.1.2.3) have been 
established. Long-term cultivation of monoclonal cell lines in the exponential growth phase 
was found to yield in a volumetric production increase whereas the cultivation in the absence 
of MTX resulted in a significant yield decrease (III.1.2.2). 
Eventually, two gene amplification strategies for the establishment of high level IgG 
producing cell cultures have been tested (III.1.3). In this context the highest IgG yield ever 
reported for a tricistronic expression system was achieved with the monoclonal cell line 
DG44_H10I_64.5 (III.1.3.1). 
IV.1.1 Generation of two polycistronic vector systems for high-level antibody 
production 
A vector system is composed of one ore more vectors encoding for at least one GOI (e.g. 
antibody LC or HC) and a selectable marker gene having their specific arrangement of 
regulatory sequences (e.g. promoter or IRES). By now, several vector systems have been 
established for high level antibody production in CHO. The most popular one, the so called 
two vector system, is composed of two independent vectors bearing their specific selectable 
marker gene (e.g. antibiotic resistance gene or DHFR) and encoding for either antibody LC or 
HC. The cloning of these vectors is, compared to other vector systems, very fast and easy. 
However, the selection procedure after cotransfecting of both vectors is more time 
consuming. Since a selection of both transfected vectors at once results in excessive cell 
death, it became common to induce the selection pressure for one vector at first and two 
weeks later for the second one (Page and Sydenham 1991, Xiong et al. 2005, Chusainow et 
al. 2009). Doing so, a time efford of approximately four weeks in total is required until stable 
cultures are established. If subsequent MTX induced gene amplification is performed it was 
observed that the first GOI (e.g. antibody LC) encoded on the DHFR bearing vector was 
present in a higher copy number compared to the second GOI (e.g. antibody HC), which is 
located on the second vector. In case of IgG production, this inbalanced gene expression 
(Jiang and Sharfstein 2009) leads to an inbalanced antibody HC:LC ratio and in turn to a loss 
of assembled IgG (Kim et al. 1998b, Chusainow et al. 2009). 
 A second applied vector system implies the use of vectors bearing HC, LC and the 
selectable marker gene on the same plasmid, but in independent expression cassettes (Jun et 
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al. 2005, Jun et al. 2006, Mason et al. 2005, Schlatter et al. 2005, Huang et al. 2007). This so 
called tandem vector system enables the coselection of antibody HC and LC genes with a 
single selectable marker. By this the HC:LC gene ratio remains relatively fixed even during 
gene amplification procedure as demonstrated by Jun et al. (2006) using the glutamine 
synthetase (GS) system combined with methionine sulfoximine (MSX) induced gene 
amplification.  
 The aim to express antibody HC and LC genes with a fixed polypeptide ratio lead to 
the establishment of polycistronic vector systems, connecting the genes for HC, LC and/or the 
selectable marker through IRES elements. By this, the IRES linked genes are expressed from 
one single transcript hypothesizing its very stringent correlated production. As already stated 
in chapter III.1.1.1.1, it has to be considered that in CHO cells the IRES-dependent gene 
expression is between 6% and 50% of that of a cap-dependent gene which in turn results in a 
2-16x lower expression level (Mizuguchi et al. 2000). Therefore, the positioning of the 
selectable marker downstream of an IRES element is recommended. This does not only 
ensure the tightly coupling of GOI expression with the level of selection pressure resistance, 
but it also increases the selective pressure of the cell to produce more selectable marker 
protein and by this elevated levels of the target protein. In this context, a highly transcriptional 
active integration locus of the vector and a high copy number of the expression cassette was 
found to be favorable for a high level product synthesis (Shukla and Thommes 2010). Besides 
the optimal positioning of the selectable marker gene in a polycistronic construct, the 
positioning of HC and LC gene has to be considered as well. Li et al. (2007a) described that a 
placement of LC-IRES-HC compared to HC-IRES-LC resulted in higher IgG levels and in an 
extracellular HC:LC polypeptide ratio of 1:3 to 1:5 which was in the optimal range for high 
level IgG production in stably transfected CHO cells (Li et al. 2007a, Schlatter et al. 2005).  
Currently, there are some bicistronic (Aldrich et al. 2003) and tricistronic vector 
systems (Li et al. 2007a) described for the production of antibodies (Table IV-1). 
Alternatively, Aldrich et al. (2003) introduced a system combining the bicistronic and the two 
vector system by encoding an expression cassette for LC-IRES-ABR (ABR; antibiotic 
resistance gene) in one vector and HC-IRES-DHFR in the other one. Sleiman et al. (2008) 
used the same strategy, but in contrast to Aldrich et al. (2003) they used two different 
fluorescent proteins (YFP, GFP) as selectable marker, allowing the specific FACS-based 
sorting of clones bearing the brightest YFP and GFP fluorescence which corresponded to high 
IgG production. However, what is still not published to my knowledge is an efficient 
polycistronic vector system allowing gene amplification and at the same time providing a 
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constant extracellular HC:LC polypeptide ratio. Therefore two polycistronic vector systems 
capable of DHFR-mediated gene amplification were established during this thesis: A 
tricistronic vector system (pAPI:H10; III.1.1.1.1) and a bicistronic tandem vector system 
(pAPT:H10; III.1.1.1.2). Table IV-1 lists the currently available vector systems for 
recombinant antibody production in CHO cells including those developed in this work. Listed 
are as well the maximal achieved IgG levels and the corresponding specific productivities 
achieved with stably transfected CHO cell lines in a normal batch process. Nevertheless, these 
values are not ultimate since these cell lines had been obtained by more or less intensive 
selection and screening as well as different batch cultivation conditions.   
 
Table IV-1: Vector systems for high level, recombinant antibody production in CHO cells. Shown are the 
maximal IgG levels and specific productivities, determined for stably transfected CHO cells in a batch process.  
Vector system (VS) Vector 1 Vector 2 
IgG 
level 
[µg/ml] 
Specific 
productivity 
[pg/cell/day] 
Ref. 
Two VS HC + ABR  LC + ABR  0.9  n.k. 1 
Two VS HC + GS LC + GS n.k. n.k. 2 
Two VS HC + ABR  LC + DHFR 450 75  3 
Tandem VS HC + LC + GS - n.k. 1.2, 3.2  2, 4 
Tandem VS HC + LC + DHFR - n.k., 17 10, 33  5, 6 
Bicistronic two VS LC-IRES-ABR HC-IRES-DHFR 400 20 7 
Bicistronic two VS LC-IRES-GFP HC-IRES-YFP 9.5 10  8 
Bicistronic VS LC-IRES-HC + ABR - 1.0  n.k. 1 
Bicistronic VS HC-IRES-LC + ABR - 1.0  n.k. 1 
Tricistronic VS HC-IRES-LC-IRES-YFP+ ABR - n.k. n.k. 1 
Tricistronic VS LC-IRES-HC-IRES-YFP+ ABR - 0.45  n.k. 1 
Tricistronic VS LC-IRES-HC-IRES-DHFR - 312  23  9 
Bicistronic tandem 
VS 
HC + LC-IRES-DHFR - 554 25 9 
VS = vector system; HC = antibody heavy chain gene; LC = antibody light chain gene; ABR = gene encoding for 
an antibiotic resistance selectable marker; GS = gene encoding for the glutamine synthetase selectable marker; 
IRES = internal ribosome entry site of the Encephalomyocarditis virus (EMCV); DHFR = gene encoding for the 
dihydrofolate reductase selectable marker; YFP = gene encoding for the yellow fluorescent protein; GFP = green 
fluorescent protein; + = genes are placed on the same vector within a monocistronic expression cassette; -
 = genes are connected within a polycistronic expression cassette; n.k. = not known; Ref. = reference; 1 = Li et 
al. (2007a) ; 2 = Schlatter et al. (2005); 3 = Chusainow et al. (2009); 4 = Jun et al. (2006); 5 =  Nasoff et al. 
(1997); 6 = Jun et al. (2005); 7 = Aldrich et al. (2003); 8 = Sleiman et al. (2008); 9 = this work. (Jun et al. 2005, 
Jun et al. 2006, Mason et al. 2005) (Nasoff et al. 1997, Aldrich et al. 2003) (Sleiman et al. 2008); 
IV.1.1.1 Arrangement of expression cassettes 
During their production in mammalian cells, antibodies pass along the cellular secretory 
pathway to reach their final destination outside the cell. Antibody HC and LC enter the 
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endoplasmatic reticulum (ER) as unfolded polypeptides, which are then modified and 
assembled to a molecule consisting of two HCs and two LCs. In contrast to free LC in form of 
monomers or dimers (Dul et al. 1996) free HC molecules are not secreted (Morrison and 
Scharff 1975), unless assembled with LC into immunoglobulin molecules (Leitzgen et al. 
1997). Therefore an excess of LC over HC polypeptide in the ER is favorable and may 
minimize accumulation of unfolded HC polypeptide, increasing the rate of antibody folding 
and assembly and reducing stress in the ER which is due to unfolded-protein response 
(Gonzalez et al. 2002, Bertolotti et al. 2000).  
These aspects had to be considered for the establishment of a suitable antibody 
production vector system for stably transfected CHO cells. For the cloning of the tricistronic 
vector pAPI:H10 (III.1.1.1.1) the expression cassette was assembled in the order 
LC-IRES-HC-IRES-DHFR. The LC was placed at the first position since it is described that 
the arrangement LC-IRES-HC results in a more efficient IgG production than the other way 
around (Li et al. 2007a, Schlatter et al. 2005). In addition, a LC over HC excess in the 
endoplasmatic reticulum (ER) is favorable for increased rate of monoclonal antibody folding 
and assembly (Bertolotti et al. 2000, Schlatter et al. 2005). Moreover, the positioning of the 
DHFR selectable marker at the third position should increase the selection pressure and in 
turn the generation of clones with high copy numbers of the whole expression cassette and 
exhibiting highly expressional active plasmid integration loci.  
Before the construction of pAPI:H10, however, the vector pIRESII:H10 (III.1.1.1.1), 
bearing the bicistronic expression cassette LC-IRES-HC, was constructed first and tested for 
its suitability of H10 production. However, the maintainance of this vector required G418 
selection pressure which turned out to be not sufficient for the generation of high level H10 
productive clones (data not shown). Therefore, its bicistronic expression cassette was 
subsequently subcloned into pOptiVEC vector (II.1.8), which enabled gene amplification for 
further yield increase (III.1.1.2.1). If there had been the plan to use this mammalian 
production vector right from the start, the cloning procedure could have been shortened, 
exluding several intermediate steps. Nevertheless, cloning of tricistronic constructs remains a 
very time consuming process since several intermediate cloning steps are required (Li et al. 
2007a). Alternatively, it would be possible to order a synthetic construct, which would be 
more time-saving but also very expensive. Another concern was whether the quite long (5 kb) 
tricistronic expression cassette of the pAPI:H10 vector was capable of being gene amplified 
completely. Since the average amplification unit in the dhfr adjacent regions in the host 
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chromosomal DNA is approximately 100 – 3,000 kb large (Kaufman 1990), the amplification 
of a complete tricistronic cassette was, however, expected to be unproblematic. 
In contrast to pAPI:H10 the cloning of the bicistronic tandem vector pAPT:H10 
(III.1.1.1.2) required less cloning steps. This vector contained two separate expression 
cassettes on the same vector: one encoding for the antibody LC and one for the bicistronic 
construct HC-IRES-DHFR. Both expression cassettes were driven by the same PCMV promoter 
in order to achive equal expression levels. Even though there had been some concerns about 
the risk of homologous recombination when using identical promoters (Pugachev et al. 2000), 
the use of two PCMV promoter derivatives in one plasmid is currently successfully used by the 
company Lonza in their GS vector system and was already described to be suitable for high 
level antibody production by Schlatter et al. (2005). Furthermore it was not expected that the 
presence of IRES-DHFR in the HC expression cassette has an influence on the HC expression 
level. Bouabe et al. (2008) stated that in a comparison of several polycistronic, IRES bearing 
vectors no significant alteration in the cap-dependent gene expression level of the gene, 
placed at the first position was found even if up to four genes were expressed downstream. (Bouabe et al. 2008). 
IV.1.1.2 Comparison of the tricistronic and the bicistronic tandem vector system 
In chapter III.1.1.1 the cloned tricistronic and bicistronic tandem vector have been compared 
regarding their efficiency to promote high level antibody production. Aspects like the optimal 
number of amplification rounds (III.1.1.2.1), the impact of the MTX presence on cell growth 
(III.1.1.2.2) and the influence of the HC:LC expression ratio on the final IgG yield 
(III.1.1.2.3) have been analysed. 
IV.1.1.2.1 Different, optimal MTX concentration for both vector systems 
Gene amplification by MTX selection is generally obtained by gradual increase of the MTX 
selection pressure. Direct exposure to high concentrations, however, may either result in 
excessively high death rates, in altered MTX transport properties (Assaraf and Schimke 1987) 
or even in the development of  MTX-resistant DHFR enzymes (Flintoff and Essani 1980). 
Furthermore, a gradual instead of a rapid MTX concentration increase is more effective for 
the construction of high producing, recombinant CHO cell lines (Yoshikawa et al. 2000a). 
Though, there is no general protocol available how this gradual increase should be proceeded. 
Protocols vary between 2-fold (Chusainow et al. 2009) to 4-fold increments (Kim et al. 
1998b, Kingston et al. 2002, Jun et al. 2005). Since pAPI:H10 and pAPT:H10 originate from 
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the Invitrogen pOptiVEC vector, the gene amplification protocol from OptiCHO Express Kit 
(Introgen), with a 2-fold MTX concentration increments was used in this work.  
The majority of reports, using MTX-induced, gene amplification, did not exceed MTX 
concentrations above 1-5 µM MTX (Jiang et al. 2006, Kim et al. 1998b), even though 
publications describe an exposure of up to 80 µM MTX (Kingston et al. 2002). One reason 
for the use of relatively low MTX concentrations is probably the long time period of 3-4 
weeks which is necessary for each amplification round (Kotsopoulou et al. 2010). In this 
work, however, the protocol for each gene amplification round was shortened. According to 
the OptiCHO Express (Invitrogen) manual the next amplification step can be induced when 
the cell culture reaches a viability of 95% which was achieved here within one week. Due to 
this time saving it was possible to increase the MTX concentration in 2-fold increments from 
50 nM to up to 512 µM MTX within 14 weeks (III.1.1.2.1, Figure III-3). Thereby the most 
suitable MTX concentration for each vector system could be identified.  
As previously stated (III.1.1.1.1), the gene expressed downstream of an IRES element 
is produced 2-16 times lower compared to a cap-dependent gene in CHO cells (Mizuguchi et 
al. 2000). Therefore it would be expected that cells transfected with the tricistronic vector 
pAPI:H10 (LC-IRES-HC-IRES-DHFR) would be exposed to higher MTX-induced selection 
pressure compared to cells transfected with the bicistronic tandem vector pAPI:H10 (LC + 
HC-IRES-DHFR) if they were cultured in the presence of the same MTX concentration. 
Contradicting to this assumption, however, was the observation that the optimal MTX 
concentration of pAPI:H10 transfected cells for highest H10 yields was found to be 64 µM 
MTX, whereas pAPT:H10 transfected cells already showed highest H10 yields at 8 µM MTX 
(III.1.1.2.1).  
One explanation for this result might be that only very few clones of the pAPI:H10 
transfected polyclonal culture survived the initial selection pressure right after transfection 
which was mediated by the transfer of the culture from HT-containing to HT-depleted 
medium (II.2.2.3). These remaining clones probably exhibited not only a highly 
transcriptional active genomic integration locus of the pAPI:H10 plasmid but were also 
functionally equipped for high level protein expression, e.g higher levels of chaperones or  a 
more efficient vesicle transport (Dinnis et al. 2006). These features would enable the 
expression of DHFR protein in levels that allowed the production of sufficient HT amounts 
necessary for their survival. This hypothesis was supported by the excessive cell death of the 
initial DG44_H10I_0.p culture, which was observed within two weeks after transfection 
procedure (data not shown) indicating an enormeous selection process. With subsequent 
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MTX-induced selection rounds those remaining, enhanced cells would have been capable of 
elevating its DHFR levels further by excessive gene amplification of the LC-IRES-HC-IRES-
DHFR expression cassette and would survive the increasing MTX-induced selective pressure. 
Due to the initial selection of top produces, having many GOI copies in a highly 
transcriptional locus and which were as well functionally equipped for high level protein 
expression, the culture would be able to produce high amounts of H10 at 64 µM MTX. 
Though, higher MTX concentrations did not lead to further yield increases. Kingston et al. 
(2002) described that an exposure with MTX concentrations higher than 80 µM MTX induces 
no further gene amplification and thereby no further yield increase since the transport of MTX 
becomes limited. In addition, it has to be noted that the volume of MTX solution added to the 
culture medium (1 mM MTX in PBS) increased with increasing MTX exposure levels and 
replaced at 256 µM MTX already approximately one third of the medium volume and at 
512 µM MTX even half of the volume. Therefore the reduced nutrient reduction might be at 
least one major reason for further H10 yield decrease with MTX concentrations higher than 
128 µM MTX (III.1.1.2.1).  
In contrast to pAPI:H10 transfected cells pAPT:H10 transfected cultures achieved the 
highest H10 yield already at 8 µM MTX (III.1.1.2.1). Concentrations higher than this (until 
128 µM MTX) did not lead to a significant decrease in H10 yield. These observations had 
been confirmed by the repetition of this assay and the cultivation for a longer time period of 
12 days (data not shown). One explanation for this result might be that pAPT:H10 transfected 
cells, in contrast to those transfected with pAPI:H10, were capable of producing DHFR in 
sufficient levels to survive the initial HT- selection pressure and the subsequent selection 
round even if the plasmid had been integrated in lower transcriptional active loci. However, 
no initial selection for potential top producers, which were functionally highly equipped for 
efficient protein synthesis, would have occurred as assumed in the case of pAPI:H10 
transfected cultures. At 8 µM MTX the cells probably reached their limit of H10 and DHFR 
production, not because the gene copy number was too low, but because the expression 
apparatus inside the cell was probably overburdened. Since H10 and DHFR production are 
tightly coupled due to the vector setup, cells would be at this point only capable of cell growth 
if a certain level of DHFR accumulated in the cell enabling indirectly the production of 
nucleotides necessary for the cell proliferation. During this DHFR collection state cells would 
rest und in turn cell growth would be slowed down. This latter assumption could be approved 
by the observation of cell growth decrease with increasing MTX concentration from 4 to 
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128 µM (III.1.1.2.1, Figure III-4) and could also be confirmed in a repetition of this 
experiment (data not shown). 
IV.1.1.2.2 The influence of MTX on cell growth and the formation of resistant clones 
In chapter III.1.1.2.1 the influence of different MTX concentrations in the production media 
on cell growth and target protein production level was tested. It was found that MTX 
concentration lower than 4 µM MTX did not affect cell growth significantly in pAPI:H10 and 
pAPT:H10 transfected cells compared to the non-amplified initial culture and WT DG44 cells 
(Figure III-4). MTX concentrations higher than 4 µM, however, lead to a reduction of cell 
growth which indicates that MTX indeed has an influence on cell proliferation. On the other 
hand it could also be assumed that not MTX is the cause for reduced growth rates, but the 
cells’ increased metabolic burden to produce elevated levels of target proteins which comes 
along with increasing MTX concentrations (Jiang et al. 2006). Actually, there are 
contradictory reports on the effects of target protein overexpression on cell growth. Several 
publications reported that the specific growth rate was inversely proportional to the level of 
recombinant protein expression (Page and Sydenham 1991, Jiang et al. 2006). In contrast to 
this, it was also observed that there is no influence (Fann et al. 2000) or no correlation 
detectable between high and low producing cell lines (Chusainow et al. 2009).  
Fann et al. (2000) tested MTX concentrations from 0.04 – 625 µM MTX for optimal 
tissue-type plasminogen activator (tPA) production in CHO cells. Thereby, no influence in 
cell growth reduction was observed even at 625 µM MTX. Though, the tPA yield decreased 
with MTX concentrations above the MTX optimum of 5 µM. The authors could demonstrate 
that an increasing MTX resistance of the cells might be responsible for the maintainance of 
high cell growth levels even at MTX levels above the production optimum (Fann et al. 2000). 
However, in this report 5-fold MTX increment steps for the generation of gene amplified 
cultures have been used which had been described to result in a higher chance of the 
formation of MTX-resistant clones (Yoshikawa et al. 2000a). In contrast to this, only 2-fold 
MTX increment steps have been used in this thesis which came along with a reduction in cell 
growth with increasing MTX concentrations from 4 µM to 128 µM (III.1.1.2.1, Figure III-4). 
In addition, the production levels of cell cultures decreased (pAPI:H10 transfected cultures) or 
remained relatively constant (pAPT:H10 transfected cultures) above the observed MTX 
optimum for highest H10 yields (III.1.1.2.1, Figure III-3). These observations indicated that in 
contrast to Fann et al. (2000) no MTX-resistant cultures had developed. Furthermore, it can 
be assumed that MTX has indeed an effect on the observed cell growth reduction.  
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It may be assumed that an exposure to high MTX concentrations might have led to the 
reduction of cell growth, because MTX blocks the activity of DHFR which is part of the 
cascade for nucleic acid production (I.1.2). Thereby the cell has to produce a specific DHFR 
amount until this enzyme is indirectly capable of inducing the production of sufficient nucleic 
acids required for subsequent cell devision.  
In summary, it can be stated that the established CHO production platforms including 
the two vector systems pAPI and pAPT as well as the selection strategy were suitable to avoid 
the development of MTX resistant clones. In addition, MTX affected cell growth if applied in 
concentrations higher than 4 µM. 
IV.1.1.2.3 The impact of HC:LC ratio on the IgG production level 
Previous reports, which focused on the HC:LC ratio, determined this ratio either via 
2D-PAGE, ELISA or immunoblot (Schlatter et al. 2005, Li et al. 2007b). However, these 
methods are quite time and cost intensive. The immunoblot method for example is performed 
by the separation of antibody samples on an SDS-gel under reducing conditions, followed by 
the detection of antibody HC and LC via specific detection antibodies labelled with a 
chromophor and finally the determination of the pixel intensity from each band. Thereby the 
HC:LC ratios are normalised according to a standard IgG sample. However, there still 
remains a risk that signals run into saturation phase and are by this likely to lead to wrong 
results. In order to overcome this problem, a less sensitive method using Coomassie stained 
SDS-gels was used in this thesis. This method was shown to be a suitable alternative 
providing reproducible results for the determination of the extracellular HC:LC ratio 
(III.1.1.2.3). In contrast to the procedure described by Schlatter et al. (2005) and Li et al. 
(2007b), no need for the use of detection antibodies or specialised equipment is necessary 
which makes this strategy time and cost saving. Yet, it has to be kept in mind that this method 
is only suitable for the determination of the extracellular HC:LC ratio under serum-free 
conditions because otherwise contaminating proteins would avoid the identification of the 
exact antibody HC and LC bands in the Coomassie stained SDS-gel.  
Direct cell growth and production level comparison between gene amplified DG44 cell 
lines bearing the tricistronic expression vector pAPI:H10 or the bicistronic tandem vector 
pAPT:H10, respectively, showed that pAPT:H10 mediates a 2-2.5 fold higher assembled IgG 
expression compared to pAPI:H10 (III.1.1.2.1, Figure III-5). A reason for this is probably the 
higher transcription efficiency of the HC gene encoded on the pAPT:H10 vector (LC + HC-
IRES-DHFR). In contrast to pAPI:H10 (LC-IRES-HC-IRES-DHFR) the HC expression in 
pAPT:H10 is cap-dependent, which is reported to result in a stronger gene expression when 
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compared to the IRES-dependent expression (Mizuguchi et al. 2000). This assumed higher 
HC expression could be confirmed by analysing the extracellular antibody HC:LC ratio in the 
culture supernatant from DG44_H10I_4.p and DG44_H10T_4.p cells (III.1.1.2.3). In 
addition, the former culture secreted a larger LC excess (approx. 2 LC per IgG molecule) 
compared to the latter (approx. 0.5 LC per IgG molecule), which became visible by analysing 
the culture supernatant on a Coomassie stained SDS-gel (III.1.1.2.1, Figure III-5). This LC 
excess is probably due to a deficiency of HC production followed by a lower efficiency of 
producing assembled IgGs in the pAPI:H10 setup.  
According to the extracellular antibody HC:LC ratios (III.1.1.2.3), the relative 
expression levels of HC and LC protein via pAPI:H10 or pAPT:H10 could be determined 
(Figure IV-1). Thereby the IRES-dependent HC expression level driven by the pAPI:H10 
vector was 40-50% of those found for the cap-dependent LC expression (2-2.5 times lower 
expression). Surprisingly the HC expression in the pAPT:H10 vector, which was like the LC 
expression cap-dependent, was only 60-80% of the LC. This could be explained with a slower 
HC synthesis as also found in B-lymphocytes (Bergman et al. 1981) and with the competitive 
reaction of LC2 formation in the ER (Schlatter et al. 2005). Since the GOI expression level 
was described to be proportional to the number of IRES-GOI repeats in a polycistronic vector 
(Bouabe et al. 2008), the expression level of DHFR was accordingly estimated. Thereby the 
DHFR expression level in pAPI:H10 (LC-IRES-HC-IRES-DHFR) and pAPT:H10 
(HC-IRES-DHFR) was assumed to be 16-25% and 24-40%, respectively (Figure IV-1). 
 
Figure IV-1: Determined LC, HC and DHFR expression levels using the pAPI:H10 and pAPT:H10 
systems. The HC gene placed downstream of an IRES element is expressed 40-50% of the cap-dependent LC 
gene as determined according to the extracellular antibody HC:LC ratios (III.1.1.2.1, Figure III-5). Since the 
GOI expression level is proportional to the number of IRES-GOI repeats in a polycistronic vector (Bouabe et al. 
2008), the expression level of DHFR was accordingly estimated. 
 
Tricistronic vector  pAPI:H10
Bicistronic tandem vector  pAPT:H10
LC: 100% HC: 60-80%
LC: 100% HC: 40 - 50% DHFR: 16 - 25% 
(hypothetically)
Expression level:
DHFR: 24-40% 
(hypothetically)
Expression level:
PCMV PAH10_LCλ leader H10_HCVH leaderIRESFSKozak IRESFS DHFR
PCMV PAH10_LCλ leaderKozak IRESFS DHFRPA PCMV Kozak H10_HCVH leader
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As show in Figure IV-1 it is possible to produce up to 40% more HC molecules with the 
pAPT:H10 vector when compared to the pAPI:H10 vector. This would, at least to some part, 
explain the observed 2-2.5 fold higher IgG level in the culture supernatant of 
DG44_H10T_4.p in contrast to those found with DG44_H10I_4.p (III.1.1.2.2, Figure III-5).  
An extracellular antibody HC:LC ratio of 1 would be the optimum in order to produce 
the maximum possible assembled IgG yield and to have neither HC nor LC excess. Up to now 
there are only a few reports about the antibody HC:LC ratio in CHO cells (Schlatter et al. 
2005, Li et al. 2007a, Li et al. 2007b). In these publications the main focus was on the 
intracellular HC:LC ratio in transient transfected HEK293T or CHO-K1 cells. Thereby 
differences of HC:LC ratio between the used production cell lines and the state of vector 
stability (transient or stable) were observed. Furthermore, a difference between the 
intracellular and extracellular antibody HC:LC ratio was reported. The extracellular HC:LC 
ratio of approximately 0.6-0.8, which was observed in this work with pAPT:H10 (LC + HC-
IRES-DHFR) in stably transfected CHO DG44 cells (III.1.1.2.3), is higher than those reported 
for CHO K1 cells (0.3-0.6) which had been stably transfected with the tridem vector pcB72.3 
(LC + HC + GS) (Schlatter et al. 2005). However, in the report of Schlatter et al. (2005) only 
three independent monoclonal cell lines were analysed which had been selected with the 
much more stringent GS selective instead of the DHFR selectable marker. Therefore, the 
achieved production levels of 0.85-1.22 pg/cell/day are not comparable with those gained in 
this thesis with the non-gene amplified cultures DG44_H10I_0.p (0.06 pg/cell/day) and 
DG44_H10T_0.p (0.09 pg/cell/day) (data not shown). As shown in chapter III.1.1.2.1 (Figure 
III-5) and III.1.1.2.3 (Figure III-7 and Figure III-8), there is a correlation between the 
antibody HC:LC ratio and the efficiency of IgG production. However, the achieved 
extracellular HC:LC ratio in this thesis was higher than those achieved by Schlatter et al. 
(2005) which indicates a more efficient mAb production with the bicistronic tandem vector 
pAPT:H10 than with the monocistronic tridem vector pcB72.3.  
Besides the differences in LC excess production, there was also a difference in the 
degree of coupled HC and LC expression in pAPI:H10 and pAPT:H10 transfected cells 
(III.1.1.2.3). The tricistronic vector system allows a more stringent coupling of HC and LC 
expression which remains even relatively constant with increasing MTX induced genomic 
amplication rounds. In contrast to this, pAPT:H10 transfected cultures show higher 
fluctuations of antibody HC:LC ratio, which is an indication for a larger degree of genomic 
instability separating the HC from the LC encoding expression cassette. Still, with both vector 
systems no significant decline of the antibody HC:LC ratio with increasing MTX 
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concentrations was observed, like often stated when the two vector strategy was used (Jiang 
and Sharfstein 2009, Kim et al. 1998b, Chusainow et al. 2009). It can therefore be concluded 
that both vector systems are suitable for the production of assembled IgG and efficient gene 
amplification since the antibody HC:LC ratio remains more or less constant with increasing 
exposure to MTX. For high level IgG production, however, the bicistronic tandem vector 
pAPT:H10 led to a higher level of assembled IgG with a lower LC excess compared to the 
tricistronic vector pAPI:H10. 
IV.1.1.3 Functional comparison of H10 derived from both vector system 
To confirm that both vector systems were capable of producing fully functional IgG, 
DG44_H10I_4.p and DG44_H10T_4.p cells were cultivated at small scale (50 ml) and H10 
was purified from the culture supernatant and tested regarding its functionality.  
As described in chapter III.1.1.2.2 and III.1.1.2.3 the cell cultures transfected with the 
tricistronic vector pAPI:H10 or the bicistronic tandem vector pAPT:H10, respectively, 
produced a LC excess besides the assembled H10 antibody. Since protein A binds to the HC 
but not to LC molecules, free LC molecules as well as contaminating proteins could be 
removed by protein A affinity chromatography (III.1.1.3.2, Figure III-9). In this context, the 
vector design of pAPI:H10 and pAPT:H10 is again advantageous, since no HC excess is 
produced, which is not removable by protein A affintiy chromatography. Furthermore the 
vector systems enable the development of a purification strategy which is routinely used 
without the risk of HC excess since HC and LC expression are tightly coupled on one single 
vector. In contrast to this is an HC excess not predictable with the commonly used two vector 
system, since this depends on the transfected vector ratio, the state of MTX-induced selection 
and the risk of gene silencing (Jiang et al. 2006, Kim et al. 1998b, Chusainow et al. 2009). A 
protein A based purification strategy is commonly used as part of large-scale downstream 
processing (Birch and Racher 2006) and the removal of excess HC would require an extra 
purification step leading to higher costs. 
For the introduction of a novel vector system some authors demonstrate the 
functionality of the produced protein (Li et al. 2007a, Xiong et al. 2005). Therefore, the 
functionality of purified H10 derived from both vector systems regarding CEA antigen 
binding was demonstrated by flow cytometric analysis (III.1.1.3.2, Figure III-10). There was 
no significant difference in the antigen binding capacity of H10 observed, indicating that the 
used vector system has no influence on the antibody functionality. 
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IV.1.2 Testing of different production conditions 
The cultivation conditions are known to have a major impact on the level of the final product 
(Shukla and Thommes 2010). Therefore different serum-free CHO media (III.1.2.1) and 
different cultivation devices (III.1.2.3) as well as cultivation in the abscence of MTX 
(III.1.2.2) had been tested. 
IV.1.2.1 Testing of serum-free CHO cultivation media 
Media for the cultivation of mammalian cells are very complex and consist of several 
ingredients that range from amino acids, vitamins, trace elements and nucleosides (Chartrain 
and Chu 2008). In the past, fetal bovine serum was an essential component as well. However, 
due to its undefined character, its cost and the risk of transmitting adventitious agents like 
bovine viruses and prions it was more and more rejected for the production of pharmaceutical 
proteins (Wurm 2004). Over time serum was replaced by plant or yeast derived hydrolysates 
(Chartrain and Chu 2008) and by recombinant proteins like human insulin (Jones et al. 2007). 
Since hydrolysates as well as recombinant proteins are still relatively undefined and its 
composition can vary significantly between different vendors and batches, completely 
protein-free, chemically-defined media are nowadays the standard for industrial processes 
(Wurm 2004). Different serum-free media which are optimised for many production cell 
lines, like hybridoma, HEK293 and CHO, are nowadays commercially available. In order to 
test which commercial, serum-free CHO-specific production medium is most suitable for the 
H10 production process, the DG44_H10I_4.p production cell line was used as a model 
(III.1.2.1, Figure III-11). Interestingly, there was a significant yield increase of 1.6-2.6 fold 
detectable between the media specialised for cell maintainance (RPMI, CD DG44 and 
CD CHO) and the production media (HyQ SFM4CHO, ProCHO5, ProCHO4, Panserin C6000 
and PowerCHO2). This points out that the production medium can boost the target protein 
production notably. As stated by Wurm et al. (2004), media for rapid growth involving 
subcultivation have formulations different from those of production media considering that a 
production process in a batch process (6-21 days) is much longer than a typical subcultivation 
period (3-5 days). In addition, the aim of production media is not only to support cell growth 
but mainly the formation of product.  
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IV.1.2.2 Long-term cultivation in the presence and absence of MTX 
Since the presence of MTX was found to have a negative effect on cell growth (III.1.1.2.2, 
IV.1.1.2.2), it was hypothized that the cultivation of gene amplified cultures in the absence of 
selective pressure might result in an elevated cell growth and in turn in an increase in 
antibody yield (III.1.2.2). Li et al. (2007a) showed that a removal of antibiotic induced 
selective pressure in recombinant CHO cells resulted in an increase in antibody yield within a 
period of 3 to 35 days. Longer cultivation periods, however, lead to a significant reduction in 
yield and productivity.  
Confirming the above stated theory, a significant cell growth increase over time could 
be observed for all tested cultures (III.1.2.2, Figure III-12). However, this enhanced cell 
growth did not come along with increasing H10 yields or an increase in specific productivity. 
In contrast to Li et al. (2007a), who removed antibiotic-induced selective pressure, the 
removal of MTX from the culture medium did not result in an improvement of target protein 
yield. Similar observations like shown here had been described in a variety of reports (Kim et 
al. 1998a, Fann et al. 2000, Yoshikawa et al. 2000a, Yoshikawa et al. 2000b). CHO cells are 
known to have a very unstable karyotype due to chromosome rearrangements arising from 
translocations and homologous recombination, especially in response to amplification 
procedures like those induced by MTX (Barnes et al. 2003). Therefore a loss in cell line 
production stability in the absence of selective pressure has been linked to a loss of gene copy 
number. Nevertheless, the main reason for the instability of clones was described to be due to 
a decrease in transcription (Strutzenberger et al. 1999, Chusainow et al. 2009) which comes 
along with chromosome rearrangements and the formation of transcriptionally inactive 
heterochromatin (Barnes et al. 2003).  
Interesting was, however, that the long-term cultivation over a period of 102 days 
(30 passages) of the monoclonal cell lines DG44_H10I_64.14 and DG44_H10I_64.5 in the 
presence of MTX led to a yield increase (1.2-1.6 fold) which came along with a boost in 
viable cell density (III.1.2.2, Figure III-12). Similar to this, Chusainow et al. (2009) reported 
that during the cultivation of monoclonal, antibody producing CHO cells antibody levels 
increased 1.8 fold over a period of 36 passaging cycles in the presence of MTX (Chusainow et 
al. 2009). Actually it would have been expected that monoclonal cell lines would not change 
their growth and production characteristic during long-term cultivation since monoclonal cells 
are genetically identical among themselves. However, it has been demonstrated that there is 
indeed heterogeneity in monoclonal cell cultures (Pilbrough et al. 2009, Barnes et al. 2003). 
This phenomenon can in part be explained by random fluctuation in chromatin folding leading 
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to a fluctuation in target protein expression (Sato et al. 2004). However, the whole mechanism 
is not yet fully understood and depends on internal and external factors (Barnes et al. 2003). 
Since the monoclonal cell lines in this thesis (III.1.2.2, Figure III-12) were passaged every 3-4 
days in the exponential growth phase, the selection for fast growing cell lines would have 
been promoted. As a consequence a “monoclonal” population of faster growing cells had been 
generated resulting in a higher volumetric target protein yield. In summary, it can be stated 
that the selection for fast growing clones by their maintainance in the exponential growth 
phase and in the presence of selective pressure can increase the volumetric target protein yield 
of monoclonal cell lines. 
For large-scale production of recombinant antibodies for therapeutic purposes, not 
only the expression level but the stability of cell lines is critical (Kim et al. 1998b). A 
significant production decrease between initial cells and the end-of-production cells could 
result in the rejection of a particular cell line after months of wasted development effort 
(Barnes et al. 2003). Therefore the identification of cell cultures exhibiting stable production 
levels over a long period of time is important for the development of efficient industrial 
production processes. Like observed here, the first step to stabilise a production culture is the 
generation of monoclonal cell lines. The polyclonal cell culture (DG44_H10I_64.p) used here 
showed a much faster productivity loss compared to the monoclonal cell lines 
(DG44_H10I_64.14 and DG44_H10I_64.5) (III.1.2.2, Figure III-12). As stated in chapter 
III.1.3 (Figure III-14, Figure III-15) polyclonal cell cultures mainly contain low or medium 
producing clones and only a minority of clones exhibit high productivities. Due to the cells’ 
increased metabolic burden to produce elevated levels of target proteins high producing 
monoclonal cell lines show often a slower cell growth characteristic compared to low 
producers (Jiang et al. 2006, Barnes et al. 2003). These differences could be shown here as 
well. The high producer DG44_H10I_64.5 exhibited an average slower cell growth compared 
to the low producer DG44_H10I_64.14 (III.1.2.2, Figure III-12). Considering this, is a 
polyclonal culture, like DG44_H10I_64.p, more likely to be overgrown by low or medium 
producers over time, resulting in a faster productivity decline compared to isolated clones 
(Lee et al. 1991) as observed here (III.1.2.2, Figure III-12). It has been reported that a growth 
advantage of as little as 9% is sufficient for overgrowth by low/non-producers to occur after 
25 passages (Kromenaker and Srienc 1994). Therefore the generation of monoclonal cell lines 
is mandatory if long-term production stability is required. 
Even though the lack of MTX-induced selection pressure results in a significant target protein 
yield decrease (Kim et al. 1998a, Fann et al. 2000, Yoshikawa et al. 2000a, Yoshikawa et al. 
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2000b), the presence of MTX as a toxic drug in industrial processes leading to a therapeutic is 
not recommended (Kim et al. 1998a). It displays a contamination of the produced therapeutic 
protein and is as well very expensive (Wurm 2004). The time period for a typical industrial 
process including culture scale up and harvest usually comprises 30-40 passages with 
passaging cycles every 3-4 days (Chusainow et al. 2009). However, up to now there are only 
very few reports published where the volumetric production level of a CHO production cell 
line remained constant over long-term cultivation in the absence of MTX (Kim et al. 1998b). 
Kim et al. (1998b) stated that gene amplified CHO clones with high volumetric productivities 
have a bigger chance of being long-term stable in the absence of MTX than low producers. 
Similar observation was done with the monoclonal low producer DG44_H10I_64.14 
compared to the monoclonal high producer DG44_H10I_64.5, showing that the former was 
less stable (III.1.2.2, Figure III-12).  
Besides the specific screening for high producing monoclonals there is as well the 
possibility to influence a clone’s long-term stablilty via the genomic integration locus of the 
transfected plasmid. The analysis of transgene integration during long-term cultivation of 
DHFR- CHO cells in the absence of MTX has suggested that amplified genes located near the 
telomeric regions are more likely to be stable than those in other regions of the CHO cell 
genome (Yoshikawa et al. 2000b, Kim and Lee 1999). In addition, a gradual increase of MTX 
exposure has been shown to lead to higher numbers of amplified genes at the telomeric 
regions rather than in other regions of the genome (Yoshikawa et al. 2000a, Yoshikawa et al. 
2000b). Accordingly, the gene amplification strategy with two fold MTX concentration 
increments, as used in this thesis, is suitable for the generation of high producing clones 
exhibiting stable expression levels for a long period of time in the absence of MTX 
(IV.1.1.2.1). Similar to Chusainow et al. (2009), who used two fold MTX concentration 
increments as well, the here developed monoclonal, high producing cell line 
DG44_H10I_64.5 is relatively stable. The H10 concentration decreased only 1.75-2 fold after 
102 days without MTX-induced selection pressure. This is in the range of the most stable 
CHO cell line M500-11 described by Chusainow et al. (2009) whose IgG accumulation level 
decreased 1.75 fold within a cultivation period of 30 passages (approximately 100 days) in the 
absence of MTX.  
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IV.1.2.3 Testing of different cultivation vessels 
For target protein production purposes, mammalian cells are generally cultivated in 
suspension using agitating cultivation systems. Erlenmeyer flasks represent the most 
frequently used alternative to spinner flasks and bioreactors for the cultivation of mammalian 
cells. In 2005, however, Muller et al. presented square shaped bottles as a suitable alternative 
to the common cultivation devices. In this thesis the cultivation of CHO cells in polycarbonate 
Erlenmeyer flasks with and without baffle (Ewb and Ew/ob) as well as glass square bottles 
were compared regarding cell growth and target protein production (III.1.2.3, Figure III-13). 
Even though different vessel materials were used, it had been previously shown that this does 
not have a significant influence on cell growth (Muller et al. 2005). 
Cultures in Ew/ob, followed by square bottles, achieved higher viable cell densities 
compared to Ewb. Furthermore, the H10 concentration of the culture supernatant at the end of 
the cultivation period (17 dpi) was very similar in Ew/ob and square bottles. In Ewb an 
approximately 30% lower H10 concentration was detected which might be explained by 
differences in liquid turbulences and shear forces to which the cells were exposed. While 
Ew/ob were described to provide an absolutely regular rotating liquid flow, the insertion of 
baffles induces turbulences in the cultivation medium (Büchs et al. 2007). Similar to this the 
corners of the square bottles function as negative baffles resulting in improved mixing of the 
culture medium. However, square bottles were described to induce relatively mild turbulences 
allowing viabilities above 95% (Muller et al. 2005). An increase in turbulences is most likely 
present in the order Ew/ob < square bottles << Ewb and is assumed to come along with 
increased oxygen transfer. While shear forces, induced by turbulences, have a negative effect 
on cell growth, an enhanced oxygen transfer in the medium is advantageous. This might be an 
explanation why cells cultivated in Ewb showed a higher specific productivity compared to 
other cultivation systems (III.1.2.3, Figure III-13). Anyway, it has to be considered that 
mammalian cells have a relatively low demand for oxygen but are more sensitive to shear 
forces compared to yeast or bacteria (Cherry 1993). Therefore the negative impact of shear 
forces probably overcame the positive impact of increased oxygen availability in the medium. 
As a consequence a vessel system inducing high culture medium turbulences, like Ewb, 
induces high specific productivities but results in higher cell death and thereby lower cell 
densities which results in  lower volumetric target protein yields (III.1.2.3, Figure III-13).   
As a conclusion, Ew/ob as well as square bottles are suitable CHO cultivation and 
production vessels for target protein production in an orbital shaker. Since square bottles were 
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shown to be quite space-saving due to their geometry and since they are reusable, these 
cultivation devices were chosen for future large-scale production of H10 (III.2.1.3.1).  
IV.1.3 Establishment of a high level IgG producing cell culture 
The pool strategy and the individual clone strategy (I.1.3) had been used for the establishment 
of high level IgG producing monoclonal cell cultures (III.1.3). Both strategies are commonly 
used, whereas the former is known to be faster and the latter to result in higher GOI 
expression levels (Jun et al. 2005). Since the here used vector systems had not been described 
in literature, both amplification systems were tested.  
The achieved H10 yields of polyclonal cultures, which had been generated via the pool 
strategy (III.1.1.2.1), were already discussed in chapter IV.1.1.2.1 in the context of vector 
system comparison. In chapter III.1.3.1, the generation of monoclonal cell lines, originating 
from the initial cultures DG44_H10I_64.p and DG44_H10T_8.p (III.1.1.2.1), were described. 
The characterisation of the resulted monoclonal cell lines showed that the majority of isolated 
clones produced H10 in the range of the initial polyclonal culture or even below (Figure 
III-14). The clones of the bicistronic tandem vector system (DG44_H10T_8.m), however, 
showed an average of two fold higher H10 production levels compared to those of the 
tricistronic vector system (DG44_H10I_64.m) (III.1.3.1, Figure III-14). This confirmed the 
previously documented production differences between both vector stystems (III.1.1.2.2, 
Figure III-5).  
Notable is that the polyclonal, initial cultures DG44_H10I_64.p and DG44_H10T_8.p, 
which were used as a reference, produced H10 in a significantly lower level (27 µg/ml and 
68 µg/ml) as determined in chapter III.1.4 (Figure III-18) (65 µg/ml and 102 µg/ml) even 
though the same seeding densities and culture media had been used. The only difference 
between both assays had been the cultivation volume (1 ml and 10 ml) and the cultivation 
device (T25 flasks and 24-well plates). This difference could probably be explained by slower 
growth characteristics of the cells in microtiter plates compared to those found in T-flasks. 
This phenomenon was generally observed several times (data not shown).  
 In chapter III.1.3.1 (Figure III-14), only a small number of 22-32 monoclonal cell lines 
was generated resulting in a 1.5 fold or even no significant yield improvement (III.1.4, Figure 
III-18). Considering that only a minority of monoclonal cell lines shows production levels 
significantly above the average production level of all clones (Browne and Al-Rubeai 2007), 
the isolation of a significantly higher producing cell line, depends on the number of generated 
clones. Confirming this, the screening of 1320 clones resulted in an improvement factor of 10, 
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creating a production increase from 0.15 µg/ml to 1.57 µg/ml H10 (III.1.3.2, Figure III-16). 
Therefore it was probably a lucky hit that the monoclonal high producing cell line 
DG44_H10I_64.5 showed significantly higher yields (94 µg/ml) compared to the initial 
culture (27 µg/ml) and the other tested clones (30-79 µg/ml), even though only 22 clones had 
been screened (III.1.3.1, Figure III-14).  
Production yields of up to 312 µg/ml H10 (23 pg/cell/day) could be documented here 
with the monoclonal high producer DG44_H10I_64.5 (III.1.4). To my knowledge this is the 
highest antibody level ever reported with a tricistronic vector system. In 2007, Li et al. 
achieved IgG yields of maximal 0.45 µg/ml with CHO-K1 cells transfected with the 
tricistronic vector pTLIY. This vector encodes for a tricistronic expression cassette containing 
the antibody LC and HC as well as the yellow fluorescent protein (YFP) in a tricistronic 
expression cassette (LC-IRES-HC-IRES-YFP). By FACS-based screening according to 
brightest YFP fluorescent, the initial production level of 0.05 µg/ml IgG was improved to 
0.45 µg/ml IgG. In this work, however, higher initial production levels between 0.2 and 
1.0 µg/ml IgG were achieved with pAPI:H10 transfected DG44 cells even before gene 
amplification (III.1.1.2.1, Figure III-3). At this moment production optimisation of the high 
producing, gene amplified, monoclonal cell line DG44_H10I_64.5 is ongoing and yields of up 
to 0.5 g/L are currently achieved with this cell line (personal communication Tamar Ziehm, 
Fraunhofer IME, Aachen).  
Even though the individual clone strategy is known to result in higher H10 yields 
compared to the pool strategy (Jun et al. 2005), most of the DG44_H10T_0.m_8.p cell 
cultures, established with this strategy, produced the H10 antibody in significantly lower 
levels (III.1.3.2, Figure III-17) than the DG44_H10T_8.p culture (III.1.3.1, Figure III-14), 
which had been generated with the pool strategy. This indicates that MTX resistant clones had 
been formed during the amplification process, which was also observed by Jun et al. (2005) 
with gene amplified parental monoclonal cell lines.  
The occurence of CHO cells being resistant to MTX induced selective pressure had 
been reported in several publications (Assaraf and Schimke 1987, Yoshikawa et al. 2000a, 
Kim et al. 2001). MTX resistance can be caused by several events. First, a mutation in the 
active site of the DHFR gene resulting in a DHFR protein version beeing unable to be bound 
by MTX (Volpato et al. 2007). Second, the development of a MTX transport deficiency 
(Assaraf and Schimke 1987). Third, the uncoupling of the GOI and the DHFR gene by 
fragmentation of the genomically integrated vector resulting in amplification of the DHFR 
gene only (Ng et al. 2010). In this thesis, the expression vector settings of pAPI:H10 and 
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pAPT:H10 is favorable to reduce the formation of MTX resistant clones, because the GOI is 
tightly linked with the DHFR selectable marker gene in a polycistronic expression cassette 
(III.1.1.1, IV.1.1.1). By this, the chance of GOI and DHFR uncoupling was reduced. 
However, the first and second cause stated above can not be excluded, but only limited by the 
here chosen selection strategy of gradual MTX concentration increase, as recommended by 
Yoshikawa et al. (2000a). It has to be noted, that during the establishment of high producing, 
DG44_H10T_0.m_8.p cultures via the individual clone strategy, the gene amplification 
procedure was slightly changed compared to the pool strategy (III.1.3.2). This was done 
because of the high number of vials, which had to be handled in parallel and the possibility to 
use cultivation conditions, which were closer to industrial processes than those previously 
used. The cultivation for the individual clone strategy took place in 50 ml bioreactor tubes on 
an orbital shaker instead of non-agitating cultivation in T25 flaks, as used for the pool strategy 
(III.1.3.1). In addition, instead of complete OptiCHO medium, the chemically defined 
PowerCHO2 medium was used. Furthermore, the seeding density at the beginning of each 
new amplification round was not adjusted and no complete medium exchange took place. 
Instead, the cells were passaged into fresh medium, supplemented with the next higher level 
of MTX, in a ratio of 1:2 or 1:4, depending on the previously achieved cell density. This 
fluctuative MTX concentration exposure might probably be the reason for the development of 
MTX resistant clones and not the use of the individual clone strategy itself. The gene 
amplification of selected DG44_H10T_0.m clones via the individual clone strategy is 
currently repeated. This time a more regular MTX supplementation is provided by the 
adjustment of seeding densities and the complete exchange of the selective medium for every 
amplification round. However, due to time limitations the results are not stated in this thesis. 
Therefore a direct comparison of both amplification strategies was not possible. 
The cultivation in 50 ml bioreactor tubes turned out to be more suitable for suspension 
cell cultivation than the commonly used T-flasks or microtiter plates. One reason for this was 
that the cells are homogeniously distributed in the cultivation medium and do not attach to the 
vessel’s bottom as observed in other, non agitating cultivation devices. This avoids the use of 
cell scrapers and thereby additional working steps and material. Furthermore, dead cells 
attach to the vessel walls due to their stickiness and can be removed easily by pipetting. Time 
and cost saving was as well the possibility to use the 50 ml bioreactor tubes as centrifucation 
devices. Due to the reduced effort necessary for cell passaging, this cultivation procedure 
allows the cultivation of many cell cultures in parallel and was therefore established at the 
Fraunhofer IME as a standard procedure for CHO suspension cell cultivation at small-scale. 
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A final comparison between the highest producing polyclonal cultures generated by the pool 
and the individual clone strategy was shown in chapter III.1.4 (Figure III-19). Thereby the 
DG44_H10T_8.p cultures, established via the pool strategy (III.1.3.1), showed with 
554 µg/ml H10 significantly higher H10 production levels compared to the 
DG44_H10T_0.119_8.p culture (304 µg/ml H10), which had been generated via the 
individual clone strategy (III.1.3.2). The pool strategy was shown to be shorter, less labour 
intensive and more efficient in the generation of a high level H10 producing polyclonal 
culture. However, since many clones, generated in the frame of the individual clone strategy, 
became MTX resistant during the gene amplification process (III.1.3.2, Figure III-17), the 
whole potential of this strategy, commonly known as more efficient (Jun et al. 2005), was 
probably not fully exploited.  
Specific productivities of 23 pg/cell/day were evaluated for the high producing 
monoclonal cell line DG44_H10I_64.5, which had been transfected with pAPI:H10 
(III.1.1.1.1) and up to 25 pg/cell/day and 15 pg/cell/day for the high producing polyclonal cell 
lines DG44_H10T_8.p and DG44_H10T_0.119_8.p, which had been transfected with 
pAPT:H10 (III.1.1.1.2). These values were calculated according to the slope of the 
corresponding growth and H10 production curves in the exponential growth phase of cultures 
cultivated in filter tube 50 bioreactors (data not shown). They are in the range of specific 
antibody productivities of good producing CHO cells (20-90 pg/cell/day) (Shukla et al. 2010). 
IV.2 Production and analysis of two H10 glycoforms in CHO cells 
Within the scope of this thesis, high amounts of H10 with a complex (H10_CHO_WT) and a 
bisected N-glycan structure (H10_CHO_GnTIII) were produced and subsequently analysed 
regarding its binding characteristics (III.2). The first challenge was to generate a DG44 cell 
line secreting a glycoengineered H10 version, bearing high amounts of bisected N-glycan 
structures. This had been done by the overtransfection of an H10_CHO_WT producing, 
monoclonal cell line with a previously cloned GnTIII encoding expression vector (III.2.1.1, 
III.2.1.2). Furthermore, the resulted H10_CHO_GnTIII and the H10_CHO_WT complex 
glycoform version had to be produced in a larger scale with the final goal of purifying 200 mg 
of each H10 version (III.2.1.3). Glycoanalysis of both antibody versions confirmed the 
presence of the expected N-glycan structures. In case of H10_CHO_GnTIII even high levels 
of 70% bisected N-glycans were documented (III.2.1.4). 
The second goal has been the characterisation of the H10 binding to CEA. This was 
demonstrated by the analysis of the H10 binding to recombinant and full-size CEA in a 
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variety of assays, including IHC on human tissue (III.2.2). In this context, it was shown that 
glycoengineering does not affect the antibody’s binding characteristic as indicated by equal 
binding properties of H10_CHO_WT and H10_CHO_GnTIII (III.2.2.1).   
The last challenge had been to analyse whether or not the glycoengineered 
H10_CHO_GnTIII has indeed an enhanced efficiency to induce ADCC compared to 
H10_CHO_WT as expected according to Umana et al. 1999b. SPR analysis of both H10 
glycovariants, however, showed that the glycoengineered H10_CHO_GnTIII had no 
improved affinity to the FcγRIIIa indicating that the ADCC induction efficiency can not be 
increased by the insertion of a bisected N-glycan structure.  
IV.2.1 Production and purification of H10 bearing a complex and a bisected 
N-glycan structure 
IV.2.1.1 Establishment of an H10_CHO_GnTIII producing cell line  
Actually there had been two strategies for the production of H10_CHO_GnTIII producing 
DG44 cells. The first strategy comprised the cotransfection of WT DG44 cells with pAPI:H10 
and pTRACER:GnTIII followed by the selection for GnTIII transfected cells via zeocin and 
subsequent MTX-induced gene amplification rounds of generation of the tricistronic 
expression cassette LC-IRES-HC-IRES-DHFR. Even though this strategy had been 
recommended by Invitrogen and was additionally applied in several publications (Page and 
Sydenham 1991, Xiong et al. 2005, Chusainow et al. 2009) it was neglected here. The main 
reasons were that this strategy turned out to be very time consuming and cost intensive since 
the complete MTX-induced gene amplification procedure had to be done including the 
parallel selection with the expensive antibiotic zeocin. In addition, an overexpression of 
GnTIII, which would have been induced with this strategy, was described to inhibit cell 
growth (Umana et al. 1999a).   
Therefore a second, alternative strategy was performed comprising the 
overtransfection of the already available, high producing H10 cell line DG44_H10I_64.5 
(III.1.3.1) with pTRACER:GnTIII. Thereafter the monoclonal cell line 
DG44_H10I_64.5_GnTIII.8 was generated (III.2.1.2) which produced H10 with large amount 
of bisected N-glycan structures (III.2.1.4). This second approach turned out to be much more 
time saving, since high productivities had been already achieved with the monoclonal cell line 
DG44_H10I_64.5 (III.1.3.1) and the time consuming gene amplification procedure could be 
skipped. 
IV Discussion  125 
 
Even though it was possible to prove the genomic integration of the GnTIIIcmyc bearing 
expression cassette inside the genome of the cell line DG44_H10I_64.5_GnTIII.8 (III.2.1.2, 
Figure III-23), it was not possible to detect the GnTIII protein via its cmyc tag by immunoblot 
or ELISA (III.2.1.2). Reasons for this might have been either a GnTIII expression below the 
detection limit of the immunoblot, incomplete cell lysis or the inaccessability of the cmyc tag. 
However, the N-glycan analysis demonstrated the successful formation of bisected N-glycan 
structures demonstrating that GnTIII is expressed and functional (Table III-1). 
IV.2.1.2 Production and purification of H10_CHO_WT and H10_CHO_GnTIII 
While the production of H10_CHO_WT took place in square bottles, the production of 
H10_CHO_GnTIII was proceeded in a two-compartment bioreactor (CELLine 1000; 
III.2.1.3.2). The change to this cultivation system was done, due to time limitations. The 
previous H10_CHO_WT production, which took place in square bottles using 3.9 L medium 
(III.2.1.3.1), required a very high number of cells (>6*108 cells) for inoculation. The entire 
scale-up process for this took approximately 1 month. In contrast to this, the CELLine 1000 
two-compartment bioreactor was inoculated with 5*107 cells only, which is more time 
efficient, since the generation of a preculture could be minimised to 1-2 weeks. However, the 
H10 concentrations achieved with both cultivation devices, square bottle (III.2.1.3.1, 
56-66 µg/ml) and CELLine (III.2.1.3.2; 73 µg/ml), were comparable, favouring the two 
compartment bioreactor CELLine as a cultivation device for rapid IgG production.  
Futhermore, the purification efficiencies after protein A affinity chromatography of 
both H10 production batches were in the same range of 90% (H10_CHO_WT) and 77% 
(H10_CHO_GnTIII), respectively. While sterile filtration of the H10 product did not result in 
any H10 losses (III.2.1.3.2, Figure III-25), a high H10 loss of 10-26% was documented during 
buffer exchange using a dialysis tube (III.2.1.3.1, Figure III-24). In contrast, no yield loss was 
observed after buffer exchange via PD10 columns (III.2.1.3.2, Figure III-25) emphasizing the 
latter buffer exchange procedure as most suitable. Finally, high antibody purities of 94% and 
95% were obtained for protein A purified H10_CHO_WT and H10_CHO_GnTIII, 
respectively.  
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IV.2.2 H10 binding to CEA 
In this thesis the human, anti-CEA antibody H10 was produced in CHO cells as two 
glycovariant versions: H10_CHO_WT (III.2.1.3.1) and H10_CHO_GnTIII (III.2.1.3.2). 
Functional characterisation showed that both antibody versions bound specifically to purified 
recombinant CEANA3 (III.2.2.1), full-size CEA expressed on the outer membrane of 
CEA-positive cancer cells and recombinant CEA displayed on transgenic HEK293T cells 
(III.2.2.2, III.2.2.3, III.2.2.4.2). Furthermore, H10 binding was detected in CEA-positive, 
human tissue (III.2.2.5).  
IV.2.2.1 Binding characteristic of H10 to recombinant CEANA3 and CEA-positive cells 
Direct comparison of H10_CHO_WT and H10_CHO_GntIII by ELISA and SPR showed that 
both H10 versions are functional and capable of binding recombinantly produced CEANA3 
(III.2.2.1, Figure III-27). Supporting these results, no difference between both antibody 
N-glycovariants was observed by flow cytometric analysis on CEA expressing cells 
(III.2.2.4.2, Figure III-31). Moreover, no difference in binding efficiency between both 
antibody N-glycan versions could be observed. This result was expected since IgGs only have 
one glycosylation site, which is placed on the Fc fragment (Jefferis 2007). Thereby the 
variable domains of an antibody, which are responsible for antigen binding, are generally not 
affected by glycoengineering (Davies et al. 2001). 
Holger Spiegel (Fraunhofer IME, Aachen) determined a relatively low affinity of 
H10_CHO_WT for CHO produced CEANA3 (eqKD = 0.85 µM). However, this value is not 
very precise, since the concentration of this glycoprotein was only quantifiable via 
spectroscopic analysis due to its glycosylation heterogeneity and in turns its blurred 
appearance on SDS-gels (III.2.2.2; Diplomarbeit Pascal Thom, Fraunhofer IME, Aachen). 
Anyway, compared to other anti-CEA antibodies, the determined affinity of H10_CHO_WT 
for CEA is very low (PR1A3: KD = 1.5 nM; T84.66: KD = 55.5 nM; MN-14: KD = 1 nM) 
(Kim et al. 2000, Behr et al. 2000). 
In chapter III.2.2.2 the non-specific binding of CEA on several non-CEA proteins in 
the lysate of human cells was documented via immunoblot (Figure III-28). This observation 
was reproducible and even occured when lower H10 concentrations were applied (data not 
shown). However, since the protein band of CEA appeared at first during substrate 
incubation, it can be assumed that the affinity for these non-CEA proteins was probably 
lower. These observations indicate that H10 recognises an epitope which is at least to some 
part present in other cellular proteins. However, since there was no unspecific binding of H10 
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observed on intact cells, as shown by flow cytometric analysis of CEA-negative HEK293T 
cells (III.2.2.4.2, Figure III-31), the non-CEA proteins detected in the immunoblot are 
probably intracellular proteins and are not accessible on intact cells. This could be confirmed 
by immunofluorescence assays with CEA-negative HEK293T cells (III.2.2.3, Figure III-29) 
and CEA-negative regions of human tissue (III.2.2.5, Figure III-32). 
Members of the CEA cell adhesion molecule (CEACAM) family share domains with a 
relatively high amino acid sequence homology (Hammarstrom 1999). In particular the 
N-domain of CEA (also referred to as CEACAM5) was stated to be approximately 80% 
identical to those of the CEA member NCA (CEACAM6) (Nasu et al. 1999). NCA is 
commonly found on the epithelia of the lung, colon as well as coloncarcinoma. Since it is also 
expressed on the cell surface of macrophages and granulocytes antibodies that cross-react 
with this protein, are not considered to be useful for the imaging of CEA-producing tumors 
(Sharkey et al. 1995). Many of the published anti-CEA antibodies had therefore been tested 
regarding their NCA cross-reactivity and were eventually rejected for clinical trials (Sharkey 
et al. 1995, Gaida et al. 1992). H10 has been reported to bind an epitope at the N-domain of 
CEA as well (Hombach et al. 2007) and, as a consequence the cross-reaction to this CEA 
familiy member might be quite probable. However, the immunoblot with cell extract from 
HEK293T (CEA-/NCA-), LS174T (CEA+/NCA+) and MCF-7 (CEA-/NCA+) (Blumenthal et 
al. 2005a) (III.2.2.2, Figure III-28) as well as the flow cytometric analysis of HEK293T, 
HEK239T-CEA_16 and MCF-7 cells (III.2.2.4.2, Figure III-31) indicated that there is no 
detectable cross-reactivity to NCA. It has to be considered that no anti-NCA antibody had 
been available for these assays which would have served as a positive control for NCA 
expression of MCF-7 cells. Nevertheless, the used MCF-7 cells had been in culture for only 
3 months at the time of the assay performance and derived from a cryovial which had been 
frozen immediately after arrival from DSMZ. Therefore the presence of NCA on the surface 
of these cells was quite probable. 
Internalisation of the antibody by the target cell would reduce its accessablilty to 
natural killer cells and therby its efficiency to induce ADCC (Lammerts van Bueren et al. 
2006, Schmidt et al. 2008). There are contradictory reports about the potential of CEA to 
induce antibody internalisation. Recently it was stated that the CEA induced endocytosis takes 
place very slowly with a half-time of 10-16 h as shown with LS174T cells (Schmidt et al. 
2008). Here no H10 internalisation of non fixed LS174T cells (III.2.2.4.2) could be observed 
by fluorescent microscopy (data not shown). However, these cells had been incubated with 
H10 for only 5 h which was probably the reason why no internalisation could be documented.  
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The high level CEA producing, monoclonal, transgenic cell line HEK293T-CEA_16 had been 
generated from the initial polyclonal culture HEK293T-CEA.p, which only showed moderate 
CEA expression levels (III.2.2.4.2, Figure III-30). Furthermore, it could be demonstrated that 
the H10 binding intensity on CEA-positive target cells depends on the CEA density on the 
cell surface (III.2.2.4.2, Figure III-30). This finding was in particular important since lower 
levels of ADCC-mediated target cell killing were observed with the initial culture compared 
to those mediated with the CEA high producing cell line (III.2.3.1, Figure III-33). This 
indicated that the CEA specific antibody opsonization of the target cell influences the degree 
of ADCC induction. Besides the antibody affinity as an important feature for the efficacy and 
kinetic of ADCC, it was stated that the antigen density is very decisive (Velders et al. 1998). 
However, as heterogeneity of a target antigen expression is common with all tumours it is 
mainly important to use high-affinity antibodies in immunotherapy (Velders et al. 1998).  
IV.2.2.2 Specific binding to CEA-positive tissue 
Several optimisation steps were required to develop a suitable protocol for the specific 
detection of CEA in human tissue via the human H10 antibody. Challenging was to overcome 
the problem of endogenous human immunoglobulin (Ig) detection in human tissue. There are 
several reports about the specific antigen detection with primary antibodies of the same 
species as the tested tissue. Nielsen et al. (1987) as well as Foulds and Eremin (1990) for 
example used monomeric Fab fragments (Fab’) which specifically bound endogenous Igs in 
the tissue. Alternatively Lu and Partridge (1998) stated a more efficient blocking strategy 
using papain-digested whole fragments (Fab and Fc fragments) of unlabled, secondary Igs 
which were enriched with additional Fc fragments. Furthermore, boiling of unfixed 
cryosection in PBS was introduced as a very simple method for background reduction 
(Mundegar et al. 2008) whereas microwaving does not elute antibodies, but prevents their 
reactions with subsequently applied reagents (Tornehave et al. 2000). Though, this method is 
only suitable for the detection of thermostable antigen and still high background levels 
remain. In summary, most of the described methods show either insufficient background 
reduction, are quite complicated and time intensive or their applications are limited (Nielsen 
et al. 1987, Foulds and Eremin 1990, Lu and Partridge 1998, Mundegar et al. 2008). 
The indirect method is often preferred to the direct method mainly because the 
immunological tree, used to detect the primary antibody, provides signal amplification 
(Hierck et al. 1994). Very popular for IHC staining is the ABC method which is based on an 
avidin-biotin-HRPO complex formation (Bratthauer 2010). For these reasons the first 
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approach to detect CEA on a human tissue section was the establishment of an indirect IHC 
protocol based on H10Biotin (III.2.2.5). However, with this method very high background 
signals were detected even when avidin-biotin blocking solution (VectorLaboratories) was 
applied or long blocking periods of up to 12 h with NHS were performed (data not shown). It 
was reported that the use of the avidin-biotin-peroxidase (ABC) system, like applied here, 
causes very strong background staining, in particular in colon, gastric mucosa, liver and 
kidney, which was very difficult to block completely (Vosse et al. 2007). In addition, high 
background signal with avidin based detection methods are described to be common for 
avidin based detection methods (Kumar and Rudbeck 2009).  
Due to above described reasons an avidin-independent, indirect IHC protocol was 
established using StrepCy3 instead of the ABC complex (II.2.4.5.2, III.2.2.5). This 
immunofluorescence protocol allows the use of only small amounts of H10Biotin (> 1 µg/ml) as 
well as low exposure times (400 ms) to detect CEA specifically (III.2.2.5, Figure III-32). The 
observed background staining of StrepCy3 can be explained by the presence of endogenous 
biotin (Bratthauer 2010). Especially the human intestine, where biotin is assimilated by the 
food, might contain high levels of biotin. The levels of endogenous biotin are usually higher 
in frozen tissue sections than those encountered in paraffin-embedded specimens (Key 2006). 
This might explain the high background staining observed when paraffin-embedded tissue 
was tested (III.2.2.5). Because of endogenous biotin it is rather recommended to use a biotin 
independent immunochemical staining method if no fluorescence background is required 
(Vosse et al. 2007). As an alternative, it is possible to set a threshold on signal intensity to 
exclude unspecific staining or background from final images (Key 2006). 
 The second approach for specific CEA detection via H10 was based on a direct 
immunofluorescence assay. The use of directly fluorescent labeled primary antibodies in 
immunofluorescence IHC assays is a widely used method and has been exploited for half a 
century (Molne et al. 2005). No secondary antibody or detection protein is needed in this 
method. Therefore no unspecific binding has beed observed when H10DyLight549 was applied 
on the tissue (III.2.2.5, Figure III-32). However, a non-specific, fluorescently labled antibody 
was missing as a control. Thus, it has been described that the fluorescence-based, direct IHC 
method generally results in very low background staining even with a negative control 
antibody (Brown et al. 2004). Probably because the immunological tree providing signal 
amplification (Hierck et al. 1994) was missing here, the required exposure time (> 3 sec) as 
well as the H10DyLight549 amount (> 5 µg/ml) was much higher compared to the indirect 
H10Biotin based IHC method.  
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The results of both protocols showed that H10 attaches to the epithelial surface of the colon 
mucosa, and the upper crypts in the nomal colon mucosa, to the neoplastic tissue inside the 
tumor gland lumens and along the apical and luminal border of coloncarcinoma tissue. Since 
this distribution pattern matches the expected localisation of CEA (Rognum et al. 1980, Kim 
et al. 1999, Hammarstrom 1999) it can be assumed that the H10 binding on the tested human 
tissue is CEA-specific. According to Kim et al. (1999) the distribution pattern of CEA-
positive, neoplastic tissue is characterised into an apicoluminal and a diffuse-cytoplasmic 
pattern. Patients with the apicoluminal CEA pattern were described to achieve longer survival 
than patients with the diffuse-cytoplasmic pattern in the invasive tumor margin (Kim et al. 
1999). Here, a rather diffuse-cytoplasmic CEA distribution pattern was observed in the 
coloncarcinoma tissue, but whether or not tissues of the invasive tumor margins were 
analysed is not known (III.2.2.5, Figure III-32).  
 Furthermore, it was stated that the proximity of the epitope to the membrane might be 
decisive for the intensity of the expected IHC signal (Kim et al. 1999). PR1A3 which binds 
the membrane proximal A3 domain of CEA was described to show a lower signal compared 
to the A3B3-specific T84.66 and even lower compared to the A1-specific PR3B10. According 
to this, the CEAN-domain specific H10 antibody might be a suitable candidate for efficient 
IHC staining.  
IV.2.3 H10 mediated induction of ADCC  
ADCC is considered to be the major mechanism through which tumor cells, upon treatment 
with anti-tumor mAbs, are eliminated in vivo (Velders et al. 1998). Two CHO produced H10 
glycovariants H10_CHO_WT and H10_CHO_GnTIII were previously shown to specifically 
bind CEA on the target cell surface (III.2.2) and meet thereby the requirement for specific, 
ADCC mediated tumor cell killing (III.2.3).  
Within this thesis the monoclonal HEK293T-CEA_16 cell line, exhibiting elevated CEA 
densities on its cell surface, was generated by FACS from the polylclonal, CEA low 
producing HEK293T-CEA_p culture (III.2.2.4.2, Figure III-30). ADCC assays of both cell 
cultures showed that ADCC response can be improved by increased antigen density on the 
target cell surface (III.2.3.1, Figure III-33). Cancer cells with lower antigen density would 
therefore be less effectively destroyed than those expressing higher antigen levels on the cell 
surface (Velders et al. 1998, Schuster et al. 2005). As a consequence, antibodies with 
enhanced ADCC induction potency would target a much broader spectrum of target cells 
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expressing different antigen densities using the same antibody concentrations (Schuster et al. 
2006).  
One approach to achieve higher IgG efficacy is the modification of N-linked glycan 
structures as conducted in this thesis by the modification of the complex biantennary 
N-glycan structure to a bisected triantennary N-glycan one (III.2.1.2). This modified glycan 
structure is described to show significantly enhanced FcγRIIIa binding, resulting in improved 
induction of ADCC mediated target cell killing (Ferrara et al. 2006a, Umana et al. 1999b, 
Ashraf et al. 2009). Increased ADCC induction would eventually allow the reduction of 
immunglobulins doses in therapeutic application (Davies et al. 2001). With this intention the 
H10 complex N-glycan structure (H10_CHO_WT) was glycoengineered in this work, leading 
to high levels of 70.8% bisected N-glycan structures (H10_CHO_GnTIII, III.2.1.4). These 
levels are comparable to those found by Davies et al. (2001) for CHO produced GnTIII 
glycoengineered mAbs, which were in the range of 48%-71% and are even higher than those 
described by Umana et al.(1999b) (45-50%). Umana et al.(1999b) showed that antibody 
batches with 25% bisected N-glycans resulted in a significantly lower ADCC than batches 
with 45-50%. In contrast, Davies and coworkers demonstrated that there was no significant 
increase of ADCC induction when using antibodies with bisected N-glycan amounts from 
48% to 71% (Davies et al. 2001).  
ADCC assays are very time consuming, labour intensive and require the availability of 
fresh human blood. Since there is a strong correlation between antibody-FcγRIIIa interaction 
and ADCC (Umana et al. 1999b, Shields et al. 2002), the use of SPR-based approaches to 
study this interaction in vitro, represents a powerful tool to predict the expected ADCC 
induction efficiency. For this reason the affinity of the glycovariants H10_CHO_WT and 
H10_CHO_GnTIII were compared by this technique (III.2.3.2). However, in contast to the 
expectations no significant increase in FcγRIIIa affinity could by documented with the 
glycoengineered version, bearing large amounts of bisected N-glycan structures, when 
compared to the non-glycoengineered counterpart.  
In fact, there are quite contradictory reports about the influence of a bisected N-glycan 
structure on ADCC induction efficiency. Some groups stated a 10-fold ADCC improvement 
by the modification of the complex biantennary N-glycan structure to the bisected 
triantennary (Umana et al. 1999b, Ashraf et al. 2009) whereas others observed that there is no 
effect at all (Shinkawa et al. 2003). It has been reported that GntIII overexpression often 
comes along with a reduction of antibody fucosylation (Umana et al. 1999b). Since a reduced 
fucose content results in a much higher ADCC response (up to 100-fold) than the presence of 
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a bisected N-glycan structure (Shinkawa et al. 2003), it is very likely that in many cases the 
reported ADCC improvement is not due to the presence of bisected N-glycan stuctures, but 
rather due to a reduction of core fucosylation. In this work, however, the fucose content of 
both N-glycovariants was almost identical (H10_CHO_WT: 0% of bisected Gn, 99% Fuc; 
H10_CHO_GnTIII: 71% of bisected Gn, 100% Fuc; III.2.1.4). Since no significant 
improvement in FcγRIIIa affinity was documentable by the insertion of a bisected N-glycan 
structure (III.2.3.2), it can be concluded that this glycoengineering approach is not suitable for 
efficient ADCC induction improvement. Actually, similar N-glycan structures, like those 
found in this work, were reported by Shinkawa et al. (2003) (IgG1 expressed in WT DG44:  
0% of bisected Gn, 94% Fuc; IgG1 expressed in DG44 GnTIII: 74% of bisected Gn, 100% 
Fuc) resulting in insignificant ADCC improvement by the application of a glycoengineered 
IgG compared to the non-glycoengineered version. These results fit nicely to the SPR results 
gained with the here produced H10 glycovariants. However, if the results obtained by SPR 
indeed predict the expected ADCC still needs to be tested. Therefore ADCC assays with 
H10_CHO_WT and H10_CHO_GnTIII are currently ongoing.  
In summary, the human anti-CEA IgG1 H10, bearing a complex or a bisected N-glycan 
structure, was successully produced in CHO within this work (III.2.1.3). Subsequently both 
glycovariants have been characterised showing similar binding characteristics to recombinant, 
CHO produced CEANA3 (III.2.2.1, III.2.2.2) as well as to full-size CEA on the cell surface of 
CEA-expressing cells (III.2.2.3). Furthermore, H10 specifically binds to CEA on CEA-
positive tissue (III.2.2.5) and mediates ADCC (III.2.3.1), which is due to FcγRIIIa binding 
(III.2.3.2). Though, the H10 antibody is probably not suitable for efficient cancer 
immunotherapy. Main reasons are its cross-reactivity to intracellular proteins (III.2.2.2) and 
its low affinity to CEA (IV.2.2.1). Anyway, it is as a nice model antibody for the 
establishment of a variety of antibody based assays and applications including antibody 
glycoengineering (III.2.1), cell line improvement via FACS (III.2.2.4.1), optimisation of IHC 
on human tissue (III.2.2.5) and SPR based FcγR binding studies (III.2.3.2). 
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V Outlook 
In the frame of this thesis a production platform for monoclonal antibody expression in CHO 
cells was established (III.1). Besides the introduction of novel expression vectors (III.1.1), 
several gene amplification (III.1.3) and production improvement steps (III.1.2) had been 
developed.  
During the establishment of a suitable CHO expression vector, the bicistronic tandem 
vector pAPT:H10 was shown as most suitable for high level antibody expression. However, 
there was still an excess of LC molecules found in the cultures supernatant (III.1.1.2.2, 
III.1.1.2.3), indicating that there is a remaining potential for further HC:LC ratio improvement 
and in turn a further increase in IgG production. An exchange of the PCMV promoter of the 
HC-IRES-DHFR expression cassette with a stronger promoter might be a possible alternative 
for an increase in HC expression level and thereby an even more favourable HC:LC ratio for 
high level IgG expression. For this purpose the elongation factor 1α (EF-1α) promoter, which 
was reported to promote stronger expression in CHO cells than the commonly used PCMV 
promoter (Running Deer and Allison 2004, Li et al. 2007a), would be a suitable alternative. 
Furthermore, it would be promising to improve the gene expression of HC and LC by 
the insertion of genetic elements that enable the integrated plasmid to create a 
transcriptionally active region at any integration locus on the chromosome. Thereby higher 
transcription levels in a higher percentage of transfectants would be achieved which would in 
turn result in less screening effort and a higher chance to isolate extremely high producing cell 
lines. Such elements are for example the ubiquitous chromatin opening elements (UCOE) or 
the matrix attachment regions (MAR) elements (Benton et al. 2002, Harraghy et al. 2008).  
The culture supernatant used for H10 quantifications were harvested from cell lines 
cultivated under standardised, lab-scale conditions, which do not necessarily represent the 
optimal production conditions for high antibody levels. Even though some efforts were made 
to improve the final yield in batch systems (III.1.2), there is still a significant potential for the 
achievement of higher yields. In industrial processes, fed-batch fermentation strategies are 
routinely used, resulting in extremely high cell densities, elongated production periods and at 
the end very high target protein yields (Wurm 2004, Wurm 2007). According to Fan et al. 
(2009) a 4-8 fold IgG yield increase is possible by the conversion of batch to fed-batch 
strategy. (Fan et al. 2009) 
Besides the possibility of a fed-batch fermentation, it would also be possible to run a 
perfusion process. This process is based on the continuous cell retention and as a consequence 
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the achievement of very high cell densities. Seeding densities of 5*106 cells/ml, as tested with 
the monoclonal high producer DG44_H10I_64.5, had already shown to result in a 5-fold H10 
level improvement compared to inoculation with 2.5*105 cells/ml. Thereby H10 
concentrations of up to 0.5 g/L were reached within 3-5 days (personal communication Tamar 
Ziehm, Fraunhofer IME, Aachen), indicating the performance of a perfusion process as very 
likely to be successful. 
Recently the company DSM Biologics developed a so called XD process combining 
fed-batch and perfusion systems to a hybrid process leading to CHO cell densities as high as 
6*107 cells/ml and IgG productions of 12.6 g/L (Zouwenga et al. 2010). By this, a 10-fold 
IgG production level improvement could be achieved compared to normal fed-batch 
fermentation. According to these reports, the high producing DG44_H10I_64.5 monoclonal 
cell line, which produces approximately 0.1 g/L H10 during 10 ml batch cultivation 
(III.1.3.1), could hypothetically achieve yields of 0.4-0.8 g/L (4-8-fold improvement) by 
changing to fed-batch conditions and even up to 4-8 g/L H10 in a XD fermentation processes 
(10-fold improvement).  
The addition of sodium butyrate or similar histone deacetylate inhibitors (HDIs), like 
valproic acid, had been reported to increase the cells’ productivity significantly and is 
therefore widely used in CHO production processes (Sung and Lee 2005). The major cause 
for enhanced gene expression mediated by HDIs is histone hyperacetylation, which facilitates 
access of the general transcription factors (Lee et al. 1993). In the frame of this work sodium 
butyrate and valproic acid have been tested regarding its effects on the H10 yield. Even 
though a significant increase in specific productivity could be achieved (2-fold), the excessive 
cell death led to a significant H10 yield loss of 2-fold compared to a non-supplemented 
positive control (data not shown). In fact, it has been shown that HDI-induced apoptosis can 
be suppressed efficiently by overexpressing of the antiapoptosis protein Bcl-2, resulting in 
enhanced, 2-5-fold higher antibody production due to extended longevity (Kim and Lee 2000, 
Lee and Lee 2003). Coexpression of Bcl-2 and the subsequent exposure to a HDI, like sodium 
butyrate, would therefore be a promising approach to increase the final yield in an H10 
producing cell line.  
The requirement for an efficient, highly productive processs is based on the 
availability of a suitable, high producing monoclonal cell line (Browne and Al-Rubeai 2007). 
Therefore it would be useful to put some more effort into the improvement of gene 
amplification strategies and the development of high throughput screening (HTS) procedures. 
The individual clone strategy is known to result in CHO clones with higher productivities 
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compared to the pool strategy (Jun et al. 2005). In this work, however, a high number of MTX 
resistant clones developed while proceeding this strategy (III.1.3.2). This development was 
probably due to aperiodic exposure to MTX. For this reason, the repetition of this 
amplification strategy with regular MTX exposure steps is currently ongoing and would 
probably lead to the generation of extremely high productive monoclonal cell lines.  
The usual procedure for the generation of monoclonal, high producing cell lines 
comprises the performance of at least one round of LD followed by excessive screening via 
ELISA or SPR analysis (III.1.3). Since this process is quite time consuming the change to a 
more efficient screening and selection system would be advantageous. Recently Brezinsky et 
al. (2008) and Zuberbuhler et al. (2009) presented a simple FACS based screening procedure 
for the selection of cells exhibiting high specific productivities by directly labeling of IgG 
secreting CHO cells with fluorescent dye conjugated secondary antibodies which are specific 
for the secreted IgGs (Brezinsky et al. 2003, Zuberbuhler et al. 2009). Such FACS-based 
screening assays had been already performed in the frame of this work but further 
improvement is still necessary (data not shown). (Brezinsky et al. 2003, Zuberbuhler et al. 2009) 
Highly productive cell lines are often reported to exhibit a slower cell growth due to 
their increased metabolic burden to produce high levels of target proteins (Jiang et al. 2006). 
This might elongate an industrial production process and reduces yields. The continuous 
selection for fast growing subclones had been shown to result in a changed population, 
featuring faster growth characteristics and thereby improved yields (III.1.2.2). In order to 
shorten the production process and to boost the product yield it would therefore be 
advantageous to continuously select for fast growing subclones, once a suitable monoclonal 
production cell line is established. 
 An interesting approach would also be to check the gene copy number and the mRNA 
level of antibody HC and LC as well as the DHFR gene from established monoclonal cell 
lines by real time PCR or Southern blot. This would provide insight whether or not the vector 
system has an influence on the gene copy number of HC, LC and DHFR.  
 In the second part of this thesis, the CEA antigen binding activity of H10_CHO_WT 
and H10_CHO_GnTIII was shown (III.2.2). In this context a lot of effort was put into the 
evaluation of a suitable protocol for the detection of a human antibody specifically bound on 
human tissue. Eventually, the direct, immuofluorescent IHC method was shown to be most 
suitable for this purpose (III.2.2.5). However, this method is not very flexible since the 
detection antibody, in this case H10, had to be directly conjugated with a fluorescent dye, 
making the testing of a larger number of human antibodies quite expensive and time intensive. 
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In 2004 Brown and coworkers introduced a very flexible detection system which allowed the 
simultaneous detection of multiple antigens with primary antibodies derived from the same 
species. Thereby the primary, human antibody is bound to a fluorescent dye labled anti-
human Fab fragment. Excess anti-human Fab fragments are subsequently blocked by human 
serum and the labled, primary antibodies can be applied to human cryosections. This method 
was found to be as effective as the direct immunofluorescence IHC method used in this thesis 
(Brown et al. 2004). If multicolour staining or the testing of several human antibodies would 
be required, this method would be a suitable alternative to the here applied direct IHC. 
Within this thesis, the H10 antibody was shown not to cross-react with NCA (III.2.2.2, 
III.2.2.4.2). However, an NCA-positive control was missing to show that NCA is indeed 
detectable on the cell surface of the used MCF-7 under the applied conditions. Therefore it 
would be useful to repeat the flow cytometric (III.2.2.4.2) and immunological (III.2.2.2) 
assays with an anti-NCA antibody as a positive control.  
 Here, SPR analysis with human FcRγIIIa indicate that probably no improvement in 
H10 mediated ADCC induction can be achieved by the insertion of a bisected N-glycan 
structure (III.2.3.2). Whether or not the SPR result correlate with the results gained via ADCC 
assay still needs to be tested. There are quite contradictory reports about the influence of a 
bisected N-glycan structure on ADCC induction efficiency published. Some reports state a 
10-fold ADCC improvement by the insertion of a bisected N-glycan structure (Umana et al. 
1999b, Ashraf et al. 2009) whereas some do not observe an effect at all (Shinkawa et al. 
2003). A significantly higher enhancement of ADCC of about 100-fold was reported by the 
removal of the α-1,6 fucose (Shields et al. 2002). Accordingly, the production of H10 in 
α-1,6 fucosyltransferase (FUT8) knockout CHO cells, resulting in the production of 
antibodies lacking fucose (Yamane-Ohnuki et al. 2004), would be a suitable suggestion for 
further glycoengineering of the H10 providing enhanced ADCC efficiency.  
It was reported that antibodies recognising an epitope on the N-domain of CEA are 
capable of inhibiting the CEA-mediated tumor cell aggregation. This was described to be due 
to the prevention of the CEA-CEA binding of CEA-positive tumor cells as induced by the 
antibody’s binding to CEA (Stanners and Fuks 1998, Yoshioka et al. 1998). By testing the 
capability of H10 to avoid the CEA-mediated cell aggregation of CEA-positive cells, it might 
be elucidated whether or not this antibody would have the potential to prevent the formation 
of metastasis. Besides the induction of ADCC, this property would be an additional feature of 
the H10 antibody for efficient cancer treatment. 
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VI Summary 
Monoclonal antibodies (mAbs) are constantly gaining importance as a major class of 
recombinant protein therapeutics and diagnostics. Especially the field of cancer 
immunotherapy expanded remarkably within the last years. Nowadays, the majority of 
therapeutic mAbs is produced in CHO cells, which represent the current gold standard for the 
production of recombinant glycoproteins in the biopharmaceutical industry. To meet the 
market demand, it is necessary to generate production processes capable of delivering 
sufficient quantities of product. Thereby not only an optimised production strategy, but also 
the availability of high producing cell lines is essential.  
In the frame of this work a strategy for high level IgG production in CHO suspension cells 
was established based on new vector designs and improved screening and cultivation 
procedures. The objective was to produce the human, full-size IgG1 H10 in the dihydrofolate 
reductase (DHFR) deficient, suspension CHO cell line DG44. For this purpose two novel, 
polycistronic CHO expression vectors were designed: The tricistronic vector pAPI:H10 and 
the bicistronic tandem vector pAPT:H10. Both vectors allowed tightly linked antibody heavy 
chain (HC) and light chain (LC) expression with a ratio suitable for high level antibody 
production. In addition, efficient MTX-induced gene amplification was performed, resulting 
in a 410- to 480-fold IgG yield improvement. During a comparative study of both vector 
systems, the pAPT:H10 vector turned out to allow higher IgG yield production due to a more 
favourable antibody HC:LC ratio and a lower MTX-mediated cell growth inhibition. Further 
optimisation steps like the testing of different, commercially available CHO cell culture 
media, long-term cultivation of cell cultures and the comparison of different cultivation 
vessels for orbital shaking cultivation conditions promised significant yield improvement and 
suspension cell culture scale up. Furthermore, two commonly used MTX-based gene 
amplification strategies had been tested. In this context, serum-independent, high throughput 
automated limiting dilution with single cell regeneration documentation was performed. In 
addition, a comparative high throughput cultivation and gene amplification in 50 ml 
bioreactor tubes was carried out, allowing the parallel screening of a large number of clones 
under process-orientated conditions. Thereby H10 yields of to 304 μg/ml H10 (15 pg/cell/day) 
were achieved. Eventually the best producing, gene amplified DG44 culture, transfected with 
the vector pAPT:H10, achieved production levels of up to 554 μg/ml H10 (25 pg/cell/day) in 
a normal batch culture. Furthermore, yields of up to 312 μg/ml H10 (23 pg/cell/day) were 
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documented here with a monoclonal, pAPI:H10 transfected, high producer. To my knowledge 
this is the highest antibody level ever reported with a tricistronic vector system.  
In the second part of this thesis, the human anti-CEA H10 antibody was analysed regarding its 
functional binding to the carcinoembryonic antigen (CEA) and its efficiency to induce 
ADCC-mediated cell target killing. CEA is a well characterised tumor marker and 
overexpressed in a variety of tumors, like human coloncarcinoma. The use of an anti-CEA 
antibody in the context of cancer immunotherapy therefore represents a promising approach 
to specifically localise and destroy CEA-positive cancer cells. To test the suitability of H10 as 
a potential therapeutic antibody it was produced in DG44 cells with two different N-glycan 
structures: A complex CHO glycoform (H10_CHO_WT) and a glycoengineered version 
bearing a bisected N-glycan (H10_CHO_GnTIII). The latter glycoform is known to induce 
ADCC more efficiently than the normal complex CHO glycoform. The bisected N-glycan 
structure was generated by the coexpression of Golgi localized β1-4-N-
acetylglucosaminyltransferase III (GnTIII) in an H10_CHO_WT secreting DG44 cell line. 
Thereby, large amounts of up to 70% bisected N-glycan structures were achieved. Subsequent 
functional analysis of the H10 glycovariants showed similar activities regarding CEA antigen 
binding on the cell surface of CEA-positive cells, like LS174T or the recombinant HEK293T-
CEA_16 cell line, which has been improved by FACS-based sorting within this work. There 
was no indication of cross-reactivity to the CEA related non-specific cross-reacting antigen 
NCA, which is often observed with antibodies recognising the N-domain of CEA, like the 
H10 antibody. However, cross-reactivity to intracellular, non-identified proteins in the cell 
extract of CEA-expressing and non-CEA-expressing human cells was found, whose binding 
could not be observed on intact cells. Two strategies were established to detect human CEA in 
human tissue via the H10 antibody without cross-reacting to human, endogenous tissue 
immunglobulins. Thereby, H10 was shown to specifically bind CEA and higher CEA levels 
were observed in coloncarcinoma sections compared to tissue of normal colon mucosa.  
Finally, H10 was shown to have the potential of killing target cells via ADCC, 
whereas the efficiency was dependent on the CEA antigen density on the cell surface. Even 
though high levels of bisected N-glycan structures could be achieved by glycoengineering of 
H10, SPR-analysis of both H10 glycoversions showed clearly that this glycomodification has 
no improving effect on the FcγIIIa receptor binding affinity. This indicates that no ADCC 
induction increase can be accomplished by the insertion of bisected N-glycans in CHO 
produced IgGs. 
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VII Attachment 
VII.1 Vector maps 
 
Figure VII-1: Tricistronic CHO expression vector pAPI:H10. PCMV = human Cytomegalovirus (CMV) 
immediate-early promoter/enhancer; H10_LC = H10 human lamda light chain (LC) gene with the human lamda 
LC leader sequence; IRES = Encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES); 
H10_HC = H10 human heavy chain (HC) gene with the human leader sequence of the HC variable region (VH); 
DHFR = dihydrofolate reductase gene; TK PA = Herpes Simplex Virus Thymidine Kinase polyadenylation 
signal; pUCori = pUC origin of replication; AmpR = ampicilin resistance (ß-lactamase) gene.  
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Figure VII-2: Bicistronic tandem CHO expression vector pAPT:H10. PCMV = human Cytomegalovirus 
(CMV) immediate-early promoter/enhancer; H10_LC = H10 human lamda light chain (LC) gene with the human 
lamda LC leader sequence; IRES = Encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES); 
H10_HC = H10 human heavy chain (HC) gene with the human leader sequence of the HC variable region (VH); 
DHFR = dihydrofolate reductase gene; TK PA = Herpes Simplex Virus Thymidine Kinase polyadenylation 
signal; pUCori = pUC origin of replication; AmpR = ampicilin resistance (ß-lactamase) gene. 
 
 
Figure VII-3: Mammalian expression vector pTRACER:GnTIII. PSV40 = Simian Virus (SV40) early 
enhancer/promoter; GnTIII = human β1-4-N-acetylglucosaminyltransferase III; cmyc = cmyc tag; BGH PA = 
bovine growth hormone (BGH) polyadenylation signal; PCMV = human Cytomegalovirus (CMV) immediate-
early promoter/enhancer; GFP-Zeocin = Cycle 3-GFP-Zeocin resistance gene fusion; SV40 PA = SV40 
polyadenylation signal. 
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VII.2 List of oligonucleotides 
 
Table VII-1: Primer used for pGEX-5x-3:CEANA3 shuttle vector cloning and sequencing of the pGEX-
5x-3 expresssion cassette. 
Name Sequence (5’-3’ orientation) Purpose 
   
F CEANA3 CGG GAT CCC GGT CGA CCT CGA GCC ATG 
GAT GGG TAA GCT CAC TAT TG 
Insertion of BamHI, SalI, XhoI, NcoI 
into pGEX-5x-3 
   
B CEANA3 TCG AGC GGC CGC GAA TTC TCT AGA CAT 
AGA GGA CAT CCA GGG TG 
Insertion of XbaI, EcoRI, NotI into 
pGEX-5x-3 
   
F pGEX  GGG CTG GCA AGC CAC GTT TGG TG Sequencing primer specific for pGEX 
promoter 
   
B pGEX  TTT CAA CAG TCT ATG CGG CCC C Sequencing primer specific for pGEX 
GST 
   
F = Forward primer; B = Backward primer 
 
 
 
Table VII-2: Primer used to check the genomic integration of the GnTIIIcmyc gene. 
Name Sequence (5’-3’ orientation) Purpose 
   
F-GnTIII  ATG AAG ATG AGG AGG TAC AAG TTG TT Insert specific GnTIII primer to check 
the genomic integration of GnTIII 
   
B-GnTIII GTT CAA GTC TTC TTC TGA GAT AAG C Cmyc tag specific primer to check the 
attachment of a cmyc tag to the GnTIII 
gene 
   
F = Forward primer; B = Backward primer 
  
VII Attachment  142   
 
Table VII-3: Primer used for pAPI:H10 and pAPT:H10 cloning as well as sequencing of H10 LC and HC. 
Name Sequence (5’-3’ orientation) Purpose 
   
F XhoI-EcoRI-IRES CCG CTC GAG GAA TTC TCC GCC CCT 
CTC CCT CCC CCC 
Insertion of XhoI and EcoRI into pIRES 
for the conversion of IREST into IRESFS 
   
B NcoI-IRESFS CAC CAT GGT TGT GGC CAT ATT ATC 
ATC GTG TTT TTC AAA GG 
Insertion of NcoI into pIRES for the 
conversion of IREST  into IRESFS 
   
   
F XhoI-Kozak-
lambda leader 
GTC GAC CTC GAG GCC GCC ACC 
ATG GCC TGG GCT CTG CTG CTC CTC 
 
Insertion of a Kozak sequence and a 
XhoI restricion site for the cloning of 
H10 LC-IRES-HC and H10 LC, 
sequencing of H10 LC 
   
B XbaI-H10_LC  TCG AGG ATC CTC TAG ACT ATG AAC 
ATT CTG TAG G 
Insertion of XbaI restricion site for the 
cloning of H10 LC,  
sequencing of H10 LC  
   
   
F XhoI-Kozak-VH 
leader  
GTC GAC CTC GAG GCC GCC ACC 
ATG GAC TGG ACC TGG AGA ATC C 
Insertion of  Kozak sequence and a XhoI 
restricion site for the cloning of H10 HC  
   
B XbaI-H10_HC  GAG CTG GAT CCT CTA GAT CAT TTA 
CCC GGA GAC A 
Insertion of a XbaI restricion site for the 
cloning of H10 LC-IRES-HC and H10 
LC, 
Sequencing of H10 HC 
   
   
F SspI PCMV GGA TCC AAT ATT CGG GAG ATC AGT 
TGA C 
Insertion of a SspI restricion site 
   
B SspI PA GCT AGC AAT ATT GAC CAT GAT TAC 
GCC AAG CTC 
Insertion of a SspI restricion site 
   
   
CMV forward  CGC AAA TGG GCG GTA GGC GTG Sequencing primer specific for PCMV 
   
EMCV IRES reverse CCT TAT TCC AAG CGG CTT CG Sequencing primer specific for EMCV 
IRES (IRESFS and IREST) 
   
LC Lamda SOE GGC CAG CCC AAG GCT GCC CCC TCG Sequencing primer for H10 LC 
   
H10 VL Backward GGG GCA GCC TTG  GGC TGG CCG 
AGG ACG GTC ACC TTG 
Sequencing primer for H10 LC 
   
B PA TK 
sequencing  
CCG CTC ATG AGA CAA TAACCC Sequencing primer specific for the 
pOptiVEC vector backbone between TK 
polyandenylation site (PA) and PCMV 
   
F AmpR sequencing  TTC ACC AGC GTT TCT GGG TGA G Sequencing of H10 LC and the 
confirmation of correct insert location 
   
F = Forward primer; B = Backward primer; Lonza recommended Kozak sequence 
(http://www.lonza.com/group/en/products_services/Custom_Manufacturing/mammalian/geneexpressions/faq_s/
question_3.html) = grey 
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VII.3 List of abbreviation  
°C Degree celsius 
dpi Days post inoculation 
HT- HT free 
µg Microgram 
µl Microliter 
AP Alcaline phosphatase 
ADCC Antibody dependent cellular cytotoxity 
bp Basepairs 
BSA Bovine serum albumin 
C Cross linker concentration 
CD Chemically defined 
CD64, 32, 16 Cluster of Differentiation 64, 32, 16 
CEA Carcinoembryonic antigen 
CEANA3 N- and A3-domain of the carcinoembryonic antigen  
CHO Chinese hamster ovary 
C-terminal Carboxy-terminal 
dd H2O  Double destilated H2O from MilliQ-filter machine 
DMSO Dimethylsulfoxide 
DNA Desoxyribonucleic acid  
Ewb Erlenmeyer flasks with baffle 
Ew/ob Erlenmeyer flask without baffle 
E. coli Escherichia coli 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmatic reticulum 
EtOH Ethanol 
FACS Fluorescent activated cell sorting 
FCS Fetal calf serum 
g Gram; gravitational acceleration (9.81 ms2) 
GAH Goat anti human antibody 
GAHFITC Goat anti human FITC conjugated 
GFP Green fluorescent protein 
GFP-ZeoR Fusionprotein of Cycle 3-GFP and a zeocin resistance protein 
GnTIII β1-4-N-acetylglucosaminyltransferase III 
h Hour(s) 
H10 Monoclonal, human full-size IgG1specific for the CEA N-domain  
HC Heavy chain 
HDI Histone deacetylate inhibitors 
HEK Human embryonic kidney cells 
HT Hypoxanthine and thymidine 
IHC Immunohistochemistry 
IRES Internal ribosome entry site 
k Kilo 
KB Kilo bases 
kDa Kilo dalton 
L Liter 
LC Light chain 
M Mol 
mA Milliamper  
mg Milligram 
min Minute(s) 
ml Milliliter 
mM Millimol 
mRNA Messenger RNA 
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MTX Methrotrexate 
NaCl Sodim chloride 
ng Nanogramm 
nm Nanometer 
NK Natural killer cells 
N-terminal Amino-terminal 
OD Optical density 
ON Over night 
PA Polyadenylation site 
PBS Phosphate buffered saline 
PBST 0,1% tween-20 in PBS 
PCI Phenol chloroform isoamylalcohol  
PCR Polymerase chain reaction 
pH Potentiometric hydrogen ion concentration 
pg Picogram 
pM Picomol 
pNpp p-Nitrophenylphosphat 
PVDF Polyvinyliden fluorid 
RNA Ribonucleic acid 
rpm Revolution per minute  
RT Room temperature 
RU Response Unit 
SAH Sheep anti human antibody 
SB Square bottles 
SDS Sodium dodecyl sulphate 
SDS-PAGE SDS-polyacrylamid gelelektrophoresis 
T Total acrylamide-bisacrylamide monomer concentration 
TBE Tri-buffered saline electrophoresis buffer 
TEMED N,N,N’,N’-tetramethylen-ethylendiamin 
U Units 
v/v Volume per volume 
w/w Weight per volume 
WT Wild type 
ZeoR Zeocin resistance 
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